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    [diagnosis_date], 
    [primary_diagnosis] primary_diagnosisraw, 
 
 case 
  when ( 
   primary_diagnosis like '%f30%' or 
   primary_diagnosis like '%f31%' or 
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   primary_diagnosis like '%manic%' or 
   primary_diagnosis like '%mania%' or 
   primary_diagnosis like '%bipolar%' or 
   primary_diagnosis like '%bpad%' or 
   primary_diagnosis like '%affective disorder%' 
or 
   primary_diagnosis like '%mixed affective%') and 
   primary_diagnosis not like '%trichotillomania%' 
and 
   primary_diagnosis not like '%kleptomania%' 
  then 'Bipolar' 
   
  when ( 
   primary_diagnosis like '%psychotic%' or 
   primary_diagnosis like '%psychosis%' or 
   primary_diagnosis like '%schizophreni%' or 
   primary_diagnosis like '%scizophreni%' or 
   primary_diagnosis like '%schizotyp%' or 
   primary_diagnosis like '%scizotyp%' or 
   primary_diagnosis like '%delusion%' or 
   primary_diagnosis like '%hallucin%' or 
   primary_diagnosis like '%f20%' or 
   primary_diagnosis like '%f21%' or 
   primary_diagnosis like '%f22%' or 
   primary_diagnosis like '%f23%' or 
   primary_diagnosis like '%f24%' or 
   primary_diagnosis like '%f28%' or 
   primary_diagnosis like '%f29%') and 
   primary_diagnosis not like '%affective%' and 
   primary_diagnosis not like '%bipolar%' and 
   primary_diagnosis not like '%bpad%' and 
   primary_diagnosis not like '%mania%' and 
   primary_diagnosis not like '%manic%' and 
   primary_diagnosis not like '%depress%' and 
   primary_diagnosis not like '%mood%' and 
   primary_diagnosis not like '%f3%' 
  then 'NonAffectPsychosis' 
 
  when ( 
   primary_diagnosis like '%schizoaffective' or 
   primary_diagnosis like '%f25%') 
  then 'Schizoaffective' 
   
  when ( 
   primary_diagnosis like '%psychosis%' or 
   primary_diagnosis like '%psychotic%' or 
   primary_diagnosis like '%with psyc%') and 
   (primary_diagnosis like '%depress%' or 
   primary_diagnosis like '%f32%' or 
   primary_diagnosis like '%f33%') and 
   primary_diagnosis not like '%without%' and 
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   primary_diagnosis not like '%bipolar%' 
  then 'PsychoticDepression' 
 
  when ( 
   primary_diagnosis like '%depress%' or 
   primary_diagnosis like '%f32%' or 
   primary_diagnosis like '%f33%') and 
   (primary_diagnosis not like '%schizophren%'and 
   primary_diagnosis not like '%manic%'and 
   primary_diagnosis not like '%mania%' and 
   primary_diagnosis not like '%bipolar%' and 
   primary_diagnosis not like '%f25%' and 
   primary_diagnosis not like '%schizoaffective%' 
and 
   primary_diagnosis not like '%personality%' and 
   primary_diagnosis not like '%with psyc%' and 
   primary_diagnosis not like '%psychotic 
depress%' and 
   primary_diagnosis not like '%psychosis and 
depression%' and 
   primary_diagnosis not like '%psychosis; 
depression%') 
  then 'UnipolarDepressionWithoutPsychosis' 
   
  when ( 
   primary_diagnosis like '%cyclothymia%' or 
   primary_diagnosis like '%dysthymi%' or 
   primary_diagnosis like '%f34%' or 
   primary_diagnosis like '%f38%' or 
   primary_diagnosis like '%f39%' or 
   primary_diagnosis like '%mood disorder%' or 
   primary_diagnosis like '%affective disorder%' 
or 
   primary_diagnosis like '%affective illness%' or 
   primary_diagnosis like '%affective symptoms%' 
or 
   primary_diagnosis like '%mood disturbance%' or 
   primary_diagnosis like '%Mood [affective] 
disorder%' or 
   primary_diagnosis like '%Mood (affective) 
disorder%' or 
   primary_diagnosis like '%organic mood%') 
  then 'OtherAffectiveDisorder' 
 
  when ( 
   primary_diagnosis like '%psychotic%' or 
   primary_diagnosis like '%psychosis%' or 
   primary_diagnosis like '%schizophreni%' or 
   primary_diagnosis like '%scizophreni%' or 
   primary_diagnosis like '%schizotyp%' or 
   primary_diagnosis like '%scizotyp%' or 
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   primary_diagnosis like '%delusion%' or 
   primary_diagnosis like '%hallucin%' or 
   primary_diagnosis like '%f20%' or 
   primary_diagnosis like '%f21%' or 
   primary_diagnosis like '%f22%' or 
   primary_diagnosis like '%f23%' or 
   primary_diagnosis like '%f24%' or 
   primary_diagnosis like '%f28%' or 
   primary_diagnosis like '%f29%') and 
   (primary_diagnosis like '%affective%' or 
   primary_diagnosis like '%bipolar%' or 
   primary_diagnosis like '%bpad%' or 
   primary_diagnosis like '%mania%' or 
   primary_diagnosis like '%manic%' or 
   primary_diagnosis like '%depress%' or 
   primary_diagnosis like '%mood%' or 
   primary_diagnosis like '%f3%') 
  then 'OtherAffectivePsychosis' 
   
  when ( 
   primary_diagnosis like '%f4%' or 
   primary_diagnosis like '%anxiety%' or 
   primary_diagnosis like '%panic%' or 
   primary_diagnosis like '%adjustment%' or 
   primary_diagnosis like '%phobic%' or 
   primary_diagnosis like '%phobia%' or 
   primary_diagnosis like '%ocd%' or 
   primary_diagnosis like '%obsessi%' or 
   primary_diagnosis like '%compulsi%' or 
   primary_diagnosis like '%acute stress%' or 
   primary_diagnosis like '%dissociative%' or 
   primary_diagnosis like '%somatoform%' or 
   primary_diagnosis like '%somatization%' or 
   primary_diagnosis like '%bdd%' or 
   primary_diagnosis like '%dysmorph%' or 
   primary_diagnosis like '%hypochondria%' or 
   primary_diagnosis like '%neurosis%' or 
   primary_diagnosis like '%neurotic%' or 
   primary_diagnosis like '%neurasthenia%' or 
   primary_diagnosis like '%fatigue%' or 
   primary_diagnosis like '%chronic pain%' or 
   primary_diagnosis like '%pain syndrome%' or 
   primary_diagnosis like '%pain disorder%' or 
   primary_diagnosis like '%briquet%' or 
   primary_diagnosis like '%psychosomatic%' or 
   primary_diagnosis like '%ptsd%' or 
   primary_diagnosis like '%post traumatic%' or 
   primary_diagnosis like '%traumatic stress%' or 
   primary_diagnosis like '%stress disorder%' or 
   primary_diagnosis like '%stress reaction%' or 
   primary_diagnosis like '%post-traumatic%' or 
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   primary_diagnosis like '%conversion%') 
  then 'AnxietyDisorder' 
   
  when ( 
   primary_diagnosis like '%personality%' or 
   primary_diagnosis like '%emotionally unstable%' 
or 
   primary_diagnosis like '%borderline%' or 
   primary_diagnosis like '%histrionic%' or 
   primary_diagnosis like '%narcissistic%' or 
   primary_diagnosis like '%f60%' or 
   primary_diagnosis like '%f61%' or 
   primary_diagnosis like '%f62%' or 
   primary_diagnosis like '%f69%' and 
   primary_diagnosis not like '%learning%') 
  then 'PersonalityDisorder' 
 
  when ( 
   primary_diagnosis like '%f63%' or 
   primary_diagnosis like '%f64%' or 
   primary_diagnosis like '%f65%' or 
   primary_diagnosis like '%f66%' or 
   primary_diagnosis like '%f68%' or 
   primary_diagnosis like '%identity%' or 
   primary_diagnosis like '%gambling%' or 
   primary_diagnosis like '%transsex%' or 
   primary_diagnosis like '%transvest%' or 
   primary_diagnosis like '%fetish%' or 
   primary_diagnosis like '%voyeur%' or 
   primary_diagnosis like '%paedophil%' or 
   primary_diagnosis like '%pedophil%' or 
   primary_diagnosis like '%masochis%' or 
   primary_diagnosis like '%psychosex%' or 
   primary_diagnosis like '%trichotill%' or 
   primary_diagnosis like '%kleptoman%' or 
   primary_diagnosis like '%pyroman%' or 
   primary_diagnosis like '%gender%') 
  then 'OtherF6Disorder' 
 
  when ( 
   primary_diagnosis like '%f00%' or 
   primary_diagnosis like '%f01%' or 
   primary_diagnosis like '%f02%' or 
   primary_diagnosis like '%f03%' or 
   primary_diagnosis like '%f04%' or 
   primary_diagnosis like '%f05%' or 
   primary_diagnosis like '%dementia%' or 
   primary_diagnosis like '%cognitive%' or 
   primary_diagnosis like '%delirium%' or 
   primary_diagnosis like '%alzheimer%' or 
   primary_diagnosis like '%lewy%') and 
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   primary_diagnosis not like '%F00-F99%' 
  then 'DementiaDelirium' 
 
  when ( 
   primary_diagnosis like '%f06%' or 
   primary_diagnosis like '%f07%' or 
   primary_diagnosis like '%f09%' or 
   primary_diagnosis like '%g0%' or 
   primary_diagnosis like '%g1%' or 
   primary_diagnosis like '%g2%' or 
   primary_diagnosis like '%g3%' or 
   primary_diagnosis like '%g4%' or 
   primary_diagnosis like '%g8%' or 
   primary_diagnosis like '%g9%' or 
   primary_diagnosis like '%s06%' or 
   primary_diagnosis like '%frontal%' or 
   primary_diagnosis like '%intracranial%' or 
   primary_diagnosis like '%brain injury%' or 
   primary_diagnosis like '%brain damage%' or 
   primary_diagnosis like '%brain disease%' or 
   primary_diagnosis like '%traumatic brain%' or 
   primary_diagnosis like '%head injury%' or 
   primary_diagnosis like '%concuss%' or 
   primary_diagnosis like '%organic%' or 
   primary_diagnosis like '%encaphal%' or 
   primary_diagnosis like '%huntingt%' or 
   primary_diagnosis like '%parkinson%' or 
   primary_diagnosis like '%neuron%' or 
   primary_diagnosis like '%sclerosis%' or 
   primary_diagnosis like '%epilep%' or 
   primary_diagnosis like '%seizure%' or 
   primary_diagnosis like '%global amnesia%') 
  then 'OtherOrganicBrainDisorder' 
 
  when ( 
   primary_diagnosis like '%f10%' or 
   primary_diagnosis like '%alcohol%') 
  then 'AlcoholMisuseDependence' 
 
  when ( 
   primary_diagnosis like '%f11%' or 
   primary_diagnosis like '%f12%' or 
   primary_diagnosis like '%f13%' or 
   primary_diagnosis like '%f14%' or 
   primary_diagnosis like '%f15%' or 
   primary_diagnosis like '%f16%' or 
   primary_diagnosis like '%f18%' or 
   primary_diagnosis like '%f19%' or 
   primary_diagnosis like '%cannabis%' or 
   primary_diagnosis like '%opioid%' or 
   primary_diagnosis like '%opiate%' or 
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   primary_diagnosis like '%cocaine%' or 
   primary_diagnosis like '%amphetamine%' or 
   primary_diagnosis like '%drug%' or 
   primary_diagnosis like '%methadone%') 
  then 'DrugMisuseDependence' 
   
  when ( 
   primary_diagnosis like '%f50%' or 
   primary_diagnosis like '%f51%' or 
   primary_diagnosis like '%f52%' or 
   primary_diagnosis like '%f53%' or 
   primary_diagnosis like '%f54%' or 
   primary_diagnosis like '%f55%' or 
   primary_diagnosis like '%f59%' or 
   primary_diagnosis like '%eating%' or 
   primary_diagnosis like '%anorexia%' or 
   primary_diagnosis like '%bulimia%' or 
   primary_diagnosis like '%somnia%' or 
   primary_diagnosis like '%sleep%' or 
   primary_diagnosis like '%nightmare%' or 
   primary_diagnosis like '%sexual%' or 
   primary_diagnosis like '%erectile%' or 
   primary_diagnosis like '%ejaculat%' or 
   primary_diagnosis like '%puerper%' or 
   primary_diagnosis like '%postnatal%' or 
   primary_diagnosis like '%postpartum%') and 
   primary_diagnosis not like '%abuse%' 
  then 'F5Disorders' 
 
  when ( 
   primary_diagnosis like '%f7%' or 
   primary_diagnosis like '%reading%' or 
   primary_diagnosis like '%spelling%' or 
   primary_diagnosis like '%mathematic%' or 
   primary_diagnosis like '%learning%') 
  then 'MentalRetardation' 
 
  when ( 
   primary_diagnosis like '%f8%' or 
   primary_diagnosis like '%pervasive 
development%' or 
   primary_diagnosis like '%pdd%' or 
   primary_diagnosis like '%autis%' or 
   primary_diagnosis like '%asd%' or 
   primary_diagnosis like '%asperger%' or 
   primary_diagnosis like '%language%' or 
   primary_diagnosis like '%speech%' or 
   primary_diagnosis like '%hearing%' or 
   primary_diagnosis like '%development%') 




  when ( 
   primary_diagnosis like '%f90%' or 
   primary_diagnosis like '%f91%' or 
   primary_diagnosis like '%f92%' or 
   primary_diagnosis like '%f93%' or 
   primary_diagnosis like '%f94%' or 
   primary_diagnosis like '%f95%' or 
   primary_diagnosis like '%f96%' or 
   primary_diagnosis like '%f97%' or 
   primary_diagnosis like '%f98%' or 
   primary_diagnosis like '%adhd%' or 
   primary_diagnosis like '%attention%' or 
   primary_diagnosis like '%hyperactivity%' or 
   primary_diagnosis like '%hyperkinetic%' or 
   primary_diagnosis like '%conduct%' or 
   primary_diagnosis like '%defiant%' or 
   primary_diagnosis like '%encopresis%' or 
   primary_diagnosis like '%enuresis%' or 
   primary_diagnosis like '%tourette%' or 
   primary_diagnosis like '%tic disorder%' or 
   primary_diagnosis like '%tic syndrome%') 
  then 'F9Disorder' 
 
  when ( 
   primary_diagnosis like '%f99%' or 
   primary_diagnosis like '%fxx%' or 
   primary_diagnosis like 'other' or 
   primary_diagnosis like 'mental illness' or 
   primary_diagnosis like 'mental disorder%' or 
   primary_diagnosis like 'mental state' or 
   primary_diagnosis like '%no Axis 1%' or 
   primary_diagnosis like '%z71.1%' or 
   primary_diagnosis like '%z0%' or 
   primary_diagnosis like '%unspecified disorder%' 
or 
   primary_diagnosis like '%unspecified mental%' 
or 
   primary_diagnosis like '%xNx%') 
  then 'UnrecordedDiagnosis' 
   
  else 'OtherDiagnosis' 
   
































      ,[source_table] 
      ,[drug] 
 
      , case 
  when ( 
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   drug like '%benper%' or 
   drug like '%anquil%' or 
   drug like '%benquil%') 
  then 'Benperidol' 
 
  when ( 
   drug like '%proch%') 
  then 'Prochlorperazine' 
 
  when ( 
   (drug like '%chlorp%' or 
   drug like '%chlop%' or 
   drug like '%largactil%') and 
   drug not like '%chlorphenamine%') 
  then 'Chlorpromazine' 
 
  when ( 
   ((drug like '%depix%' or 
   drug like '%depex%' or 
   drug like '%depox%' or 
   drug like '%flupent%') and 
   (drug like '%dec%' or 
   drug like '%depot%' or 
   drug like '%injection%' or 
   drug like '%im%' or 
   drug like '%conc%')) and 
   drug not like '%tablet%' and 
   drug not like '%capsule%' and 
   drug not like '%oral%') 
  then 'FlupentixolLAI' 
 
  when ( 
   drug like '%depix%' or 
   drug like '%depex%' or 
   drug like '%depox%' or 
   drug like '%flupent%' or 
   drug like '%fluan%') 
  then 'Flupentixol' 
 
  when ( 
   ((drug like '%haloper%' or 
   drug like '%haliper%' or 
   drug like '%dozic%' or 
   drug like '%hald%' or 
   drug like '%hadol%' or 
   drug like '%seren%') and 
   (drug like '%dec%' or 
   drug like '%depot%')) and 
   drug not like '%tablet%' and 
   drug not like '%capsule%' and 
   drug not like '%oral%') 
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  then 'HaloperidolLAI' 
 
  when ( 
   drug like '%haloper%' or 
   drug like '%haliper%' or 
   drug like '%dozic%' or 
   drug like '%hald%' or 
   drug like '%hadol%' or 
   drug like '%seren%') 
  then 'Haloperidol' 
 
  when ( 
   (drug like '%levom%' or 
   drug like '%methotrim%' or 
   drug like '%nozinan%') and 
   drug not like '%levomenthol%') 
  then 'Levomepromazine' 
 
  when ( 
   (drug like '%pericy%' or 
   drug like '%perici%' or 
   drug like '%neula%') and 
   drug not like '%neulasta%') 
  then 'Pericyazine' 
 
  when ( 
   drug like '%perph%' or 
   drug like '%fentaz%') 
  then 'Perphenazine' 
 
  when ( 
   drug like '%pimoz%' or 
   drug like 'orap%') 
  then 'Pimozide' 
 
  when ( 
   drug like 'promaz%') 
  then 'Promazine' 
 
  when ( 
   (drug like '%amis%' or 
   drug like '%ahilsul%' or 
   drug like '%amilsul%' or 
   drug like '%amosul%' or 
   drug like '%amsulp%' or 
   drug like '%amylsus%' or 
   drug like '%asulpri%' or 
   drug like '%solian%') and 
   drug not like '%lamisil%') 




  when ( 
   (drug like '%sulpi%' or 
   drug like '%sulpr%' or 
   drug like '%sulpa%' or 
   drug like '%sulpe%' or 
   drug like '%sulpo%' or 
   drug like '%sulpu%' or 
   drug like '%dolm%') and 
   drug not like '%ami%') 
  then 'Sulpiride' 
 
  when ( 
   drug like '%trifluperidol%' or 
   drug like '%triper%') 
  then 'Trifluperidol' 
 
  when ( 
   drug like '%trifl%' or 
   drug like '%stelaz%') 
  then 'Trifluoperazine' 
 
  when ( 
   ((drug like '%zucl%' or 
   drug like '%clopixol%') and 
   (drug like '%depot%' or 
   drug like '%dec%')) and 
   drug not like '%acetate%' and 
   drug not like '%acuph%' and 
   drug not like '%tablet%' and 
   drug not like '%capsule%' and 
   drug not like '%oral%') 
  then 'ZuclopenthixolLAI' 
 
  when ( 
   drug like '%zucl%' or 
   drug like '%clopixol%' or 
   drug like '%acuph%') 
  then 'Zuclopenthixol' 
 
  when ( 
   ((drug like '%maintena%' and 
   drug not like '%tablet%' and 
   drug not like '%capsule%' and 
   drug not like '%oral%') or 
   ((drug like '%arip%' or 
   drug like '%arpip%' or 
   drug like 'abil%') and 
   (drug like '%depot%' or 
   drug like '%400%'))) and 
   drug not like '%tablet%' and 
   drug not like '%capsule%' and 
2. Methods 
Page 52 of 248 
   drug not like '%oral%' and 
   drug not like '%maintenance%') 
  then 'AripiprazoleLAI' 
 
  when ( 
   drug like '%arip%' or 
   drug like '%arpip%' or 
   drug like 'abil%') 
  then 'Aripiprazole' 
 
  when ( 
   drug like '%cloz%' or 
   drug like '%cloxap%' or 
   drug like '%denz%' or 
   drug like '%zapo%') 
  then 'Clozapine' 
 
  when ( 
   (((drug like '%olanz%' or 
   drug like '%olaza%') and 
   (drug like '%depot%' or 
   drug like '%embon%')) and 
   drug not like '%tablet%' and 
   drug not like '%capsule%' and 
   drug not like '%oral%') or 
   (drug like '%zypa%' and 
   drug not like '%tablet%' and 
   drug not like '%capsule%' and 
   drug not like '%oral%')) 
  then 'OlanzapineLAI' 
 
  when ( 
   drug like '%olanz%' or 
   drug like '%olaza%' or 
   drug like '%zypr%') 
  then 'Olanzapine' 
 
  when ( 
   ((drug like '%palip%' and 
   (drug like '%depot%' or 
   drug like '%palmi%' or 
   drug like '%injection%')) and 
   drug not like '%tablet%' and 
   drug not like '%capsule%' and 
   drug not like '%oral%') or 
   (drug like '%xeplion%' and 
   drug not like '%tablet%' and 
   drug not like '%capsule%' and 
   drug not like '%oral%')) 




  when ( 
   drug like '%palip%' or 
   drug like '%inveg%') 
  then 'Paliperidone' 
 
  when ( 
   drug like '%quet%' or 
   drug like '%seroq%') 
  then 'Quetiapine' 
 
  when ( 
   ((drug like '%consta%' and 
   drug not like '%tablet%' and 
   drug not like '%capsule%' and 
   drug not like '%oral%') or 
   (drug like '%risp%' and 
   (drug like '%depot%' or 
   drug like '%injection%'))) and 
   drug not like '%tablet%' and 
   drug not like '%capsule%' and 
   drug not like '%oral%' and 
   drug not like '%crispbread%') 
  then 'RisperidoneLAI' 
 
  when ( 
   drug like '%risp%' and 
   drug not like '%crispbread%') 
  then 'Risperidone' 
 
  when ( 
   ((drug like '%fluph%' and 
   (drug like '%depot%' or 
   drug like '%dec%' or 
   drug like '%injection%')) and 
   drug not like '%tablet%' and 
   drug not like '%capsule%' and 
   drug not like '%oral%') or 
   (drug like '%modec%' and 
   drug not like '%tablet%' and 
   drug not like '%capsule%' and 
   drug not like '%oral%')) 
  then 'FluphenazineLAI' 
 
  when ( 
   drug like '%fluph%' or 
   drug like '%modit%') 
  then 'Fluphenazine' 
 
  when ( 
   drug like '%pipo%') 




  when ( 
   drug like '%asen%' or 
   drug like '%sycr%') 
  then 'Asenapine' 
 
  when ( 
   drug like '%luras%' or 
   drug like '%latud%') 
  then 'Lurasidone' 
 
  when ( 
   drug like '%zotep%' or 
   drug like '%zolep%') 
  then 'Zotepine' 
 
  when ( 
   drug like '%sertin%' or 
   drug like '%serdol%') 
  then 'Sertindole' 
 
  when ( 
   drug like '%thior%' or 
   drug like '%meller%') 
  then 'Thioridazine' 
 
  when ( 
   drug like 'loxa%') 
  then 'Loxapine' 
 
  when ( 
   drug like '%oxyper%') 
  then 'Oxypertin' 
 
  when ( 
   drug like '%drope%' or 
   drug like '%drolep%') 
  then 'Droperidol' 
 
  when ( 
   drug like '%flus%' or 
   drug like '%redep%') 
  then 'Fluspirilene' 
 
  when ( 
   drug like '%remox%' or 
   drug like '%roxiam%') 
  then 'Remoxipride' 
   
  else 'OtherDrug' 
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 end as drugrecoded 
 
      ,[drug_type] 
      ,[status] 
      ,[tense] 
      ,[start_date] 
      ,[End_Date] 
      ,[dose] 
      ,[ViewDate] 
      ,[ViewText] 
      ,[CN_Doc_ID] 
      ,[dose_value] 
      ,[dose_unit] 
      ,[frequency] 
      ,[time_unit] 
      ,[interval] 
      ,[when] 
      ,[route] 
      ,[id] 
































Benperidol  Anquil/Benquil  FGA  Oral  0.25mg‐1.5mg  1.5mg     
Chlorpromazine 
Hydrochloride 
Largactil  FGA  Oral/IM/PR 25mg‐300mg  1000mg     
Flupentixol/Flupenthixol Depixol/Fluanxol  FGA  Oral  3mg‐18mg  18mg     
Haloperidol  Dozic/Haldol/Serenace  FGA  Oral/IM  0.5mg‐15mg  30mg     
Levomepromazine  Nozinan  FGA  Oral  25mg‐1000mg  1000mg    Name changed from 
"Methotrimeprazine" 
in BNF 43 (Mar02) 
Pericyazine/Periciazine  Neulactil  FGA  Oral  25mg‐300mg  300mg     
Perphenazine  Fentazin  FGA  Oral  4mg‐24mg  24mg     
Pimozide  Orap  FGA  Oral  2mg‐20mg  20mg     





  FGA  Oral  25mg‐800mg  800mg     
Sulpiride  Dolmatil/Sulpor/Sulpitil/Sulparex FGA  Oral  200mg‐
2400mg 
2400mg     
Trifluoperazine  Stelazine  FGA  Oral  1mg‐10mg (no 
max stated) 
     




Zuclopenthixol Acetate  Clopixol/Acuphase  FGA  IM  50mg‐150mg  150mg     
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Amisulpride  Solian  SGA  Oral  50mg‐800mg  1200mg  BNF 35 
(Mar98) 
 
Aripiprazole  Abilify  SGA  Oral/IM  5mg‐15mg  30mg  BNF 48 
(Sep04) 
 
Clozapine  Clozaril/Denzapine/Zaponex  Clozapine Oral  12.5mg‐
900mg 
900mg     
Olanzapine  Zyprexa  SGA  Oral  2.5mg‐20mg  20mg  BNF 33 
(Mar97) 
 
Paliperidone  Invega  SGA  Oral  3mg‐12mg  12mg  BNF 55 
(Mar08) 
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Services for people at high risk improve
outcomes in patients with ﬁrst episode
psychosis
Fusar-Poli P, Dıaz-Caneja CM, Patel R, Valmaggia L, Byrne M,
Garety P, Shetty H, Broadbent M, Stewart R, McGuire P. Services for
people at high risk improve outcomes in patients with ﬁrst episode
psychosis.
Objective: About one-third of patients referred to services for people at
high risk for psychosis may have already developed a ﬁrst episode of
psychosis (FEP). We compared clinical outcomes in FEP patients who
presented to either high risk or conventional mental health services.
Method: Retrospective study comparing duration of hospital
admission, referral-to-diagnosis time, need for compulsory hospital
admission and frequency of admission in patients with FEP who
initially presented to a high-risk service (n = 164) to patients with FEP
who initially presented to conventional mental health services
(n = 2779). Regression models were performed, controlling for several
confounders.
Results: FEP patients who had presented to a high-risk service spent 17
fewer days in hospital [95% CI: 33.7 to (0.3)], had a shorter referral-
to-diagnosis time [B coeﬃcient 74.5 days, 95% CI: 101.9 to
(47.1)], a lower frequency of admission [IRR: 0.49 (95% CI: 0.39–
0.61)] and a lower likelihood of compulsory admission [OR: 0.52 (95%
CI: 0.34–0.81)] in the 24 months following referral, as compared to FEP
patients who were ﬁrst diagnosed at conventional services.
Conclusion: Services for people at high risk for psychosis are associated
with better clinical outcomes in patients who are already psychotic.
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Signiﬁcant outcomes
• First episode psychosis (FEP) patients who present to high-risk services have a lower frequency of
hospital admission, fewer days in hospital and a lower likelihood of compulsory admission than FEP
patients who present to conventional services.
• These better outcomes may reﬂect the engagement of patients at an earlier stage of the FEP.
• Services for people at high-risk may beneﬁt patients who are already psychotic by facilitating earlier
detection.
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• Observational study: patients were not randomly assigned to the samples that were compared.
• It was not possible to control for all treatments received from the FEP diagnosis over the follow-up
time.
• However, the use of antipsychotic exposure as proxy index of illness severity and treatment oﬀered
after the diagnosis of FEP did not aﬀect the ﬁndings.
Introduction
Over the last two decades, specialised clinical
services have been developed for people at high
risk for psychosis (1, 2). Providing clinical care at
this stage may reduce the risk of these individuals
subsequently developing a psychotic disorder (3,
4). However, although they are designed for people
who are vulnerable to psychosis, about a third of
those referred are found to already be in the ﬁrst
episode of psychosis (FEP) when they are assessed
by specialised high-risk teams (1, 5). This may
reﬂect the fact that the symptoms associated with
the high-risk state are qualitatively similar to those
of ﬁrst episode psychosis, but less severe. As soon
as a diagnosis of psychosis is conﬁrmed, high-risk
services immediately refer these patients to
specialised ﬁrst episode services, where speciﬁc
treatment can be initiated.
In the absence of a specialised service for peo-
ple at high risk, an individual with signs of
high-risk state would not usually be referred for
mental health care: a referral would only be
made if the patient was considered to be psy-
chotic. Consequently, a person who was psy-
chotic but incorrectly perceived to be at high
risk is likely to be assessed by mental health ser-
vices sooner when there is a high-risk team
available. Previous studies have highlighted that
the longer the delay between the onset of psy-
chosis and the initiation of treatment, the poorer
the outcome (6). This suggests that ﬁrst episode
patients who are inadvertently referred to high-
risk services have better clinical outcomes than
those whose ﬁrst contact is with conventional
mental health services.
Aims of the study
This study tested the hypothesis that ﬁrst epi-
sode patients who presented to a high-risk ser-
vice had better clinical outcomes compared to
those presenting to conventional mental health
services, as indexed by number and duration of
hospital admissions, referral-to-diagnosis time




A retrospective review of clinical records was per-
formed using data from the South London and
Maudsley NHS Trust (SLaM) electronic Patient
Journey System (ePJS), including all information
documented by professionals involved in each
patient’s clinical care. ePJS anonymised clinical data
from over 250 000 patients receiving secondary
mental health care are available in the SLaM
Biomedical Research Council (BRC) Case Register,
which facilitates focussed searching and data extrac-
tion from structured and unstructured text ﬁelds
within the electronic health record using the Clinical
Record Interactive Search tool (CRIS) (7).
Samples
First episode patients referred to a high-risk
service. These patients were drawn from referrals
to OASIS, a clinical service for people at high risk
for psychosis in South London (1). On average,
approximately one in three of those referred to
OASIS meet criteria for a FEP (1). Patients with
this diagnosis are assertively referred to an aﬃli-
ated clinical team specialised in the management of
ﬁrst episode psychosis. OASIS was ﬁrst imple-
mented in the boroughs of Lambeth and South-
wark before later being implemented in the
boroughs of Lewisham and Croydon. From
January 2001 to September 2011, there were 1090
referrals to OASIS. For data prior to 2007,
electronic records of clinical ﬁles were not com-
plete, but a scanned copy of the written ﬁles was
available for manual review.
Between OASIS inception and September 2011,
263 referrals received a diagnosis of psychosis. Of
those, 34 received a diagnosis of multiple episode
psychosis, whereas two patients had been referred
on two occasions to the high-risk service and were
duplicated in the referral log 10 patients initially
diagnosed with an at risk state for psychosis (at
risk mental state, ARMS) and subsequently
reported to have made the transition within
3 months were also included as ﬁrst episode psy-
chosis, because a retrospective re-assessment of
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their symptoms after they were diagnosed with
psychosis made the clinicians consider that they
were already psychotic when they were referred to
the service (5, 8). Thus, the initial ﬁrst episode
sample consisted of 237 patients. Of those, nine
cases were not available in the ePJS. After careful
clinical ﬁle review, 27 patients did not fulﬁl criteria
for a FEP: three patients were actually diagnosed
with an at risk mental state and did not make the
transition; nine were diagnosed with multiple
episode psychosis, and ﬁfteen did not receive a
primary diagnosis of psychosis (six patients were
diagnosed with aﬀective disorders without psy-
chotic symptoms, four with personality disorders,
two with adjustment disorders, one with substance
use disorders, one with attention deﬁcit hyperactiv-
ity disorder and one with a learning disability).
Thus, our sample comprised 201 patients with a
conﬁrmed diagnosis of ﬁrst episode psychosis. Of
those, in 37 cases, there was no assessment or
assertive intervention by OASIS (four patients did
not engage and there were not enough signs of con-
cern to assertively refer them to other specialised
services, whereas 33 patients had already passed
the psychosis threshold and were screened out
before the assessment took place). Thus, the ﬁnal
sample comprised 164 cases with a conﬁrmed diag-
nosis of ﬁrst episode psychosis and whose initial
management included an active intervention from
OASIS (assessment and/or assertive referral to
more appropriate services) (see Figure S1).
First episode patients who presented to conventional
mental health services. In the catchment area served
by SLaM, patients thought or identiﬁed to have
ﬁrst episode psychosis usually present to generic
adult mental health community, home treatment
and inpatient teams, or directly to specialised ﬁrst
episode services. The generic mental health teams
may subsequently refer these patients to the ﬁrst
episode services, which in SLaM include the Lam-
beth Early Onset service (LEO), Southwark Team
for Early Intervention in Psychosis (STEP), Lewi-
sham Early Intervention Service (Lewisham EIS)
and Croydon Outreach Assessment Support Team
(COAST). Like OASIS, these ﬁrst episode services
accept self-referrals and referrals made by health
and non-health agencies (9) and provide a similar
form of clinical care which focuses on assertive
patient engagement and early clinical intervention
(1). In this study, we controlled for potential diﬀer-
ences in the provision of treatment by including
borough of residence and antipsychotic exposure as
covariates in all multivariable analyses.
We compared clinical outcomes of patients
whose ﬁrst contact with mental health services
for ﬁrst episode psychosis was either with a spe-
cialised high-risk service or with conventional ser-
vices. The conventional services sample
(n = 2779) was drawn from all patients who pre-
sented for the ﬁrst time between 2007 and 2011
and received a diagnosis of ﬁrst episode psy-
chosis. The period of 2007–2011 was chosen as
2007 was the ﬁrst full year in which electronic
records were used across all SLaM services. The
sample was ﬁltered to exclude any patients who
had previously been referred to OASIS with ﬁrst
episode psychosis (in order to ensure that indi-
viduals analysed in the high-risk group were not
duplicated in the conventional services group)
and to only include patients aged between 14 and
35 at the time of referral to SLaM (to reﬂect the
inclusion criteria of the high-risk service). Most
(about 80%) of this sample (n = 2284) presented
to generic adult mental health services; a minor-
ity presented directly to ﬁrst episode teams
(n = 495). Clinical record data for the entire
sample were accessed using CRIS, a bespoke
software designed to rapidly search electronic
records (7).
Data collection
The following data were extracted from both
samples: sociodemographic characteristics (age,
gender, ethnicity, marital and employment status,
borough of residence), diagnosis, referral-to-diag-
nosis time (measured in days from the date of
referral to date of recording of diagnosis), date of
ﬁrst antipsychotic prescription, dates of hospital
admissions in a 24-month follow-up period, dates
of compulsory admissions under the UK Mental
Health Act [MHA; which regulates involuntary
admission to hospital of people diagnosed with a
mental disorder for assessment and/or treatment
(10)] in a 24-month follow-up period and the total
cumulative duration of hospital admission in a
24-month follow-up period. Ethnicity was
recorded according to categories deﬁned by the
UK Oﬃce for National Statistics (11) and docu-
mented in participants’ health records at the time
of ﬁrst presentation to OASIS or conventional
mental health services. The initial diagnosis of ﬁrst
episode psychosis was made by the treating clini-
cian according to ICD-10 criteria (12) and corre-
sponded to the following categories: schizophrenia
and related disorders [including patients diagnosed
with schizophrenia (F20), delusional disorder
(F22) and other schizophrenia-like disorders (F23,
F28 and F29)]; schizoaﬀective disorder (F25);
bipolar disorder [including patients receiving a
diagnosis of mania (F30) or bipolar disorder
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(F31)]; psychotic depression (F32.3, F33.3); drug-
related psychosis (F1x.5); other psychoses. A 24-
month follow-up period started from the date of
referral to OASIS or the conventional service
where the diagnosis of ﬁrst episode psychosis was
made. This time period was selected because it per-
mitted assessment of outcomes in the entire sam-
ple, and because the outcomes in the ﬁrst 2 years
after illness onset predict the long-term outcomes
(13).
Statistical analyses
Statistical analyses were conducted to test the
association between predictors and outcomes
using STATA 12 software (14) at a signiﬁcance
level of P < 0.05. The main exposure was
whether the patients with ﬁrst episode psychosis
had been seen by OASIS or by conventional
services. The primary outcome was the cumula-
tive duration of hospital admission (in days)
during the 24 months of follow-up. This was
chosen because in patients with psychosis, the
duration of admission indicates the degree of dis-
ability and is also the greatest contributor to the
costs of clinical care (15). Secondary outcomes
were the occurrence of compulsory admission to
hospital and the frequency of hospital admission
between 2 weeks and 24 months of follow-up.
Although it was not possible to investigate diﬀer-
ences in the duration of untreated psychosis
(DUP), as this variable was not routinely docu-
mented in clinical records, an analysis was
performed to compare referral-to-diagnosis time
between patients seen by OASIS or by conven-
tional services as a proxy measure of DUP.
Age, gender, ethnicity, marital status, employ-
ment status, borough of residence, diagnosis and
exposure to antipsychotics were included as
covariates in multivariable analyses. Where miss-
ing data were present in covariates, these were
included as explanatory variables in multivariable
analyses. Further sensitivity analyses were per-
formed including only participants with complete
covariate data to assess the potential impact of
missing data.
A sensitivity analysis was performed to test
whether there were diﬀerences between OASIS
data collected before and after 2007. Because the
conventional services group included ﬁrst episode
services, supplementary three-way analyses were
performed to compare outcomes in patients who
presented to the OASIS, ﬁrst episode services and
other SLaM services in order to ascertain any
potential diﬀerences in outcomes associated
with ﬁrst episode services compared to other
SLaM services.
For descriptive analyses, continuous variables
were expressed as mean and standard deviation
(SD); categorical variables were expressed as
frequencies and percentages. Comparison of age
distribution between groups was tested using
Mann–Witney’s U-test for two-way analyses and
ANOVA for three-way analyses. Chi-square tests
were used to compare groups for discrete cate-
gorical variables. No diﬀerences in P values were
found when applying Fisher’s exact test to
contrasts where individual cell frequency was
fewer than ﬁve. Owing to non-proportionality of
hazards, multivariable regression methods were
employed at varying periods of follow-up rather
than utilising Cox regression for survival analy-
sis. Multiple linear regression models were used
to assess the association between engagement by
the high-risk service (vs. conventional mental
health services) and number of days spent as an
in-patient in the ﬁrst 12 months and 24 months
after referral to SLaM, and time to diagnosis
from referral to the high-risk service or conven-
tional mental health services. Multivariable bin-
ary logistic regression models were used to
assess the association of initial management by
the high-risk service (vs. conventional mental
health services) with compulsory hospital admis-
sion under the UK Mental Health Act at
2 weeks, 1 month, 3 months, 6 months,
12 months and 24 months after referral to ser-
vices. Multivariable Poisson regression models
were used to assess the association of initial
management by the high-risk service or conven-
tional mental health services with the number of
admissions at 2 weeks, 1, 3, 6, 12 and
24 months after referral to services. Poisson
regression to analyse number of hospital admis-
sions was employed rather than binary logistic
regression for any hospital admission to over-
come the ceiling eﬀect encountered by the latter
method for individuals with multiple hospital
admissions during the follow-up period. Despite
a large proportion of zero values for number of
hospital admissions, zero-inﬂated Poisson models
were not meaningfully diﬀerent to standard
models (Vuong P > 0.05 for all models). For
variables with variance greater than mean, nega-
tive binomial regression did not yield meaning-
fully diﬀerent results to Poisson models
(12 months IRR 0.43; 95% CI: 0.32–0.58,
24 months IRR 0.47; 95% CI: 0.36–0.62). For
consistency, standard Poisson regression esti-




Demographic and diagnostic differences between the samples
The ﬁrst episode patients that were referred to
OASIS were younger and more likely to be male,
to belong to an ethnic minority, and to have a
schizophrenia spectrum disorder (as opposed to an
aﬀective psychosis) than those in the conventional
services sample (Table 1).
Primary outcome measure
Multiple linear regression analysis (Table 2)
revealed that ﬁrst episode patients who had been
ﬁrst seen by OASIS spent 17 fewer days in hospital
in the 24 months following referral than those ﬁrst
seen by conventional services.
Secondary outcome measures
The median referral-to-diagnosis time for people
with ﬁrst episode psychosis seen by OASIS was
shorter than in those presenting to conventional
services (Figure 1). Multiple linear regression anal-
ysis comparing OASIS with conventional services
corroborated this ﬁnding [B coeﬃcient 74.5 days,
95% CI: 101.9–(47.1)]. Multivariable logistic
regression analysis (Table 3) showed that among
patients presenting with ﬁrst episode psychosis,
those initially seen by OASIS had a reduced likeli-
hood of compulsory hospital admission in the
following 24 months (Figure 2). Multivariable
Poisson regression analysis also showed that the
patients presenting to OASIS had a lower fre-
quency of admission during the follow-up period
(Figure 3 and Table 3).
Sensitivity and supplementary analyses
A sensitivity analysis comparing the data from
OASIS collected between 2001 and 2006 and
between 2007 and 2011 (Table S1) did not reveal
any signiﬁcant diﬀerences. Sensitivity analyses
revealed that there were missing covariate data
for ethnicity, marital status and employment sta-
tus, particularly for the conventional service sam-
ple (Table S2). However, multivariable analyses
including only participants with full covariate data
(Table S3a and S3b) did not signiﬁcantly diﬀer
from analyses including missing data as explana-
tory variables (Table 2 and Table 3). Supplemen-
tary three-way analyses excluding ﬁrst episode
services (Table S5a/S6a/S7) revealed similar out-
comes to the main analyses. A comparison of ﬁrst
episode services with other conventional services
showed an association of ﬁrst episode services with
reduced duration of hospital admission (Table
S5b) and compulsory hospital admission, a trend
towards reduced number of hospital admissions
(Table S6b) and no signiﬁcant diﬀerence in refer-
ral-to-diagnosis time (Table S7). A comparison of
OASIS with ﬁrst episode services revealed a
non-signiﬁcant trend towards reduced duration of
hospital admission (Table S5c), reduced likelihood
of compulsory hospital admission and a signiﬁcant
Table 1. Characteristics of patients who were assessed and diagnosed by the
high-risk service or conventional mental health services
High-risk
service (n = 164)
Conventional
mental health
services (n = 2779)
Mean age (SD) 23.6 (4.88) 25.1 (5.95) z = 3.5
P < 0.001




Caribbean/Black African) 93 (56.7%) 942 (35.6%) v2 = 30.0
Asian 7 (4.3%) 222 (8.4%) P < 0.001
White 51 (31.1%) 1175 (44.5%)
Other 13 (7.9%) 304 (11.5%)
Marital status (%)
Married/cohabiting 12 (7.5%) 275 (11.0%) v2 = 2.4
Divorced/separated 5 (3.1%) 99 (4.0%) P = 0.31
Single 144 (89.4%) 2129 (85.1%)
Employment status (%)
Employed 36 (22.9%) 145 (19.1%) v2 = 2.4
Student 31 (19.8% 188 (24.8%) P = 0.31
Unemployed 90 (57.3%) 426 (56.1%)
Initial diagnosis (%)
Schizophrenia spectrum 123 (75.0%) 1642 (59.1%)
Bipolar disorder 8 (4.9%) 142 (5.1%)
Psychotic depression 6 (3.7%) 312 (11.2%) v2 = 21.0
Schizoaffective disorder 1 (0.6%) 90 (3.2%) P = 0.001
Drug-related psychosis 5 (3.1%) 157 (5.7%)
Other psychosis 21 (12.8%) 436 (15.7%)
Borough of residence (%)
Lambeth 111 (67.7%) 473 (17.0%)
Southwark 40 (24.4%) 472 (17.0%) v2 = 292.9
Lewisham 11 (6.7%) 442 (15.9%) P < 0.001
Croydon 2 (1.2%) 498 (17.9%)
Other borough 0 (0.0%) 894 (32.2%)
SD, standard deviation.
Table 2. Primary outcome: association of prior contact with the high-risk service
(n = 164) compared to conventional mental health services (n = 2779) on number
of days spent in hospital
Cumulative change in number of days
spent in hospital B coefficient (95% CI)
12 months 12.7 (22.5 to (2.8))
24 months 17.0 (33.7 to (0.3))
Multiple linear regression adjusted for age, gender, ethnicity, marital status,
employment status, diagnosis, borough of residence and whether receiving antipsy-
chotic medication. Follow-up period commenced from date of referral to the high-
risk service or to conventional mental health services.
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association with reduced number of hospital
admissions (Table S6c) and signiﬁcant reduction in
referral-to-diagnosis time (Table S7).
Discussion
To our knowledge, this is the ﬁrst study to assess
the association of presentation to high-risk services
on the outcome of patients referred with a provi-
sional diagnosis of a high-risk state, but found to
have ﬁrst episode psychosis when assessed by the
high-risk team. We compared clinical outcomes in
this group with those in patients with ﬁrst episode
psychosis who presented to generic mental health
services, which included specialised ﬁrst episode
teams. We found that in the 2 years following
presentation, patients who initially presented to
a high-risk service required fewer hospital
admissions were less likely to require compulsory
admission and spent fewer days in hospital. These
results were independent of diﬀerences in age,
gender, ethnicity, marital and employment status,
borough of residence, psychotic diagnosis and
previous exposure to antipsychotic drugs.
The patients who were initially seen by the
high-risk team may have been referred to mental
healthcare services earlier than they would have
been if a high-risk team had not been available.
The referrers thought (incorrectly) that these indi-
viduals were at high risk for psychosis. However,
once they had been fully assessed by a specialist
team they were found to be already psychotic. This
is relatively common among referrals to high-risk
services (1), as it is often diﬃcult to diﬀerentiate
between the high-risk state and the early stages of
ﬁrst episode psychosis: the symptoms are qualita-
tively similar, diﬀering only in severity, and the full
clinical picture may not emerge until there has
been a detailed and lengthy assessment (16). When
there is no high-risk service, a patient that is per-
ceived as vulnerable but not frankly psychotic may
not be referred to mental health services, as these
do not conventionally oﬀer clinical support for this
group.
The ﬁrst episode patients who were referred to
OASIS may have been more likely to have been
mistaken for being in a high risk as opposed to a
psychotic state because their clinical presentation
did not conform to that typically encountered in
ﬁrst episode patients. In the UK, there is often a
long period between the onset of psychosis and
ﬁrst presentation, by which time the patient is
acutely disturbed with severe psychotic symptoms.
Patients who present at an earlier stage with less
overt psychotic symptoms, or whose symptoms
had an insidious rather than an acute onset may be
more likely to be misclassiﬁed as high risk. Further



















High risk service Conventional mental health service
P < 0.001
Fig. 1. Time to diagnosis in high-risk
service compared to conventional
mental health services.
Table 3. Secondary outcomes: association of prior contact with the high-risk
service (n = 164) compared to conventional mental health services (n = 2779) on
compulsory admission under the UK Mental Health Act and the number of hospital
admissions in a given time period
Any compulsory hospital
admission* Odds ratio (95% CI)
Number of hospital admissions†
Incidence rate ratio (95% CI)
2 weeks 0.26 (0.10–0.66) 0.13 (0.06–0.30)
1 month 0.29 (0.13–0.62) 0.16 (0.08–0.29)
3 months 0.45 (0.26–0.78) 0.27 (0.18–0.41)
6 months 0.46 (0.28–0.78) 0.34 (0.24–0.48)
12 months 0.53 (0.33–0.84) 0.41 (0.31–0.55)
24 months 0.52 (0.34–0.81) 0.49 (0.39–0.61)
*Multivariable binary logistic regression.
†Multivariable Poisson regression.
All analyses are adjusted for age, gender, ethnicity, marital status, employment
status, diagnosis, borough of residence and whether receiving antipsychotic medica-
tion. Follow-up period commenced from date of referral to the high-risk service or to
conventional mental health services.
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group may help to elucidate whether this is the
case. Analysis of the demographic features of the
two samples in the present study indicated that the
patients initially seen by OASIS were signiﬁcantly
younger than those presenting to conventional ser-
vices. This is consistent with the notion that these
patients may have presented at an earlier stage of
the ﬁrst episode.
We also considered whether the better outcomes
in the OASIS sample might reﬂect the presence of
sociodemographic features associated with a rela-
tively good prognosis in-patients with ﬁrst episode
psychosis, such as female gender (17), not
belonging to an ethnic minority (18) or having a
non-schizophrenic psychotic disorder (17). How-
ever, comparison of the demographic data from
the two samples indicated that the reverse applied:
the patients who presented to OASIS were
younger, and more likely to be male, from an
ethnic minority and to have a schizophreniform
psychosis. This may reﬂect the ethos of high-risk
services like OASIS, which mainly operate in a
primary care setting, and are designed to be as
accessible to patients and referrers as possible.
Referrals can be made from any health or non-
health agency and via self-referral, and clients are
can be seen in their local GP surgery, at home or at
a team base in the community. These features may
particularly facilitate access to mental health care
among patients who are young or who belong to
ethnic minority groups (1).
A further potential factor, independent of the
nature of clinical features, is that as soon as the
patients seen by OASIS had been identiﬁed as
having ﬁrst episode psychosis, they were immedi-
ately and assertively referred to specialised ﬁrst
episode teams, with an unequivocal diagnosis of
ﬁrst episode psychosis (and not a high-risk state,
or any other diagnosis) that was based on a
detailed specialist assessment. This ‘fast-track’
form of referral with a clear diagnosis to a clo-
















Time elapsed following date of accepted referral
High risk service Conventional mental health service
Fig. 2. Cumulative percentage of
patients detained under Mental Health
Act assessed and diagnosed by the
high-risk service (n = 164) compared to


























Time elapsed following referral to clinical service
High risk service Conventional mental health service
Fig. 3. Mean number of hospital
admissions following referral to the
high-risk service (n = 164) and
conventional mental health services
(n = 2779).
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resulted in a relatively rapid acceptance of the
diagnosis by the receiving team (without the need
for further assessment), and relatively quicker ini-
tiation of antipsychotic treatment. Delays in
accessing specialised services for ﬁrst episode psy-
chosis can signiﬁcantly increase the interval
between the onset of psychosis and the initiation
of antipsychotic treatment, the DUP (19, 20).
The greater its duration, the greater the duration
of hospitalisation and the risk of rehospitalisa-
tion during the ﬁrst 2 years after referral (21).
Although most of the patients who presented to
conventional services were seen by generic mental
health teams, about 20% of this sample contacted
specialised ﬁrst episode teams directly. We then
tested whether the eﬀect of presenting to a high-
risk service was still evident when compared to
presenting to a ﬁrst episode, as opposed to a
generic service. Supplementary three-way analyses
showed that the there was still a signiﬁcant reduc-
tion in number of hospital admissions, and in the
referral-to-diagnosis time in those who presented
to the high-risk service, as well as trends towards
reduced duration of hospital admission, and
reduced rates of compulsory admission. The
persistence of diﬀerences relative to patients who
presented directly to ﬁrst episode teams suggests
that the beneﬁcial eﬀects of presenting to high-risk
services are not simply a function of being ‘fast-
tracked’ to a specialised ﬁrst episode care. Rather,
it is consistent with the notion that high-risk
services are particularly likely to be referred
patients who are in the early stages of the ﬁrst
episode or whose clinical presentation does not
immediately suggest that they are psychotic.
In the present study, patients who were initially
seen by a high-risk service had fewer hospital
admissions and spent 17 fewer days in hospital
within the ﬁrst 2 years than patients who presented
to conventional services. Hospital admissions are
the single largest contributor to the direct costs
associated with the care of schizophrenia (15). In
the UK, the average cost of a night in a psychiatric
bed is £350 GBP (15), and an average cost of
£12 198 GBP per admission has been estimated
(22). We also found that the patients who were
initially seen by a high-risk service were less likely
to require a compulsory admission under the
Mental Health Act. Compulsory admissions are
usually longer than voluntary admissions and are
associated with higher direct costs (22). In addi-
tion, the experience of compulsory admission can
be a negative one for both the patient and their
family: this may have an adverse eﬀect on the
patient’s subsequent engagement with mental
health services and their adherence to treatment,
and is associated with an increased risk of further
compulsory admissions (23).
This was an observational study, and patients
were not randomly assigned to the two samples
that were compared. However, as high-risk
services are not designed to manage ﬁrst episode
patients, a study in which patients were randomly
allocated to high risk and conventional teams
would be impractical and ethically problematic. In
our study, we investigated variations in clinical
outcomes in a single provider of mental health care
(SLaM). Another approach which could be investi-
gated in future studies is to compare outcomes in
diﬀerent providers of mental health care depending
on whether or not they provide high-risk clinical
services. However, such an approach would not
necessarily overcome these limitations because of
heterogeneity due to diﬀerences in characteristics
between diﬀerent mental healthcare providers. We
performed a retrospective assessment of the data
and used information that had been entered by
clinicians in the patients’ records. Data completion
was satisfactory for all the relevant outcomes, and
sensitivity analysis did not show signiﬁcant diﬀer-
ences with respect to missing data. However, the
information in the clinical records did not include
a standardised measure of illness severity at the
time of the ﬁrst episode psychosis diagnosis, and
we were therefore unable to control for this poten-
tially confounding factor in the analysis. However,
we chose not to employ a propensity score
approach as there is evidence that this method
does not overcome the limitation of residual
confounding (24). We were also unable to control
for all treatments received from the ﬁrst episode
psychosis diagnosis over the follow-up time. How-
ever, the use of antipsychotic exposure as proxy
index of treatment oﬀered after the ﬁrst episode
psychosis diagnosis did not aﬀect our ﬁndings.
This study provides the ﬁrst evidence that ser-
vices designed for people at high risk of psychosis
may be associated with better outcomes in patients
who are already psychotic, but were referred
because they were thought to be at high risk. This
may result from the referral of patients at a
relatively early stage of the ﬁrst episode and from
the fast-tracking of these patients to specialised
ﬁrst episode services. Both are likely to reduce the
interval between the onset of psychosis and the
initiation of antipsychotic treatment.
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sion under the UK Mental Health Act and the
number of hospital admissions in a given time per-
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covariate data.
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SERVICES FOR PEOPLE AT HIGH RISK IMPROVE OUTCOME IN PATIENTS 
WITH FIRST EPISODE PSYCHOSIS – SUPPLEMENTARY MATERIAL 
 



















Abbreviations: ARMS= At Risk Mental State, FEP= First Episode Psychosis. 
  
Referrals receiving an initial diagnosis of psychosis 
N=263 
Patients with an initial diagnosis of FEP  
N=237 
Patients with a confirmed diagnosis of FEP in whom the 
high risk service played an active role 
N=164
Patients with a confirmed diagnosis of FEP 
N=201                                                
289 referrals diagnosed with ARMS 
248 diagnosed with other disorders 
28 no psychopathology 
262 not assessed 
34 patients diagnosed with multiple-
episode psychosis 
2 patients repeated in the referral log 
9 not available in the clinical files 
27 did not fulfill criteria for FEP after 
careful clinical file review 
33 found to have passed the threshold 
and screened out 
4 did not engage  
10 patients initially diagnosed with 
ARMS making the transition within 
<3 months
Referrals to the high risk service (2001-2011) 
N=1090 
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eTable1: Characteristics of patients referred to the high risk service in 2001-2006 compared to 
patients referred in 2007-2011 
 
High risk service 
2001-2006 
(n=72) 









Male gender (%) 53 (73.6%) 59 (64.1%) χ2=1.68 p=0.20 
Ethnicity (%) 
Black (Black British/ Black 


































































Initial diagnosis (%) 
- Schizophrenia-like 
- Bipolar disorder 
- Psychotic depression 
- Schizoaffective disorder 
- Drug-related psychosis 
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eTable 2: Characteristics of patients who were assessed and diagnosed by the high risk service or 
conventional mental health services including missing covariate data 










Male gender (%) 112 (68.3%) 1663 (59.8%) χ2=4.6 p=0.03 
Ethnicity (%) 
Black (Black British/ Black 
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eTable 3a: Primary outcome: association of prior contact with the high risk service (n=164) 
compared to conventional mental health services (n=2779) on number of days spent in hospital. 
Analysis including only participants with full covariate data. 
 Cumulative change in number of days spent in hospital 
B coefficient (95% CI) 
12 months -15.6 days (95% CI -25.2 to -6.0) 
24 months -22.2 days (95% CI -38.5 to -6.0) 
Multiple linear regression adjusted for age, gender, ethnicity, marital status, employment status, diagnosis, borough 
of residence and whether receiving antipsychotic medication 
Follow-up period commenced from date of referral to the high risk service or to conventional mental health services 
 
eTable 3b: Secondary outcomes: association of prior contact with the high risk service (n=164) 
compared to conventional mental health services (n=2779) on compulsory admission under the UK 
Mental Health Act and the number of hospital admissions in a given time period. Analysis including 
only participants with full covariate data. 
 Any compulsory hospital admission* 
Odds ratio (95% CI) 
Number of hospital admissions** 
Incidence rate ratio (95% CI) 
2 weeks 0.16 (0.05 to 0.48) 0.12 (0.05 to 0.29) 
1 month 0.18 (0.08 to 0.45) 0.15 (0.08 to 0.30) 
3 months 0.32 (0.17 to 0.61) 0.29 (0.19 to 0.44) 
6 months 0.33 (0.18 to 0.60) 0.36 (0.25 to 0.52) 
12 months 0.40 (0.24 to 0.69) 0.43 (0.32 to 0.58) 
24 months 0.42 (0.26 to 0.70) 0.48 (0.38 to 0.62) 
*Multivariable binary logistic regression 
**Multivariable Poisson regression 
All analyses are adjusted for age, gender, ethnicity, marital status, employment status, diagnosis, borough of residence 
and whether receiving antipsychotic medication 
Follow-up period commenced from date of referral to the high risk service or to conventional mental health services 
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eTable 4: Characteristics of patients who were assessed and diagnosed by the high risk service, first 
episode service or to other conventional mental health services 
 High risk service (n=164) 













Male gender (%) 112 (68.3%) 338 (68.3%) 1325 (58.0%) χ2=22.5 p<0.001 
Ethnicity (%) 
Black (Black British/ 
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eTable 5a: Association of prior contact with the high risk service (n=164) compared to other 
conventional mental health services, not including first episode services (n=2284) on number of days 
spent in hospital. 
 High risk service 
Cumulative change in number of days spent in hospital 
B coefficient (95% CI) 
12 months -15.3 (-13.3 to -1.6) 
24 months -20.7 (-37.8 to -3.7) 
Multiple linear regression adjusted for age, gender, ethnicity, marital status, employment status, diagnosis, 
borough of residence and whether receiving antipsychotic medication 
Follow-up period commenced from date of referral to the high risk service or to other conventional mental 
health services 
 
eTable 5b: Association of prior contact with the first episode service (n=495) compared to other 
conventional mental health services (n=2284) on number of days spent in hospital. 
 First episode service 
Cumulative change in number of days spent in hospital 
B coefficient (95% CI) 
12 months -7.4 (-13.3 to -1.6) 
24 months -10.5 (-20.5 to -0.6) 
Multiple linear regression adjusted for age, gender, ethnicity, marital status, employment status, diagnosis, 
borough of residence and whether receiving antipsychotic medication 
Follow-up period commenced from date of referral to the first episode service or to other conventional 
mental health services 
 
eTable 5c: Association of prior contact with the high risk service (n=164) compared to the first 
episode service (n=495) on number of days spent in hospital. 
 High risk service 
Cumulative change in number of days spent in hospital 
B coefficient (95% CI) 
12 months -7.9 (-18.4 to 2.7) 
24 months -10.2 (-28.1 to 7.7) 
Multiple linear regression adjusted for age, gender, ethnicity, marital status, employment status, diagnosis, 
borough of residence and whether receiving antipsychotic medication 
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eTable 6a: Association of prior contact with the high risk service (n=164) compared to other 
conventional mental health services, not including first episode services (n=2284) on compulsory 
admission under the UK Mental Health Act and the number of hospital admissions in a given time 
period. 
 Any compulsory hospital admission* 
Odds ratio (95% CI) 
Number of hospital admissions** 
Incidence rate ratio (95% CI) 
2 weeks 0.20 (0.08 to 0.53) 0.13 (0.06 to 0.28) 
1 month 0.23 (0.10 to 0.50) 0.15 (0.08 to 0.28) 
3 months 0.37 (0.21 to 0.65) 0.26 (0.17 to 0.39) 
6 months 0.39 (0.23 to 0.66) 0.33 (0.23 to 0.46) 
12 months 0.46 (0.28 to 0.73) 0.40 (0.30 to 0.53) 
24 months 0.48 (0.31 to 0.75) 0.47 (0.37 to 0.59) 
*Multivariable binary logistic regression 
**Multivariable Poisson regression 
All analyses are adjusted for age, gender, ethnicity, marital status, employment status, diagnosis, borough 
of residence and whether receiving antipsychotic medication 
Follow-up period commenced from date of referral to the high risk service or to other conventional mental 
health services 
 
eTable 6b: Association of prior contact with the first episode service (n=495) compared to other 
conventional mental health services (n=2284) on compulsory admission under the UK Mental Health 
Act and the number of hospital admissions in a given time period. 
 Any compulsory hospital admission* 
Odds ratio (95% CI) 
Number of hospital admissions** 
Incidence rate ratio (95% CI) 
2 weeks 0.46 (0.33 to 0.65) 0.85 (0.70 to 1.02) 
1 month 0.52 (0.39 to 0.70) 0.84 (0.72 to 0.99) 
3 months 0.61 (0.46 to 0.80) 0.89 (0.77 to 1.02) 
6 months 0.62 (0.48 to 0.80) 0.88 (0.77 to 1.01) 
12 months 0.69 (0.54 to 0.88) 0.91 (0.80 to 1.03) 
24 months 0.81 (0.64 to 1.02) 0.91 (0.82 to 1.02) 
*Multivariable binary logistic regression 
**Multivariable Poisson regression 
All analyses are adjusted for age, gender, ethnicity, marital status, employment status, diagnosis, borough 
of residence and whether receiving antipsychotic medication 
Follow-up period commenced from date of referral to the first episode service or to other conventional 
mental health services 
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eTable 6c: Association of prior contact with the high risk service (n=164) compared to the first 
episode service (n=495) on compulsory admission under the UK Mental Health Act and the number 
of hospital admissions in a given time period. 
 Any compulsory hospital admission* 
Odds ratio (95% CI) 
Number of hospital admissions** 
Incidence rate ratio (95% CI) 
2 weeks 0.44 (0.16 to 1.17) 0.15 (0.06 to 0.34) 
1 month 0.44 (0.20 to 0.98) 0.17 (0.09 to 0.33) 
3 months 0.61 (0.34 to 1.09) 0.29 (0.19 to 0.45) 
6 months 0.62 (0.36 to 1.08) 0.37 (0.26 to 0.53) 
12 months 0.66 (0.40 to 1.08) 0.44 (0.33 to 0.59) 
24 months 0.59 (0.38 to 0.94) 0.51 (0.40 to 0.65) 
*Multivariable binary logistic regression 
**Multivariable Poisson regression 
All analyses are adjusted for age, gender, ethnicity, marital status, employment status, diagnosis, borough 
of residence and whether receiving antipsychotic medication 
Follow-up period commenced from date of referral to the high risk service or to the first episode service 
 
eTable 7: Association of prior contact with the high risk service (n=164), first episode service (n=495) 
and other conventional mental health services (n=2284) on referral-to-diagnosis time from referral 
to services. 
 Change in referral-to-diagnosis time 
B coefficient (95% CI) 
High risk vs. other conventional mental health services -70.3 days (-98.3 to -42.3) 
First episode vs. other conventional mental health services 12.0 days (-4.3 to 28.4) 
High risk vs. first episode services -82.3 days (-111.7 to -52.9) 
Multiple linear regression adjusted for age, gender, ethnicity, marital status, employment status, diagnosis, 













select brcid,accepted_date,spell  
from ( 
 select distinct brcid,accepted_date,ROW_NUMBER() 
 over (partition by brcid order by accepted_date) spell 
 from [brhnsql094].[SQLCRIS].[dbo].[Referral] r  
 where  
 Accepted_Date>='1 Jan 1900' 
 and Referral_Status_ID not like 'rejected' 
    ) a 




















SELECT     a.brcid, accepted_date, b.diagnosis_date 
Dateoffirstpsychosisdiagnosis, b.primary_diagnosis Firstpsychosisdiagnosis 
FROM         RPatel.rp_firstreferral_2007_2012 a LEFT JOIN 
  (SELECT     brcid, diagnosis_date, primary_diagnosis 
  FROM          (SELECT     brcid, primary_diagnosis, diagnosis_date, 
source_table, ROW_NUMBER() OVER (partition BY brcid 
  ORDER BY diagnosis_date) AS dn 
  FROM          SQLCrisImport.dbo.diagnosis_combined 
  WHERE      (primary_diagnosis LIKE '%psychotic%' OR 
  primary_diagnosis LIKE '%psychosis%' OR 
  primary_diagnosis LIKE '%with psyc%' OR 
  primary_diagnosis LIKE '%schizophreni%' OR 
  primary_diagnosis LIKE '%scizophreni%' OR 
  primary_diagnosis LIKE '%schizotyp%' OR 
  primary_diagnosis LIKE '%scizotyp%' OR 
  primary_diagnosis LIKE '%delusion%' OR 
  primary_diagnosis LIKE '%hallucin%' OR 
  primary_diagnosis LIKE '%thought disorder%' OR 
  primary_diagnosis LIKE '%first rank%' OR 
  primary_diagnosis LIKE '%schizoaffect%' OR 
  primary_diagnosis LIKE '%scizoaffect%' OR 
  primary_diagnosis LIKE '%mania%' OR 
  primary_diagnosis LIKE '%manic%' OR 
  primary_diagnosis LIKE '%f20%' OR 
  primary_diagnosis LIKE '%f21%' OR 
  primary_diagnosis LIKE '%f22%' OR 
  primary_diagnosis LIKE '%f23%' OR 
  primary_diagnosis LIKE '%f24%' OR 
  primary_diagnosis LIKE '%f25%' OR 
  primary_diagnosis LIKE '%f28%' OR 
  primary_diagnosis LIKE '%f29%' OR 
  primary_diagnosis LIKE '%f30%' OR 
  primary_diagnosis LIKE '%f31.2%' OR 
  primary_diagnosis LIKE '%f32.3%' OR 
  primary_diagnosis LIKE '%f33.3%') AND primary_diagnosis NOT LIKE 
'%without psyc%' AND  
3. Clinical outcomes in people with first episode psychosis who present to high‐risk clinical services 
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  primary_diagnosis NOT LIKE '%personality%' AND primary_diagnosis NOT LIKE 
'%trichotil%' AND  
  primary_diagnosis NOT LIKE '%kleptomani%' AND primary_diagnosis NOT LIKE 
'%hypomani%' AND diagnosis_date BETWEEN  
  '01-jan-2007' AND '31-dec-2012') AS d 
WHERE dn = 1) b ON a.BrcId = b.brcid 














    a.[accepted_date], 
    h.Accepted_Date Dateofclosestteamepisode, 
    [Dateoffirstpsychosisdiagnosis], 
    [Firstpsychosisdiagnosis] Firstpsychosisdiagnosisraw, 
 case 
  when ( 
   Firstpsychosisdiagnosis like '%schizophreni%' or 
   Firstpsychosisdiagnosis like '%scizophreni%' or 
   Firstpsychosisdiagnosis like '%schizotyp%' or 
   Firstpsychosisdiagnosis like '%scizotyp%' or 
   Firstpsychosisdiagnosis like '%f20%' or 
   Firstpsychosisdiagnosis like '%f21%' or 
   Firstpsychosisdiagnosis like '%f22%' or 
   Firstpsychosisdiagnosis like '%f23%' or 
   Firstpsychosisdiagnosis like '%f24%' or 
   Firstpsychosisdiagnosis like '%f28%' or 
   Firstpsychosisdiagnosis like '%f29%') 




  when ( 
   Firstpsychosisdiagnosis like '%schizoaffect%' or 
   Firstpsychosisdiagnosis like '%scizoaffect%' or 
   Firstpsychosisdiagnosis like '%f25%') 
  then 'Schizoaffective' 
 
  when ( 
   Firstpsychosisdiagnosis like '%f30%' or 
   Firstpsychosisdiagnosis like '%f31%' or 
   Firstpsychosisdiagnosis like '%manic%' or 
   Firstpsychosisdiagnosis like '%mania%' or 
   Firstpsychosisdiagnosis like '%bipolar%' or 
   Firstpsychosisdiagnosis like '%bpad%' or 
   Firstpsychosisdiagnosis like '%affective disorder%' 
or 
   Firstpsychosisdiagnosis like '%mixed affective%') 
and 
   Firstpsychosisdiagnosis not like 
'%trichotillomania%' and 
   Firstpsychosisdiagnosis not like '%kleptomania%' 
  then 'Bipolar' 
 
  when ( 
   Firstpsychosisdiagnosis like '%psychosis%' or 
   Firstpsychosisdiagnosis like '%psychotic%' or 
   Firstpsychosisdiagnosis like '%with psyc%' or 
   Firstpsychosisdiagnosis like '%f32.3%' or 
   Firstpsychosisdiagnosis like '%f33.3%') and 
   (Firstpsychosisdiagnosis like '%depress%' or 
   Firstpsychosisdiagnosis like '%f32%' or 
   Firstpsychosisdiagnosis like '%f33%') and 
   Firstpsychosisdiagnosis not like '%without%' 
  then 'PsychoticDepression' 
 
  when ( 
   Firstpsychosisdiagnosis like '%drug%' or 
   Firstpsychosisdiagnosis like '%alcohol%' or 
   Firstpsychosisdiagnosis like '%opioid%' or 
   Firstpsychosisdiagnosis like '%opiate%' or 
   Firstpsychosisdiagnosis like '%cannabi%' or 
   Firstpsychosisdiagnosis like '%benzo%' or 
   Firstpsychosisdiagnosis like '%hallucinogen%' or 
   Firstpsychosisdiagnosis like '%cocaine%' or 
   Firstpsychosisdiagnosis like '%cannabis%' or 
   Firstpsychosisdiagnosis like '%f10%' or 
   Firstpsychosisdiagnosis like '%f11%' or 
   Firstpsychosisdiagnosis like '%f12%' or 
   Firstpsychosisdiagnosis like '%f13%' or 
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   Firstpsychosisdiagnosis like '%f14%' or 
   Firstpsychosisdiagnosis like '%f15%' or 
   Firstpsychosisdiagnosis like '%f16%' or 
   Firstpsychosisdiagnosis like '%f17%' or 
   Firstpsychosisdiagnosis like '%f18%' or 
   Firstpsychosisdiagnosis like '%f19%') 
  then 'F1x.5DrugPsyc' 
 
  else 'OtherPsychosis' 
   
 end as Firstpsychosisdiagnosisrecode 
 
  FROM [SQLCRIS_User].[RPatel].[rp_firstreferral_psychosis_2007_2012] a 
   
left join SQLCris.dbo.Team_episode h on h.CN_Doc_ID= 
(select top 1 CN_Doc_ID from SQLCris.dbo.Team_episode h1 where 
h1.BrcId=a.BrcId and (h1.Accepted_Date <=a.Dateoffirstpsychosisdiagnosis) 






























    la_name Borough, 
 DATEDIFF(day,[accepted_date],[Dateoffirstpsychosisdiagnosis]) 
DiagnosticDelayInDays, 
 floor((datediff (day, p.cleaneddateofbirth , cast (accepted_date as 
datetime))/365)) age, 
 p.Gender_ID  Gender, 
 p.ethnicitycleaned ethnicity, 
 p.Marital_Status_ID marital_status, 
 p.Employment_ID Employment_status, 
 p.Housing_Status Accommodation_status, 
       case when ( 
  select distinct brcid 
  from 
SQLCRIS_User.RPatel.rp_firstreferral_psychosis_teamwardbefore_2007_2012 
  where ( 
   Location_Name like '%COAST%' or 
   Location_Name like '%Leo Community%' or 
   Location_Name like '%Leo Crisis%' or 
   Location_Name like '%Lewisham Early%' or 
   Location_Name like '%STEP%') 
   and 
   brcid=r.brcid 
  ) IS not null then 1 else 0 end PriorEISCommunity, 
       case when ( 
  select distinct brcid 
  from 
SQLCRIS_User.RPatel.rp_firstreferral_psychosis_teamwardbefore_2007_2012 
  where ( 
   Location_Name like '%Leo Unit%') 
   and 
   brcid=r.brcid 
  ) IS not null then 1 else 0 end PriorEISInpatientLEO, 
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       case when ( 
  select distinct brcid 
  from 
SQLCRIS_User.RPatel.rp_firstreferral_psychosis_teamwardbefore_2007_2012 
  where ( 
   Location_Name like '%OASIS%') 
   and 
   brcid=r.brcid 
  ) IS not null then 1 else 0 end PriorOASIS, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.Dateofclosestteamepisode and 
   DATEADD(d,14,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
mhasection2wFirstPsychosisReferral, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.Dateofclosestteamepisode and 
   DATEADD(m,1,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
mhasection1mFirstPsychosisReferral, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.Dateofclosestteamepisode and 
   DATEADD(m,3,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
mhasection3mFirstPsychosisReferral, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.Dateofclosestteamepisode and 
   DATEADD(m,6,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
mhasection6mFirstPsychosisReferral, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
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   Start_Date between r.Dateofclosestteamepisode and 
   DATEADD(m,12,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
mhasection12mFirstPsychosisReferral, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.Dateofclosestteamepisode and 
   DATEADD(m,24,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
mhasection24mFirstPsychosisReferral, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 
  where 
   admission_Date between r.Dateofclosestteamepisode 
and 
   DATEADD(d,14,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
inpatient2wFirstPsychosisReferral, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 
  where 
   admission_Date between r.Dateofclosestteamepisode 
and 
   DATEADD(m,1,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
inpatient1mFirstPsychosisReferral, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 
  where 
   admission_Date between r.Dateofclosestteamepisode 
and 
   DATEADD(m,3,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
inpatient3mFirstPsychosisReferral, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 
  where 
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   admission_Date between r.Dateofclosestteamepisode 
and 
   DATEADD(m,6,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
inpatient6mFirstPsychosisReferral, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 
  where 
   admission_Date between r.Dateofclosestteamepisode 
and 
   DATEADD(m,12,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
inpatient12mFirstPsychosisReferral, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 
  where 
   admission_Date between r.Dateofclosestteamepisode 
and 
   DATEADD(m,24,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
inpatient24mFirstPsychosisReferral, 
 case when ( 
  select distinct brcid 
  from 
SQLCRIS_User.RPatel.rp_medication_combined_antipsychotic_recode 
  where 
   Start_Date between r.Dateofclosestteamepisode and 
   DATEADD(d,14,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
antipsychotic2wFirstPsychosisReferral, 
 case when ( 
  select distinct brcid 
  from 
SQLCRIS_User.RPatel.rp_medication_combined_antipsychotic_recode 
  where 
   Start_Date between r.Dateofclosestteamepisode and 
   DATEADD(m,1,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
antipsychotic1mFirstPsychosisReferral, 
 
 case when ( 
  select distinct brcid 
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  from 
SQLCRIS_User.RPatel.rp_medication_combined_antipsychotic_recode 
  where 
   Start_Date between r.Dateofclosestteamepisode and 
   DATEADD(m,3,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
antipsychotic3mFirstPsychosisReferral, 
 
 case when ( 
  select distinct brcid 
  from 
SQLCRIS_User.RPatel.rp_medication_combined_antipsychotic_recode 
  where 
   Start_Date between r.Dateofclosestteamepisode and 
   DATEADD(m,6,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
antipsychotic6mFirstPsychosisReferral, 
 
 case when ( 
  select distinct brcid 
  from 
SQLCRIS_User.RPatel.rp_medication_combined_antipsychotic_recode 
  where 
   Start_Date between r.Dateofclosestteamepisode and 
   DATEADD(m,12,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
antipsychotic12mFirstPsychosisReferral, 
 
 case when ( 
  select distinct brcid 
  from 
SQLCRIS_User.RPatel.rp_medication_combined_antipsychotic_recode 
  where 
   Start_Date between r.Dateofclosestteamepisode and 
   DATEADD(m,24,r.Dateofclosestteamepisode) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  
antipsychotic24mFirstPsychosisReferral, 
 (SELECT           COUNT(*) AS noofadmissions 
  FROM  sqlcris.dbo.inpatient_episode 
  WHERE (BrcId = r.brcid) AND 
  (Admission_Date <= DATEADD(w,2,r.Dateofclosestteamepisode)) 
AND 
  (Discharge_Date >= r.Dateofclosestteamepisode) OR 
  (BrcId = r.brcid) AND 
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  (Admission_Date <= DATEADD(w,2,r.Dateofclosestteamepisode)) 
AND 
  (Discharge_Date = '1 Jan 1900') 
  GROUP BY BrcId) AS admissioncount2w, 
 (SELECT           COUNT(*) AS noofadmissions 
  FROM  sqlcris.dbo.inpatient_episode 
  WHERE (BrcId = r.brcid) AND 
  (Admission_Date <= DATEADD(m,1,r.Dateofclosestteamepisode)) 
AND 
  (Discharge_Date >= r.Dateofclosestteamepisode) OR 
  (BrcId = r.brcid) AND 
  (Admission_Date <= DATEADD(m,1,r.Dateofclosestteamepisode)) 
AND 
  (Discharge_Date = '1 Jan 1900') 
  GROUP BY BrcId) AS admissioncount1m, 
 (SELECT           COUNT(*) AS noofadmissions 
  FROM  sqlcris.dbo.inpatient_episode 
  WHERE (BrcId = r.brcid) AND 
  (Admission_Date <= DATEADD(m,3,r.Dateofclosestteamepisode)) 
AND 
  (Discharge_Date >= r.Dateofclosestteamepisode) OR 
  (BrcId = r.brcid) AND 
  (Admission_Date <= DATEADD(m,3,r.Dateofclosestteamepisode)) 
AND 
  (Discharge_Date = '1 Jan 1900') 
  GROUP BY BrcId) AS admissioncount3m, 
 (SELECT           COUNT(*) AS noofadmissions 
  FROM  sqlcris.dbo.inpatient_episode 
  WHERE (BrcId = r.brcid) AND 
  (Admission_Date <= DATEADD(m,6,r.Dateofclosestteamepisode)) 
AND 
  (Discharge_Date >= r.Dateofclosestteamepisode) OR 
  (BrcId = r.brcid) AND 
  (Admission_Date <= DATEADD(m,6,r.Dateofclosestteamepisode)) 
AND 
  (Discharge_Date = '1 Jan 1900') 
  GROUP BY BrcId) AS admissioncount6m, 
 (SELECT           COUNT(*) AS noofadmissions 
  FROM  sqlcris.dbo.inpatient_episode 
  WHERE (BrcId = r.brcid) AND 
  (Admission_Date <= 
DATEADD(m,12,r.Dateofclosestteamepisode)) AND 
  (Discharge_Date >= r.Dateofclosestteamepisode) OR 
  (BrcId = r.brcid) AND 
  (Admission_Date <= 
DATEADD(m,12,r.Dateofclosestteamepisode)) AND 
  (Discharge_Date = '1 Jan 1900') 
  GROUP BY BrcId) AS admissioncount12m, 
 (SELECT           COUNT(*) AS noofadmissions 
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  FROM  sqlcris.dbo.inpatient_episode 
  WHERE (BrcId = r.brcid) AND 
  (Admission_Date <= 
DATEADD(m,24,r.Dateofclosestteamepisode)) AND 
  (Discharge_Date >= r.Dateofclosestteamepisode) OR 
  (BrcId = r.brcid) AND 
  (Admission_Date <= 
DATEADD(m,24,r.Dateofclosestteamepisode)) AND 
  (Discharge_Date = '1 Jan 1900') 
  GROUP BY BrcId) AS admissioncount24m, 
 SQLCrisImport.dbo.getlos(Dateofclosestteamepisode, DATEADD(m, 12, 
Dateofclosestteamepisode), r.brcid) AS los_PsychosisReferralDate12m, 
 SQLCrisImport.dbo.getlos(Dateofclosestteamepisode, DATEADD(m, 24, 
Dateofclosestteamepisode), r.brcid) AS los_PsychosisReferralDate24m 
from [SQLCRIS_User].[RPatel].[rp_firstreferral_psychosis_recode_2007_2012] 
r 
left join sqlcris.dbo.epr_form p on r.brcid=p.brcid 
left join [SQLCrisImport].[dbo].[address_ons_2010_imd] h on h.CN_Doc_ID= 
(select top 1 CN_Doc_ID from [SQLCrisImport].[dbo].[address_ons_2010_imd] 



































      ,[Dateoffirstreferral] 
      ,YEAR([Dateoffirstreferral]) Yearoffirstreferral 
      ,[Dateofclosestteamepisode] 
      ,[Dateoffirstpsychosisdiagnosis] 
      ,YEAR([Dateoffirstpsychosisdiagnosis]) Yearoffirstpsychosisdiagnosis 
      ,[Firstpsychosisdiagnosisraw] 
      ,[Firstpsychosisdiagnosisrecode] 
 ,case 
  when ( 
   [Firstpsychosisdiagnosisrecode] like 
'F2xSchizophrenia') 
  then '1' 
   
  when ( 
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   [Firstpsychosisdiagnosisrecode] like 'Bipolar') 
  then '2' 
   
  when ( 
   [Firstpsychosisdiagnosisrecode] like 
'PsychoticDepression') 
  then '3' 
   
  when ( 
   [Firstpsychosisdiagnosisrecode] like 
'Schizoaffective') 
  then '4' 
 
  when ( 
   [Firstpsychosisdiagnosisrecode] like 
'F1x.5DrugPsyc') 
  then '5' 
 
  when ( 
   [Firstpsychosisdiagnosisrecode] like 
'OtherPsychosis') 
  then '6' 
   
  end as Firstpsychosisdiagnosisrecode2 
 
      ,[Borough] 
 ,case 
  when ( 
   Borough like '%Lambeth%') 
  then 'Lambeth' 
   
  when ( 
   Borough like '%Croydon%') 
  then 'Croydon' 
   
  when ( 
   Borough like '%Southwark%') 
  then 'Southwark' 
   
  when ( 
   Borough like '%Lewisham%') 
  then 'Lewisham' 
   
  when ( 
   Borough is NULL) 
  then 'NotRecorded' 
   
  else 'Other' 
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  end as BoroughRecode, 
      case 
  when ( 
   Borough like '%Lambeth%') 
  then '2' 
   
  when ( 
   Borough like '%Croydon%') 
  then '3' 
   
  when ( 
   Borough like '%Southwark%') 
  then '4' 
   
  when ( 
   Borough like '%Lewisham%') 
  then '5' 
   
  when ( 
   Borough is NULL) 
  then '6' 
   
  else '1' 
   
  end as BoroughRecode2 
      ,[DiagnosticDelayInDays] 
      ,[age] 
      ,[Gender] 
      ,case 
  when  
   Gender like 'Female' 
  then '0' 
 
  when 
   Gender like 'Male' 
  then '1' 
 
  when 
   Gender like 'Not Known' 
  then '2' 
 
  end as GenderRecode2 
      ,[ethnicity] 
      ,case 
  when ( 
   ethnicity like 'Irish (B)' or 
   ethnicity like 'Any other white background (C)' or 
   ethnicity like 'British (A)') 




  when ( 
   ethnicity like 'Bangladeshi (K)' or 
   ethnicity like 'Pakistani (J)' or 
   ethnicity like 'Chinese (R)' or 
   ethnicity like 'Indian (H)' or 
   ethnicity like 'Any other Asian background (L)') 
  then 'Asian' 
 
  when ( 
   ethnicity like 'African (N)') 
  then 'BlackAfrican' 
 
  when ( 
   ethnicity like 'Caribbean (M)') 
  then 'BlackCaribbean' 
 
  when ( 
   ethnicity like 'Any other black background (P)') 
  then 'BlackOther' 
 
  when ( 
   ethnicity like 'White and Asian (F)' or 
   ethnicity like 'White and Black African (E)' or 
   ethnicity like 'Any other mixed background (G)' or 
   ethnicity like 'Any other ethnic group (S)') 
  then 'Other' 
 
  when ( 
   ethnicity like 'Not Stated (Z)' or 
   ethnicity like 'None') 
  then 'NotRecorded' 
   
  end as ethnicrecode, 
      case 
  when ( 
   ethnicity like 'Irish (B)' or 
   ethnicity like 'Any other white background (C)' or 
   ethnicity like 'British (A)') 
  then '1' 
 
  when ( 
   ethnicity like 'Bangladeshi (K)' or 
   ethnicity like 'Pakistani (J)' or 
   ethnicity like 'Chinese (R)' or 
   ethnicity like 'Indian (H)' or 
   ethnicity like 'Any other Asian background (L)') 




  when ( 
   ethnicity like 'African (N)') 
  then '3' 
 
  when ( 
   ethnicity like 'Caribbean (M)') 
  then '4' 
 
  when ( 
   ethnicity like 'Any other black background (P)') 
  then '5' 
 
  when ( 
   ethnicity like 'White and Asian (F)' or 
   ethnicity like 'White and Black African (E)' or 
   ethnicity like 'Any other mixed background (G)' or 
   ethnicity like 'Any other ethnic group (S)') 
  then '6' 
 
  when ( 
   ethnicity like 'Not Stated (Z)' or 
   ethnicity like 'None') 
  then '7' 
   
  end as ethnicrecode2 
      ,[marital_status] 
      ,case 
  when ( 
   marital_status like 'Cohabiting' or 
   marital_status like 'Married' or 
   marital_status like 'Married/Civil Partner') 
  then 'MarriedCohabiting' 
 
  when ( 
   marital_status like 'Divorced' or 
   marital_status like 'Divorced/Civil Partnership 
Dissolved' or 
   marital_status like 'Separated') 
  then 'DivorcedSeparated' 
 
  when ( 
   marital_status like 'Single') 
  then 'Single' 
 
  when ( 
   marital_status like 'Widowed' or 
   marital_status like 'Widowed/Surviving Civil 
Partner') 




  when ( 
   marital_status like 'Not Disclosed' or 
   marital_status like 'Not Known') 
  then 'NotRecorded' 
   
  end as maritalrecode, 
      case 
  when ( 
   marital_status like 'Cohabiting' or 
   marital_status like 'Married' or 
   marital_status like 'Married/Civil Partner') 
  then '1' 
 
  when ( 
   marital_status like 'Divorced' or 
   marital_status like 'Divorced/Civil Partnership 
Dissolved' or 
   marital_status like 'Separated') 
  then '2' 
 
  when ( 
   marital_status like 'Single') 
  then '3' 
 
  when ( 
   marital_status like 'Widowed' or 
   marital_status like 'Widowed/Surviving Civil 
Partner') 
  then '4' 
 
  when ( 
   marital_status like 'Not Disclosed' or 
   marital_status like 'Not Known') 
  then '5' 
   
  end as maritalrecode2 
      ,[Employment_status] 
      ,case 
  when ( 
   Employment_status like 'Volunteer' or 
   Employment_status like 'Self Employed' or 
   Employment_status like 'Part Time Employment' or 
   Employment_status like 'Paid Employment') 
  then 'Employed' 
 
  when ( 
   Employment_status like 'Govt Training Scheme' or 
   Employment_status like 'Full Time Student' or 
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   Employment_status like 'Full Time Student - School 
age') 
  then 'Student' 
 
  when ( 
   Employment_status like 'Retired') 
  then 'Retired' 
 
  when ( 
   Employment_status like 'Registered Disabled' or 
   Employment_status like 'Unemployed') 
  then 'Unemployed' 
 
  when ( 
   Employment_status like 'Other' or 
   Employment_status like 'Not Known' or 
   Employment_status like 'xNx') 
  then 'NotRecorded' 
   
  end as employmentrecode, 
      case 
  when ( 
   Employment_status like 'Volunteer' or 
   Employment_status like 'Self Employed' or 
   Employment_status like 'Part Time Employment' or 
   Employment_status like 'Paid Employment') 
  then '1' 
 
  when ( 
   Employment_status like 'Govt Training Scheme' or 
   Employment_status like 'Full Time Student' or 
   Employment_status like 'Full Time Student - School 
age') 
  then '2' 
 
  when ( 
   Employment_status like 'Retired') 
  then '3' 
 
  when ( 
   Employment_status like 'Registered Disabled' or 
   Employment_status like 'Unemployed') 
  then '4' 
 
  when ( 
   Employment_status like 'Other' or 
   Employment_status like 'Not Known' or 
   Employment_status like 'xNx') 
  then '5' 
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  end as employmentrecode2 
      ,[Accommodation_status] 
      ,case 
  when ( 
   Accommodation_status like 'Owner') 
  then 'Owner' 
 
  when ( 
   Accommodation_status like 'Private Tenant') 
  then 'PrivateTenant' 
 
  when ( 
   Accommodation_status like 'Council Tenant') 
  then 'CouncilTenant' 
 
  when ( 
   Accommodation_status like 'Trust' or 
   Accommodation_status like 'Nursing/Residential') 
  then 'SupportedAccommodation' 
 
  when ( 
   Accommodation_status like 'Homeless') 
  then 'Homeless' 
 
  when ( 
   Accommodation_status like 'Other') 
  then 'Other' 
 
  when ( 
   Accommodation_status like 'Not known' or 
   Accommodation_status like 'xNx') 
  then 'NotRecorded' 
   
  end as accommodationrecode, 
      case 
  when ( 
   Accommodation_status like 'Owner') 
  then '1' 
 
  when ( 
   Accommodation_status like 'Private Tenant') 
  then '2' 
 
  when ( 
   Accommodation_status like 'Council Tenant') 
  then '3' 
 
  when ( 
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   Accommodation_status like 'Trust' or 
   Accommodation_status like 'Nursing/Residential') 
  then '4' 
 
  when ( 
   Accommodation_status like 'Homeless') 
  then '5' 
 
  when ( 
   Accommodation_status like 'Other') 
  then '6' 
 
  when ( 
   Accommodation_status like 'Not known' or 
   Accommodation_status like 'xNx') 
  then '7' 
   
  end as accommodationrecode2 
      ,[PriorEISCommunity] 
      ,[PriorEISInpatientLEO] 
 ,case 
  when ( 
   PriorEISCommunity=1 and 
   PriorEISInpatientLEO=1) 
  then '1' else '0' 
  end as PriorEIS 
      ,[PriorOASIS] 
      ,[mhasection2wFirstPsychosisReferral] 
      ,[mhasection1mFirstPsychosisReferral] 
      ,[mhasection3mFirstPsychosisReferral] 
      ,[mhasection6mFirstPsychosisReferral] 
      ,[mhasection12mFirstPsychosisReferral] 
      ,[mhasection24mFirstPsychosisReferral] 
      ,[inpatient2wFirstPsychosisReferral] 
      ,[inpatient1mFirstPsychosisReferral] 
      ,[inpatient3mFirstPsychosisReferral] 
      ,[inpatient6mFirstPsychosisReferral] 
      ,[inpatient12mFirstPsychosisReferral] 
      ,[inpatient24mFirstPsychosisReferral] 
      ,[antipsychotic2wFirstPsychosisReferral] 
      ,[antipsychotic1mFirstPsychosisReferral] 
      ,[antipsychotic3mFirstPsychosisReferral] 
      ,[antipsychotic6mFirstPsychosisReferral] 
      ,[antipsychotic12mFirstPsychosisReferral] 
      ,[antipsychotic24mFirstPsychosisReferral] 
      ,[admissioncount2w] 
      ,[admissioncount1m] 
      ,[admissioncount3m] 
      ,[admissioncount6m] 
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      ,[admissioncount12m] 
      ,[admissioncount24m] 
      ,[los_PsychosisReferralDate12m] 
      ,[los_PsychosisReferralDate24m] 
  FROM 
[SQLCRIS_User].[RPatel].[rp_firstreferral_psychosis_recode_2007_2012output] 
















SELECT v.brcid, 'Team' [type], te.Accepted_Date start_date, 
te.discharge_date end_date, Location_Name, cag 
 FROM [SQLCRIS_User].[RPatel].[rp_firstreferral_psychosis_2007_2012] 
v LEFT JOIN 
 sqlcris.dbo.Team_episode te ON v.brcid = te.BrcId 
WHERE     (te.accepted_Date > '1-jan-1900' AND te.Rejection_Date = '1-jan-
1900') AND te.Location_Name NOT LIKE '%test%' AND  
                      (te.Accepted_Date <= v.Dateoffirstpsychosisdiagnosis 
AND te.Accepted_Date > '1-jan-1900' AND (te.Discharge_Date >= 
v.accepted_date OR 




SELECT     v.brcid, 'Ward' [type], Actual_Start_Date start_date, 
Actual_End_Date end_date, Location_Name, cag 
FROM         [SQLCRIS_User].[RPatel].[rp_firstreferral_psychosis_2007_2012] 
v LEFT JOIN 
                      sqlcris.dbo.Ward_stay te ON v.brcid = te.BrcId 
WHERE     ((te.Actual_Start_Date > '1-jan-1900' AND te.Rejection_Date = '1-
jan-1900') AND te.Location_Name NOT LIKE '%test%' AND  
                      (te.Current_Ward_Stay_Status_ID LIKE 'closed' OR 
                      te.Current_Ward_Stay_Status_ID LIKE '%occupied%')) 
AND (Actual_Start_Date <= v.Dateoffirstpsychosisdiagnosis AND  
                      Actual_Start_Date > '1-jan-1900' AND (Actual_End_Date 
>= v.accepted_date OR 

































**Drop one case with no recorded gender** 
drop if GenderRecode2==2 
 
**Destring diagnostic delay** 
destring DiagnosticDelayInDays, replace 
recode DiagnosticDelayInDays .=0 
 
**Recoding demographic variables to deal with missing data and regrouping 
categories** 
gen ethnicrecode3 = ethnicrecode2 
recode ethnicrecode3 1=1 2=2 3=3 4=3 5=3 6=4 7=5 
gen ethnicrecode3b = ethnicrecode3 
recode ethnicrecode3b 5=. 
gen maritalrecode3 = maritalrecode2 
recode maritalrecode3 1=1 2=2 3=3 4=3 5=4 
gen maritalrecode3b = maritalrecode3 
recode maritalrecode3b 4=. 
gen employmentrecode3 = employmentrecode2 
recode employmentrecode3 1=1 2=2 3=3 4=3 5=4 
gen employmentrecode3b = employmentrecode3 
recode employmentrecode3b 4=. 
gen accommodationrecode3 = accommodationrecode2 
recode accommodationrecode3 7=6 
gen accommodationrecode3b = accommodationrecode2 
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recode accommodationrecode3b 7=. 
gen BoroughRecode3b = BoroughRecode2 
recode BoroughRecode3b 5=. 
gen fullcovariate = 1 
replace fullcovariate = 0 if 
ethnicrecode3b==.|maritalrecode3b==.|employmentrecode3b==.|BoroughRecode3b=
=. 
replace PriorEIS = 2 if PriorOASIS==1 
 
**Adding variable to test difference between 2001-2006 and 2007-2011** 
gen ePJS = Yearoffirstreferral 
recode ePJS 2001/2006=0 2007/max=1 
 
**Label variables and create ordinal exposures** 
label define Firstpsychosisdiagnosisrecode2 1 "F2xSchizophrenia" 2 
"Bipolar" 3 "PsychoticDepression" 4 "Schizoaffective" 5 "F1x.5DrugPsyc" 6 
"OtherPsychosis" 
label define AgeRecode2 1 "<16" 2 "16-24" 3 "24-49" 4 "50-64" 5 ">64" 
label define GenderRecode2 0 "Female" 1 "Male" 2 "NotRecorded" 
label define ethnicrecode2 1 "White" 2 "Asian" 3 "BlackAfrican" 4 
"BlackCaribbean" 5 "BlackOther" 6 "Other" 7 "NotRecorded" 
label define ethnicrecode3 1 "White" 2 "Asian" 3 "Black" 4 "Other" 5 
"NotRecorded" 
label define ethnicrecode3b 1 "White" 2 "Asian" 3 "Black" 4 "Other" 
label define maritalrecode2 1 "MarriedCohabiting" 2 "DivorcedSeparated" 3 
"Single" 4 "Widowed" 5 "NotRecorded" 
label define maritalrecode3 1 "MarriedCohabiting" 2 "DivorcedSeparated" 3 
"Single" 4 "NotRecorded" 
label define maritalrecode3b 1 "MarriedCohabiting" 2 "DivorcedSeparated" 3 
"Single" 
label define employmentrecode2 1 "Employed" 2 "Student" 3 "Retired" 4 
"Unemployed" 5 "NotRecorded" 
label define employmentrecode3 1 "Employed" 2 "Student" 3 "Unemployed" 4 
"NotRecorded" 
label define employmentrecode3b 1 "Employed" 2 "Student" 3 "Unemployed" 
label define accommodationrecode2 1 "Owner" 2 "PrivateTenant" 3 
"CouncilTenant" 4 "SupportedAccomodation" 5 "Homeless" 6 "Other" 7 
"NotRecorded" 
label define accommodationrecode3 1 "Owner" 2 "PrivateTenant" 3 
"CouncilTenant" 4 "SupportedAccomodation" 5 "Homeless" 6 "Other" 
label define accommodationrecode3b 1 "Owner" 2 "PrivateTenant" 3 
"CouncilTenant" 4 "SupportedAccomodation" 5 "Homeless" 6 "Other" 
label define PriorEIS 0 "StandardMentalHealth" 1 "EIS" 2 "OASIS" 
label define BoroughRecode2 1 "Lambeth" 2 "Southwark" 3 "Lewisham" 4 
"Croydon" 5 "Other" 
label define BoroughRecode3b 1 "Lambeth" 2 "Southwark" 3 "Lewisham" 4 
"Croydon" 
label values Firstpsychosisdiagnosisrecode2 Firstpsychosisdiagnosisrecode2 
label values AgeRecode2 AgeRecode2 
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label values GenderRecode2 GenderRecode2 
label values ethnicrecode2 ethnicrecode2 
label values ethnicrecode3 ethnicrecode3 
label values ethnicrecode3b ethnicrecode3b 
label values maritalrecode2 maritalrecode2 
label values maritalrecode3 maritalrecode3 
label values maritalrecode3b maritalrecode3b 
label values employmentrecode2 employmentrecode2 
label values employmentrecode3 employmentrecode3 
label values employmentrecode3b employmentrecode3b 
label values accommodationrecode2 accommodationrecode2 
label values accommodationrecode3 accommodationrecode3 
label values accommodationrecode3b accommodationrecode3b 
label values PriorEIS PriorEIS 
label values BoroughRecode2 BoroughRecode2 
label values BoroughRecode3b BoroughRecode3b 
 







**Drop if prior to ePJS** 
**drop if ePJS==0** 
 
**Drop if after ePJS** 
**drop if ePJS==1** 
 
**Test of normality for age** 
ksmirnov age, by(PriorOASIS) 
**non-normal distribution for age by PriorOASIS - use Mann Whitney U test** 
 
**Check how many have full covariate data** 
tab PriorOASIS if fullcovariate==1 
 
**Demographic variables** 
**Chi2 and Fisher's exact test** 
summ age if PriorOASIS==0, detail 
summ age if PriorOASIS==1, detail 
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ranksum age, by(PriorOASIS) 
tab PriorOASIS Firstpsychosisdiagnosisrecode2, row chi2 
**tab PriorOASIS Firstpsychosisdiagnosisrecode2, row exact** 
tab PriorOASIS GenderRecode2, row chi2 
tab PriorOASIS GenderRecode2, row exact 
tab PriorOASIS ethnicrecode3b, row chi2 
**tab PriorOASIS ethnicrecode3b, row exact** 
tab PriorOASIS maritalrecode3b, row chi2 
**tab PriorOASIS maritalrecode3b, row exact** 
tab PriorOASIS employmentrecode3b, row chi2 
**tab PriorOASIS employmentrecode3b, row exact** 
tab PriorOASIS BoroughRecode3b, row chi2 
tab PriorOASIS BoroughRecode3b, row exact 
 
**Demographic variables including missing data** 
**Chi2 and Fisher's exact test** 
tab PriorOASIS ethnicrecode3, row chi2 
**tab PriorOASIS ethnicrecode3, row exact** 
tab PriorOASIS maritalrecode3, row chi2 
**tab PriorOASIS maritalrecode3, row exact** 
tab PriorOASIS employmentrecode3, row chi2 
**tab PriorOASIS employmentrecode3, row exact** 
tab PriorOASIS BoroughRecode2, row chi2 
**tab PriorOASIS BoroughRecode2, row exact** 
 
**MHA Section** 
tab PriorOASIS mhasection2w, row 
tab PriorOASIS mhasection1m, row 
tab PriorOASIS mhasection3m, row 
tab PriorOASIS mhasection6m, row 
tab PriorOASIS mhasection12m, row 
tab PriorOASIS mhasection24m, row 
 
**Number of admissions** 
summ admissioncount2w if PriorOASIS==0, detail 
summ admissioncount2w if PriorOASIS==1, detail 
summ admissioncount1m if PriorOASIS==0, detail 
summ admissioncount1m if PriorOASIS==1, detail 
summ admissioncount3m if PriorOASIS==0, detail 
summ admissioncount3m if PriorOASIS==1, detail 
summ admissioncount6m if PriorOASIS==0, detail 
summ admissioncount6m if PriorOASIS==1, detail 
summ admissioncount12m if PriorOASIS==0, detail 
summ admissioncount12m if PriorOASIS==1, detail 
summ admissioncount24m if PriorOASIS==0, detail 
summ admissioncount24m if PriorOASIS==1, detail 
 
**Number of inpatient days** 
summ los_12m if PriorOASIS==0, detail 
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summ los_12m if PriorOASIS==1, detail 
summ los_24m if PriorOASIS==0, detail 
summ los_24m if PriorOASIS==1, detail 
 
**Diagnostic delay** 
summ DiagnosticDelayInDays, detail 
summ DiagnosticDelayInDays if PriorOASIS==0, detail 
summ DiagnosticDelayInDays if PriorOASIS==1, detail 
 
/* 
graph box DiagnosticDelayInDays, over(PriorOASIS, relabel(1 "Conventional 
mental health service" 2 "High risk service") descending) box(1, 
fcolor(navy) fintensity(inten100) lcolor(black) lpattern(solid)) box(2, 
fcolor(cranberry) fintensity(inten100) lcolor(black) lpattern(solid)) 
ytitle(Time to diagnosis (days)) ytitle(, size(small)) title(Time to 
diagnosis in high risk service compared to conventional mental health 













**Check how many have full covariate data** 
tab PriorEIS if fullcovariate==1 
 
**Demographic variables** 
**Chi2 and Fisher's exact test** 
summ age if PriorEIS==0, detail 
summ age if PriorEIS==1, detail 
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summ age if PriorEIS==2, detail 
anova age PriorEIS 
tab PriorEIS Firstpsychosisdiagnosisrecode2, row chi2 
**tab PriorEIS Firstpsychosisdiagnosisrecode2, row exact** 
tab PriorEIS GenderRecode2, row chi2 
tab PriorEIS GenderRecode2, row exact 
tab PriorEIS ethnicrecode3b, row chi2 
**tab PriorEIS ethnicrecode3b, row exact** 
tab PriorEIS maritalrecode3b, row chi2 
**tab PriorEIS maritalrecode3b, row exact** 
tab PriorEIS employmentrecode3b, row chi2 
**tab PriorEIS employmentrecode3b, row exact** 
tab PriorEIS BoroughRecode3b, row chi2 
**tab PriorEIS BoroughRecode3b, row exact** 
 
**Demographic variables including missing data** 
**Chi2 and Fisher's exact test** 
tab PriorEIS ethnicrecode3, row chi2 
**tab PriorEIS ethnicrecode3, row exact** 
tab PriorEIS maritalrecode3, row chi2 
**tab PriorEIS maritalrecode3, row exact** 
tab PriorEIS employmentrecode3, row chi2 
**tab PriorEIS employmentrecode3, row exact** 
tab PriorEIS BoroughRecode2, row chi2 
**tab PriorEIS BoroughRecode2, row exact** 
 
**MHA Section** 
tab PriorEIS mhasection2w, row 
tab PriorEIS mhasection1m, row 
tab PriorEIS mhasection3m, row 
tab PriorEIS mhasection6m, row 
tab PriorEIS mhasection12m, row 
tab PriorEIS mhasection24m, row 
 
**Number of admissions** 
summ admissioncount2w if PriorEIS==0, detail 
summ admissioncount2w if PriorEIS==1, detail 
summ admissioncount2w if PriorEIS==2, detail 
summ admissioncount1m if PriorEIS==0, detail 
summ admissioncount1m if PriorEIS==1, detail 
summ admissioncount1m if PriorEIS==2, detail 
summ admissioncount3m if PriorEIS==0, detail 
summ admissioncount3m if PriorEIS==1, detail 
summ admissioncount3m if PriorEIS==2, detail 
summ admissioncount6m if PriorEIS==0, detail 
summ admissioncount6m if PriorEIS==1, detail 
summ admissioncount6m if PriorEIS==2, detail 
summ admissioncount12m if PriorEIS==0, detail 
summ admissioncount12m if PriorEIS==1, detail 
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summ admissioncount12m if PriorEIS==2, detail 
summ admissioncount24m if PriorEIS==0, detail 
summ admissioncount24m if PriorEIS==1, detail 
summ admissioncount24m if PriorEIS==2, detail 
 
**Number of inpatient days** 
summ los_12m if PriorEIS==0, detail 
summ los_12m if PriorEIS==1, detail 
summ los_12m if PriorEIS==2, detail 
summ los_24m if PriorEIS==0, detail 
summ los_24m if PriorEIS==1, detail 
summ los_24m if PriorEIS==2, detail 
 
**Diagnostic delay** 
summ DiagnosticDelayInDays, detail 
summ DiagnosticDelayInDays if PriorEIS==0, detail 
summ DiagnosticDelayInDays if PriorEIS==1, detail 










**Multivariable analyses with missing data included** 
 
**MHA section** 
logistic mhasection2w i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic2w 
logistic mhasection1m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 




logistic mhasection3m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic3m 
logistic mhasection6m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic6m 
logistic mhasection12m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic12m 
logistic mhasection24m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 




poisson admissioncount2w i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic2w, irr 
poisson admissioncount1m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic1m, irr 
poisson admissioncount3m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic3m, irr 
poisson admissioncount6m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic6m, irr 
poisson admissioncount12m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic12m, irr 
poisson admissioncount24m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic24m, irr 
 
**Inpatient days from accepted date** 
regress los_12m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic12m 
regress los_24m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 




regress DiagnosticDelayInDays i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 

















**Multivariable analyses with missing data included** 
 
**MHA section** 
logistic mhasection2w i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic2w 
logistic mhasection1m i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic1m 
logistic mhasection3m i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic3m 
logistic mhasection6m i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic6m 
logistic mhasection12m i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic12m 
logistic mhasection24m i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 






poisson admissioncount2w i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic2w, irr 
poisson admissioncount1m i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic1m, irr 
poisson admissioncount3m i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic3m, irr 
poisson admissioncount6m i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic6m, irr 
poisson admissioncount12m i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic12m, irr 
poisson admissioncount24m i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic24m, irr 
 
**Inpatient days from accepted date** 
regress los_12m i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic12m 
regress los_24m i.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 




regress DiagnosticDelayInDays i.PriorEIS i.Firstpsychosisdiagnosisrecode2 
age i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic24m 
 
**Multivariable analyses with missing data included - EIS as reference** 
 
**MHA section** 
logistic mhasection2w ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic2w 
logistic mhasection1m ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic1m 
logistic mhasection3m ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic3m 
logistic mhasection6m ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 




logistic mhasection12m ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic12m 
logistic mhasection24m ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 




poisson admissioncount2w ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic2w, irr 
poisson admissioncount1m ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic1m, irr 
poisson admissioncount3m ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic3m, irr 
poisson admissioncount6m ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic6m, irr 
poisson admissioncount12m ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic12m, irr 
poisson admissioncount24m ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic24m, irr 
 
**Inpatient days from accepted date** 
regress los_12m ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3 i.maritalrecode3 i.employmentrecode3 
i.BoroughRecode2 i.antipsychotic12m 
regress los_24m ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 age 




regress DiagnosticDelayInDays ib1.PriorEIS i.Firstpsychosisdiagnosisrecode2 

















**Multivariable analyses with missing data dropped** 
 
**MHA section** 
logistic mhasection2w i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3b i.maritalrecode3b i.employmentrecode3b 
i.BoroughRecode3b i.antipsychotic2w 
logistic mhasection1m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3b i.maritalrecode3b i.employmentrecode3b 
i.BoroughRecode3b i.antipsychotic1m 
logistic mhasection3m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3b i.maritalrecode3b i.employmentrecode3b 
i.BoroughRecode3b i.antipsychotic3m 
logistic mhasection6m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3b i.maritalrecode3b i.employmentrecode3b 
i.BoroughRecode3b i.antipsychotic6m 
logistic mhasection12m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3b i.maritalrecode3b i.employmentrecode3b 
i.BoroughRecode3b i.antipsychotic12m 
logistic mhasection24m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 




poisson admissioncount2w i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3b i.maritalrecode3b i.employmentrecode3b 
i.BoroughRecode3b i.antipsychotic2w, irr 
poisson admissioncount1m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3b i.maritalrecode3b i.employmentrecode3b 
i.BoroughRecode3b i.antipsychotic1m, irr 
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poisson admissioncount3m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3b i.maritalrecode3b i.employmentrecode3b 
i.BoroughRecode3b i.antipsychotic3m, irr 
poisson admissioncount6m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3b i.maritalrecode3b i.employmentrecode3b 
i.BoroughRecode3b i.antipsychotic6m, irr 
poisson admissioncount12m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3b i.maritalrecode3b i.employmentrecode3b 
i.BoroughRecode3b i.antipsychotic12m, irr 
poisson admissioncount24m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3b i.maritalrecode3b i.employmentrecode3b 
i.BoroughRecode3b i.antipsychotic24m, irr 
 
**Inpatient days from accepted date** 
regress los_12m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
i.GenderRecode2 i.ethnicrecode3b i.maritalrecode3b i.employmentrecode3b 
i.BoroughRecode3b i.antipsychotic12m 
regress los_24m i.PriorOASIS i.Firstpsychosisdiagnosisrecode2 age 
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Objective: To investigate whether cannabis use is
associated with increased risk of relapse, as indexed by
number of hospital admissions, and whether
antipsychotic treatment failure, as indexed by number
of unique antipsychotics prescribed, may mediate this
effect in a large data set of patients with first episode
psychosis (FEP).
Design: Observational study with exploratory mediation
analysis.
Setting: Anonymised electronic mental health record
data from the South London and Maudsley NHS
Foundation Trust.
Participants: 2026 people presenting to early
intervention services with FEP.
Exposure: Cannabis use at presentation, identified using
natural language processing.
Main outcome measures: admission to psychiatric
hospital and clozapine prescription up to 5 years
following presentation.
Mediator: Number of unique antipsychotics prescribed.
Results: Cannabis use was present in 46.3% of the
sample at first presentation and was particularly common
in patients who were 16–25, male and single. It was
associated with increased frequency of hospital admission
(incidence rate ratio 1.50, 95% CI 1.25 to 1.80), increased
likelihood of compulsory admission (OR 1.55, 1.16 to
2.08) and greater number of days spent in hospital (β
coefficient 35.1 days, 12.1 to 58.1). The number of unique
antipsychotics prescribed, mediated increased frequency
of hospital admission (natural indirect effect 1.09, 95% CI
1.01 to 1.18; total effect 1.50, 1.21 to 1.87), increased
likelihood of compulsory admission (natural indirect effect
(NIE) 1.27, 1.03 to 1.58; total effect (TE) 1.76, 0.81 to
3.84) and greater number of days spent in hospital (NIE
17.9, 2.4 to 33.4; TE 34.8, 11.6 to 58.1).
Conclusions: Cannabis use in patients with FEP was
associated with an increased likelihood of hospital
admission. This was linked to the prescription of several
different antipsychotic drugs, indicating clinical judgement
of antipsychotic treatment failure. Together, this suggests
that cannabis use might be associated with worse clinical
outcomes in psychosis by contributing towards failure of
antipsychotic treatment.
INTRODUCTION
Cannabis remains the third most common
drug of dependence in the world after
tobacco and alcohol,1 with a growing consen-
sus that cannabis use is associated with
increased risk of development of psychotic
Strengths and limitations of this study
▪ This is the largest known study (over 2000 parti-
cipants) to investigate the association of canna-
bis use with clinical outcome in people with first
episode psychosis. As well as demonstrating that
cannabis is associated with substantially worse
clinical outcomes, our study is the first to iden-
tify a possible explanation for these findings
through a failure of antipsychotic treatment.
▪ Our study employed a novel text mining method
to identify cannabis use in routinely recorded
electronic health record. This approach benefits
from increased generalisability of our findings to
everyday clinical practice but is limited by the
fact that the presence or absence of cannabis
use may not have been comprehensively docu-
mented in all patients. This may have led to
underestimation of its use.
▪ It was not possible to obtain data on amount,
frequency and discontinuation of cannabis use
following first presentation to mental health ser-
vices. Despite this limitation, our data still
showed a significant association of cannabis use
at presentation to mental health services with
poor clinical outcomes up to 5 years later.
▪ We performed an exploratory mediation analysis
to investigate whether the association of canna-
bis use with poor clinical outcomes could be
mediated by an increase in the number of unique
antipsychotics prescribed (a marker of anti-
psychotic treatment failure). However, as this
was an observational study, the mediation ana-
lysis may have been biased by unmeasured con-
founders and temporal ambiguity between the
mediator and outcome variable.
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illnesses particularly if used in early adolescence.2 3
However, there is much less agreement regarding its
effect on outcome in those with established psychosis, a
substantial proportion of whom use the drug, especially
in the early stages of psychosis.4 Despite the widely held
view among clinicians that comorbid cannabis use is a
predictor of poor outcome in those with psychosis, the
evidence to date has been inconsistent irrespective of
the speciﬁc outcome measure examined, such as severity
of psychotic symptoms or relapse of illness (as indexed
by change in symptom severity or hospitalisation),
perhaps limited to a large extent by the size of samples
and duration of follow-up.5–10 Since use of cannabis is
potentially amenable to treatment, there is a particular
need to deﬁnitively investigate the effect of comorbid
cannabis use on a robust measure of outcome which is
indicative of relapse, such as hospitalisation. This is a
reliably estimated measure, and has signiﬁcant implica-
tions for the utilisation of healthcare resources.11
Furthermore, questions remain as to how cannabis use
may increase the risk of relapse. While increased severity
of symptoms is likely to play a role, other (but not neces-
sarily unrelated) mechanisms may be through an adverse
effect on adherence,5 12 as well as reduced response to
antipsychotic treatment.13 In a naturalistic setting where
decisions regarding medication change take into account
a number of factors including response to treatment as
well as tolerability and side effects,14 the number of
unique antipsychotics prescribed is a proxy measure
which may encompass all these factors. Hence, compared
with someone prescribed fewer unique antipsychotics, a
person prescribed a greater number of unique antipsy-
chotics may be considered to have a worse antipsychotic
response, or in effect, antipsychotic treatment failure, as
a result of either treatment resistance or tolerability to
the antipsychotic, or a combination of both. However,
whether the effect of cannabis use on the increased risk
of relapse in psychosis is partly mediated by its effect on
antipsychotic treatment failure (as indexed by the
number of unique antipsychotics prescribed) has yet to
be investigated. Understanding how cannabis use may
adversely affect outcome in psychosis is particularly
important as it may identify mechanisms that may poten-
tially be amenable to intervention.
In the present study, we attempt to address these
issues by investigating the prevalence of cannabis use
and its effect on a cohort of patients with ﬁrst episode
psychosis (FEP) receiving mental healthcare from early
intervention services. We employed novel data mining
and natural language processing (NLP) tools that
allowed us to investigate a large data set of anonymised
free-text electronic health records in order to obtain
data on cannabis use and clinical outcomes. We tested
our hypotheses that in those presenting with their ﬁrst
episode of psychosis, cannabis use is associated with
increased frequency of hospital admission (including
compulsory admission) and greater number of days
spent in hospital, and that this is mediated by non-
responsiveness to antipsychotics as indexed by the
number of unique antipsychotic medications prescribed.
METHODS
Participants
All individuals with FEP who were accepted by an early
intervention service in the South London and Maudsley
(SLaM) National Health Service (NHS) Foundation
Trust between 1 April 2006 and 31 March 2013 were
included in the study (n=2026). SLaM is one of the
largest providers of specialist mental healthcare in
Europe, serving a catchment of around 1.2 million resi-
dents in four boroughs of South London (Lambeth,
Southwark, Lewisham and Croydon).15 16
Source of clinical data
Data for this study were obtained from the SLaM
Biomedical Research Centre (BRC) Case Register, which
contains anonymised clinical data from the electronic
health records of individuals who have previously
received or are currently receiving mental healthcare
from SLaM.15 The SLaM BRC Case Register comprises
structured ﬁelds for demographic information as well as
unstructured (but de-identiﬁed) free-text ﬁelds from
case notes and correspondence where history, mental
state examination, diagnostic formulation and manage-
ment plan are primarily recorded. A patient-led over-
sight committee considers all proposed research before
access to the anonymised data is permitted. The elec-
tronic health record system was implemented in SLaM
early intervention services in April 2006, and so the
period of 1 April 2006 to 31 March 2013 was chosen for
data capture to maximise the number of participants
with at least 1 year of follow-up. Predictor, covariate and
outcome variable data were obtained from the SLaM
BRC Case Register using the Clinical Record Interactive
Search tool (CRIS),15 a search and database assembly
tool underpinning this data resource.17–20
Identification of cannabis use
NLP was used to extract documentation of cannabis use
from unstructured free-text ﬁelds in the BRC Case
Register including clinical assessments, reviews and cor-
respondence between healthcare professionals. An NLP
application was developed using TextHunter software.21
Full details of NLP application development are
described in a previous study.22 In summary, a support
vector machine learning (SVM) approach was used to
identify sentences containing a positive reference of
current or historical cannabis use. The application was
trained using 478 human-classiﬁed sentences which con-
tained the word ‘cannabis’ (or the following synonyms:
‘marijuana’, ‘weed’, ‘pot’, ‘hash’, ‘skunk’, ‘resin’) and
optimised using two rounds of active learning classiﬁca-
tion of a further 1357 sentences. The resulting applica-
tion was tested against a reference standard of 233
human-classiﬁed sentences and an SVM marginal ﬁlter
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applied to obtain a minimum precision value (equiva-
lent to positive predictive value) of 90%. As frequency
and amount of cannabis use was not documented in
electronic health records in the BRC Case Register, a
binary variable deﬁned as any documentation of canna-
bis use by the patient at presentation with FEP was used.
In order to establish baseline cannabis use at the time of
presenting with FEP, the cannabis NLP application was
applied to clinical records documented within 1 month
of presentation to early intervention service as, by this
time, all patients would have completed a detailed clin-
ical assessment including assessment of substance use
history, allowing a reliable estimation of cannabis expos-
ure at presentation with FEP.
Clinical outcome measures and covariates
The primary outcome was number of psychiatric hos-
pital admissions within the follow-up period. Secondary
outcomes included any compulsory hospital admission
(under the UK Mental Health Act (MHA)) and number
of days spent in hospital during the follow-up period.
These outcome measures were obtained from structured
ﬁelds within the BRC Case Register. The MHA23 is a UK
statute law which allows for compulsory admission to
hospital for assessment and/or treatment of a mental
illness whose nature and/or degree necessitates hospital
admission and where a patient does not consent to be
voluntarily admitted. Admission under section 2 of the
MHA allows for up to 28 days compulsory admission for
assessment of mental illness. Admission under section 3
of the MHA allows for up to 6 months compulsory
admission for treatment of mental illness. A patient
admitted under section 2 may subsequently be placed
under section 3 of the MHA. Compulsory hospital
admission in this study was deﬁned as admission to a
hospital under section 2 or 3 of the MHA.
The number of unique antipsychotic medications pre-
scribed (as a proxy measure of treatment failure) and
whether individuals were prescribed clozapine during
the follow-up period were also obtained. The number of
unique antipsychotics was analysed as a potential mediat-
ing factor in determining association of cannabis use
with the primary and secondary outcome variables.
The following variables were extracted as covariates
for multivariable analyses: age, gender, ethnicity, marital
status and diagnosis. All covariate data obtained were
those closest to the date of being accepted by an early
intervention service. Ethnicity was recorded according to
categories deﬁned by the UK Ofﬁce for National
Statistics.24 Diagnosis was recorded using the
International Classiﬁcation of Diseases (ICD)-10 classiﬁ-
cation system, in the following groups: schizophrenia
and related disorders (schizophrenia (F20), delusional
disorder (F22), schizophrenia-like disorders (F23, F28
and F29)), schizoaffective disorder (F25), mania (F30)
or bipolar disorder (F31), psychotic depression (F32.3,
F33.3), drug-related psychosis (F1x.5) and other psych-
otic disorder not otherwise speciﬁed. The data were
analysed using STATA (V.12) (StataCorp. Stata Statistical
Software: Release 12. Coll Station TX StataCorp LP.
2011) using methods described subsequently.
Follow-up period
Outcome data were collected up to 31 March 2014. All
participants were assessed for outcomes within
12 months of the date of being accepted to an early
intervention service (2026 person-years). Participants
with sufﬁcient follow-up data were also assessed for out-
comes within 24 months (n=1738; 3476 person-years),
36 months (n=1461; 4383 person-years), 48 months
(n=1185; 4740 person-years) and 60 months (n=926;
4630 person-years). Analyses were performed over dis-
crete periods of follow-up rather than using survival ana-
lysis owing to non-proportionality of hazards over time
for the clinical outcomes described above and in order




Descriptive statistics for predictor, covariate, mediating
and outcome variables were obtained as means and SDs
for continuous variables (age and number of inpatient
days), means and variances for count variables (number
of hospital admissions and number of unique anti-
psychotic medications), and as frequencies and percen-
tages for all other variables.
Associations of cannabis use with demographic factors and
clinical outcome
The Mann-Whitney test was used to analyse differences
in mean age at presentation (depending on cannabis
use) in addition to analysis of age as a categorical vari-
able in regression analyses. Owing to overdispersion (see
supplementary material: eTables 1–5), associations with
number of hospital admissions and number of unique
antipsychotic medications were analysed using multivari-
able negative binomial regression. Although there was
an excess of zero values for number of hospital admis-
sions at 1-year, 2-year and 3-year follow-up, ﬁtting a
zero-inﬂated negative binomial regression model
resulted in no meaningful difference compared with
standard negative binomial regression (Vuong p>0.05
for all models). The association of cannabis use with
compulsory hospital admission was assessed using multi-
variable binary logistic regression. Association with
number of inpatient days was assessed using multiple
linear regression. Reference groups for covariates in
regression analyses were deﬁned as those with the great-
est prevalence within each variable. Where covariate
data were not recorded (83 participants with unre-
corded marital status), this was included as a predictor
variable in regression analyses. No patients were
dropped from analyses due to missing covariate data.
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Mediation of outcomes by antipsychotic treatment failure
In order to test the potential mediation of the effect of
cannabis use on outcome variables by antipsychotic
treatment failure, an exploratory mediation analysis was
performed using the PARAMED module in STATA.25
This is an extension of the Baron and Kenny method26
in which a regression model examining the association
between the proposed mediator variable and predictor
variable is compared with a regression model examining
the association between the outcome and the predictor
together with the proposed mediator variable. A coun-
terfactual framework which allows for interactions
between the exposure and mediator variables is then
used to compare the two models to estimate the direct
effect of the predictor variable on outcome and the
indirect effect of the predictor variable on outcome via
the proposed mediator variable.27 Comparison of the
magnitude of the direct and indirect effect allows for
estimation of the proportion of total effect that is
mediated. In this study, the number of unique antipsy-
chotics (a proxy measure of treatment failure) was
selected as a potentially mediating variable of the effect
of cannabis use on outcomes (analysed as a linear vari-
able), with age, gender, diagnosis, ethnicity and marital
status as covariates. The results are reported as the
natural direct effect of cannabis use on outcomes, the
natural indirect effect of cannabis use on outcomes
mediated by number of unique antipsychotics, and the
estimated total effect representing the combined natural
direct and indirect effect (ﬁgure 1). The percentage of
the total effect mediated by number of unique antipsy-
chotics was estimated for the number of days spent in
hospital by dividing the natural indirect effect estimate
by the total effect and for the number of admissions to
hospital and compulsory hospital admission by dividing
the natural logarithm of the natural indirect effect by
the natural logarithm of the total effect.
RESULTS
Cannabis use among individuals with FEP
Of the total sample, 939 individuals (46.3%) with FEP
were found to have a documented history of cannabis
use at presentation to early intervention services. Table 1
shows the breakdown of cannabis use by age, gender,
ethnicity, marital status and diagnosis. In a multivariable
logistic regression analysis (table 1), cannabis use was
independently associated with the 16–25-year age group,
male gender, single marital status and with a diagnosis
of drug-induced psychosis. Cannabis users presented at
a younger age than those without documented cannabis
use (23.8 vs 24.9 years, Mann-Whitney z=3.84, p<0.001).
There was no signiﬁcant association of cannabis use with
ethnicity and cannabis use was less likely among those
with psychotic depression or other psychotic disorder
not otherwise speciﬁed than those with a diagnosis of
schizophrenia.
Hospital admission
Figure 2A, B illustrate the mean number of hospital
admissions and likelihood of compulsory hospital admis-
sion (under the UK MHA) up to 5 years following pres-
entation. Corroborated by multivariable regression
analyses (table 2), a recorded history of cannabis use
was associated with a signiﬁcant increase in the number
of hospital admissions each year after presentation up to
year 5, and a signiﬁcantly increased likelihood of com-
pulsory hospital admission. The data also showed a
greater mean number of days spent in hospital, signiﬁ-
cant from year 2 onwards, following presentation with a
history of cannabis use (ﬁgure 2C).
Exploratory mediation analysis
Cannabis use was associated with an increased cumulative
likelihood of clozapine (see supplementary material:
eTable 4) and number of unique antipsychotics (see sup-
plementary material: eTable 5) prescribed up to 5 years
following ﬁrst presentation. The number of unique anti-
psychotics prescribed during this period ranged from 0
to 11. While there were no statistically signiﬁcant differ-
ences in clozapine prescription on multivariable logistic
regression analysis (see supplementary material:
eTable 6), multivariable negative binomial regression
(see supplementary material: eTable 7) indicated that a
history of cannabis use was associated with an increase in
number of unique antipsychotic prescriptions per
patient. The exploratory mediation analysis revealed that
at 5-year follow-up (table 3) the total effect of cannabis
on outcomes was partially mediated by the number of
unique antipsychotics prescribed. This was indicated by a
signiﬁcant natural indirect effect of the mediated
pathway (ﬁgure 1) for each of the three outcomes. The
effect of mediation was greatest for the number of days
Figure 1 Mediation analysis.
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spent in hospital where number of unique antipsychotics
(17.9 days, 95% CI 2.4 to 33.4) mediated 51.4% of the
total effect (34.8 days, 95% CI 11.6 to 58.1). Outcomes
ascertained at follow-up prior to 5 years (see supplemen-
tary material: eTable 8) also indicated similar ﬁndings
with respect to the mediation effect of number of unique
antipsychotics on hospital admission outcomes. However,
care should be taken in interpreting these ﬁndings owing
to the possibility of unmeasured confounding and tem-
poral ambiguity between the mediator and outcome
variables.
DISCUSSION
We investigated the impact of cannabis use on outcome
as indexed by the number of hospital admissions follow-
ing onset of illness in a large sample of patients with
FEP. The analysis captured data for all 2026 residents
who received treatment from early intervention services
in four London boroughs over an 8-year timeframe and
who had been followed up for up to 5 years.
The use of data recorded in electronic health records
presented some challenges in conducting the present
study. In particular, the ascertainment of cannabis use
was dependent on documentation by a healthcare pro-
fessional in the course of delivering mental healthcare.
Despite this, it was possible to identify cannabis use from
electronic health records with a high level of precision.
The prevalence of a documented history of cannabis use
within 1 month of acceptance by early intervention ser-
vices was 46.3% in the present study. This is consistent
with the high levels of lifetime cannabis use reported in
other FEP studies (West London 63%28; Cambridge
80.3%29). However, it is possible that the prevalence
Table 1 Multivariable logistic regression analysis of clinical and demographic factors and history of cannabis use at








OR (95% CI), p value
*Multivariable analysis
OR (95% CI), p value
Age <16 years 19 10.5 0.11 (0.03 to 0.48),
p=0.003
0.12 (0.03 to 0.53), p=0.005
Age 16–25 years 1234 51.7 Reference Reference
Age 26–35 years 747 39.0 0.60 (0.50 to 0.72),
p<0.001
0.70 (0.57 to 0.85), p=0.017
Age >35 years 26 30.8 0.42 (0.18 to 0.96),
p=0.04
0.48 (0.20 to 1.14), p=0.006
Female 731 30.5 0.35 (0.29 to 0.43),
p<0.001
0.39 (0.32 to 0.48), p<0.001
Male 1295 55.3 Reference Reference
White 616 49.8 1.21 (0.99 to 1.48),
p=0.06
1.17 (0.95 to 1.45), p=0.15
Asian 126 38.9 0.78 (0.53 to 1.13),
p=0.19
0.84 (0.56 to 1.25), p=0.38
Black 1005 45.1 Reference Reference
Other 279 46.6 1.06 (0.81 to 1.39),
p=0.65
1.13 (0.84 to 1.50), p=0.42
Married/cohabiting 153 28.8 0.41 (0.28 to 0.59),
p<0.001
0.56 (0.38 to 0.82), p=0.003
Divorced/separated 63 23.9 0.32 (0.18 to 0.57),
p<0.001
0.47 (0.26 to 0.87), p=0.02
Single 1727 49.4 Reference Reference
Marital status not recorded 83 31.3 0.47 (0.29 to 0.75),
p=0.002
0.50 (0.30 to 0.82), p=0.006
Schizophrenia and related 1097 48.4 Reference Reference
Bipolar disorder 100 52.0 1.15 (0.77 to 1.74,
p=0.49)
1.44 (0.93 to 2.22), p=0.10
Psychotic depression 94 30.9 0.48 (0.30 to 0.75,
p=0.001)
0.56 (0.35 to 0.90), p=0.02
Schizoaffective disorder 35 34.2 0.56 (0.27 to 1.13,
p=0.10)
0.72 (0.35 to 1.51), p=0.39
Drug-induced psychosis 63 79.0 4.10 (0.62 to 0.92,
p<0.001)
3.12 (1.64 to 5.88), p<0.001
Other psychotic disorder 637 41.6 0.76 (0.62 to 0.92,
p=0.006)
0.79 (0.64 to 0.97), p=0.02
*Multivariable analysis adjusted for all factors presented in table (and no others).
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identiﬁed in our study underestimated cannabis use
owing to under-reporting by patients during clinical
assessment. The sample demographic was characteristic-
ally young and male, converging with demographic
characteristics of other FEP cohorts.4 10 30 31
Our ﬁndings suggest that patients with a history of
cannabis use recorded at presentation to an early inter-
vention service were more likely to be admitted to hos-
pital, to require compulsory admission to hospital, and
to spend longer in hospital in the 5 years following pres-
entation. We demonstrated an association between can-
nabis use and the number of different antipsychotics
prescribed during the follow-up period (a proxy marker
for treatment failure). Finally, the association between
cannabis use and the number of unique antipsychotics
was found to mediate the increased risk of subsequent
hospitalisation, particularly with respect to number of
days spent in hospital.
In the present study, it was not possible to establish on
the basis of data recorded in electronic health records
whether patients were deemed by clinicians to be resist-
ant to a given antipsychotic following a treatment trial at
an adequate dose for an adequate duration before they
were changed to another. It is also possible that change
to a new antipsychotic may have been prompted by
admission to hospital due to a relapse. Nevertheless,
change to a different antipsychotic, whether as a result
of treatment resistance or poor tolerability, suggests a
clinical judgement of failure of treatment with the previ-
ous antipsychotic. Regardless of whether the change to a
new antipsychotic medication occurred in the commu-
nity or after an admission to hospital, it is likely that any
change in antipsychotic represented a failure of treat-
ment, which must have preceded relapse of illness and
hospital admission. Together, these results based on clin-
ical decisions documented by clinicians unbiased by
awareness of the objectives of the present study, suggest
that cannabis use may be associated with increased risk
of hospitalisation in psychosis due to an association with
antipsychotic treatment failure. There are a number of
ways in which cannabis use may have been associated
with antipsychotic treatment failure as suggested by the
use of multiple different antipsychotics, including a poor
response to treatment, poor adherence to treatment and
the presence of adverse side effects. Recent studies have
linked a poor response to antipsychotic treatment to the
presence of a non-dopaminergic pathophysiology in a
subgroup of patients with psychotic disorders.32 It is pos-
sible that increased cannabis use among people with
greater number of unique antipsychotics could reﬂect
reduced dopamine synthesis capacity33 which could
reduce response to dopamine receptor blocking anti-
psychotic medications. Another possibility is that poor
medication adherence among such individuals could
have an inﬂuence on increased number of unique anti-
psychotics.5 12 It is noteworthy that in our study, cannabis
was associated with an increased likelihood of compul-
sory hospital admission. A previous study suggests that
poor medication adherence is associated with compul-
sory admission and might also explain its association with
cannabis use.34 While we were not able to tease apart the
precise contribution of these various factors to anti-
psychotic treatment failure, future studies would need to
focus on this area, as this may help develop newer strat-
egies for addressing the harmful effects of cannabis.
There are some limitations which should be consid-
ered in interpreting the results of this study. The
Figure 2 (A) Mean number of hospital admissions among
individuals with first episode psychosis with and without
documented cannabis use at presentation. (B) Cumulative
percentage of patients with first episode psychosis admitted to
hospital compulsorily under the UK Mental Act with and
without documented cannabis use at presentation. (C) Mean
number of days spent in hospital following first episode
psychosis depending on history of cannabis use at
presentation.
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ﬁndings presented in this study are based on observa-
tional, prospectively recorded clinical data. For this
reason, it is not possible to infer any aetiological associ-
ation between cannabis use and greater risk of hospital-
isation or treatment failure. However, it would not be
feasible or ethical to conduct a randomised controlled
trial to investigate the impact of cannabis use on clinical
outcomes. We sought to investigate the potential medi-
ation of relapse (indexed by hospital admission) by
treatment failure (indexed by the number of unique
antipsychotics prescribed). It is possible that switch to a
new antipsychotic may have occurred after hospital
admission thereby resulting in reversal of mediator and
outcome. However, even in cases where switch to a new
antipsychotic may have occurred after hospitalisation, it
is extremely unlikely that hospital admission triggered
the treatment failure that resulted in a need to change
antipsychotic therapy. This implies that even in cases
where documentation of a change in antipsychotic
occurs after hospital admission, the failure of treatment
still occurred prior to admission, and so this may have
affected the validity of the exploratory mediation analysis
resulting in an underestimate of the effect of number of
unique antipsychotics on hospital admission outcomes.
Although we sought to adjust multivariable analyses
for potentially confounding factors including age,
gender, ethnicity, marital status and diagnosis, there
may be other unmeasured confounding genetic and
environmental factors (including use of alcohol or
other illicit substances) which may have inﬂuenced the
association of cannabis use with outcomes, as well as
differences in positive and negative symptom dimen-
sions which we were unable to measure in our study.
Unmeasured confounding may also have affected the
results from the exploratory mediation analysis investi-
gating number of unique antipsychotics and the associ-
ation of cannabis on clinical outcomes. For this reason,
it is not possible to conclude that antipsychotic treat-
ment failure is the greatest determinant of poor clinical
outcomes in relation to cannabis use and there are
likely to be other genetic and environmental factors
that could inﬂuence the effect of cannabis on clinical
outcomes in FEP.
In the present study, we investigated the association of
cannabis use documented at presentation with FEP with
future clinical outcomes. This was deﬁned as cannabis use
in clinical documents recorded within 1 month of presen-
tation to early intervention services. Within the ﬁrst
month of presentation, all participants are likely to have
undergone a comprehensive clinical assessment allowing
systematic ascertainment of documented cannabis use
across the whole cohort at inception. However, this
method may have underestimated cannabis use owing to
under-reporting by patients during clinical assessment. A
further bias may have been introduced by selective docu-
mentation of assessing clinicians such that documentation
of cannabis use was more likely if it was deemed to be of
relevance to a patient’s clinical presentation.
It is possible that cannabis use varied during the period
of follow-up with some people ceasing to use cannabis
and others starting to use it. Previous studies suggest that
discontinuation of cannabis is associated with improved
clinical outcomes in people with FEP35 36 and bipolar dis-
order.37 However, owing to varying level of engagement
with mental health services, varying degrees of illness
severity and emigration outside the catchment area of
clinical services, it was not possible to systematically ascer-
tain ongoing cannabis use in clinical records analysed in
this study. It may be that future long-term outcomes were
inﬂuenced by changes in cannabis use over time.
However, if this were the case, it is likely that such vari-
ation would have diluted associations with clinical out-
comes based on assignment of cannabis use at ﬁrst
presentation to clinical services. It is therefore noteworthy
that differences in outcomes based on a history of canna-
bis use at presentation persisted even at 5-year follow-up.
In fact, preliminary analysis of ongoing work in patients
with FEP from the same catchment area (n=95) that
includes systematic documentation of continuing canna-
bis use over the follow-up period (by combining clinical
records as in the present study with face-to-face research
interviews) suggest that 70% of patients with a history of
cannabis use at presentation with FEP continued to use
cannabis after 3 years, with no new cannabis users who
started using following onset of FEP.38 Hence, taking into
consideration the effect of continuing cannabis use would
Table 2 Multivariable analyses of relationship between history of cannabis use at presentation with first episode psychosis





*Number of admissions to
hospital Incidence rate ratio
(95% CI), p value
†Compulsory hospital admission
OR (95% CI), p value
‡Number of days spent
in hospital β coefficient
(95% CI), p value
1 year 2026 1.37 (1.21 to 1.56), p<0.001 1.33 (1.06 to 1.67), p=0.02 4.1 (−0.6 to 8.7), p=0.09
2 years 1738 1.40 (1.23 to 1.59), p<0.001 1.45 (1.16 to 1.81), p=0.001 9.6 (0.7 to 18.5), p=0.03
3 years 1461 1.48 (1.28 to 1.70), p<0.001 1.65 (1.30 to 2.09), p<0.001 21.6 (8.5 to 34.8), p=0.001
4 years 1185 1.51 (1.29 to 1.76), p<0.001 1.56 (1.20 to 2.02), p=0.001 24.1 (6.1 to 42.0), p=0.009
5 years 926 1.50 (1.25 to 1.80), p<0.001 1.55 (1.16 to 2.08), p=0.003 35.1 (12.1 to 58.1), p=0.003
Results adjusted for age, gender, ethnicity, marital status and psychotic diagnosis.
*Multivariable negative binomial regression.
†Multivariable logistic regression.
‡Multiple linear regression.
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not have changed the direction of the results reported
here, but rather would have demonstrated a stronger
adverse effect of cannabis use on outcome in FEP.
Using the cannabis NLP application, it was possible to
determine history of cannabis use at presentation with
FEP, but it was not possible to determine frequency or
amount of cannabis use as this was not systematically
recorded in the electronic health record data analysed in
this study. Despite this, our ﬁndings demonstrated that
any cannabis use was signiﬁcantly associated with poor
clinical outcomes, and while the strength of this associ-
ation may have been greater with increased amount and
frequency of cannabis use, such variation is unlikely to
have substantially altered the overall association of any can-
nabis use with poor clinical outcomes that we report here.
These limitations are balanced with the strengths of
investigating cannabis use in a large sample of all indivi-
duals receiving mental healthcare in early intervention ser-
vices. Our ﬁndings are therefore directly relevant to
people who receive care for psychotic disorders in stand-
ard clinical practice. The ﬁndings presented in this study
highlight a clear association between cannabis use and
hospitalisation in people with FEP. The fact that over
5 years, cannabis use is associated with 35 additional days
spent in hospital has important implications for affected
individuals as well healthcare service providers, particularly
as almost half of the participants in our study had a history
of cannabis use at presentation to early intervention ser-
vices. This also is the ﬁrst published study to demonstrate
the potential mediation of cannabis use with poorer out-
comes by a failure of antipsychotic treatment, albeit with
the limitations described previously. Taken together, these
ﬁndings highlight the importance of ascertaining cannabis
use in people receiving care for psychotic disorders and
prompt further study to investigate the mechanisms under-
lying poor clinical outcomes in people who use cannabis
and strategies to reduce associated harms.
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eTable 1: Mean number of hospital admissions among individuals with first episode psychosis with 
and without documented cannabis use at presentation 
Follow-up period History of cannabis use 
Mean number of admissions 
(variance, n) 
No history of cannabis use 
Mean number of admissions 
(variance, n) 
1 year, n=2026 0.73 (0.80, n=939) 0.52 (0.70, n=1087) 
2 years, n=1738 1.00 (1.36, n=779) 0.70 (1.13, n=959) 
3 years, n=1461 1.31 (2.60, n=637) 0.88 (1.74, n=824) 
4 years, n=1185 1.55 (3.75, n=492) 1.03 (2.36, n=693) 
5 years, n=926 1.78 (4.64, n=367) 1.19 (3.49, n=559) 
 
eTable 2: Cumulative number of patients with first episode psychosis admitted to hospital 
compulsorily under the UK Mental Health Act with and without documented cannabis use at 
presentation 
Follow-up period History of cannabis use 
Compulsory admission n (%) 
No history of cannabis use 
Compulsory admission n (%) 
1 year, n=2026 230 (24.5%) 194 (17.9%) 
2 years, n=1738 262 (33.6%) 237 (24.7%) 
3 years, n=1461 255 (40.0%) 227 (27.6%) 
4 years, n=1185 211 (42.9%) 215 (31.0%) 
5 years, n=926 164 (44.7%) 187 (33.5%) 
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eTable 3: Mean number of days spent in hospital following first episode psychosis depending on 
history of cannabis use 
Follow-up period History of cannabis use 
Mean number of inpatient 
days (std dev, n) 
No history of cannabis use 
Mean number of inpatient 
days (std dev, n) 
1 year, n=2026 27.6 (52.2, n=939) 22.0 (50.3, n=1087) 
2 years, n=1738 50.4 (98.0, n=779) 36.6 (83.6, n=959) 
3 years, n=1461 76.2 (139.7, n=637) 48.5 (107.1, n=824) 
4 years, n=1185 95.0 (167.8, n=492) 62.3 (138.6, n=693) 
5 years, n=926 112.3 (200.0, n=367) 70.2 (150.3, n=559) 
 
eTable 4: Cumulative number of patients with first episode psychosis with and without documented 
cannabis use at presentation who were subsequently prescribed clozapine 
Follow-up period History of cannabis use 
Clozapine n (%) 
No history of cannabis use 
Clozapine n (%) 
1 year, n=2026 29 (3.1%) 33 (3.0%) 
2 years, n=1738 54 (6.9%) 57 (5.9%) 
3 years, n=1461 69 (10.8%) 64 (7.8%) 
4 years, n=1185 63 (12.8%) 76 (11.0%) 
5 years, n=926 58 (15.8%) 67 (12.0%) 
 
eTable 5: Mean number of uniquely prescribed antipsychotics among individuals with first episode 
psychosis with and without documented cannabis use at presentation 
Follow-up period History of cannabis use 
Mean number of antipsychotics 
(variance, n) 
No history of cannabis use 
Mean number of antipsychotics 
(variance, n) 
1 year, n=2026 1.67 (1.37, n=939) 1.49 (1.34, n=1087) 
2 years, n=1738 2.05 (2.14, n=779) 1.80 (2.09, n=959) 
3 years, n=1461 2.30 (2.77, n=637) 1.98 (2.70, n=824) 
4 years, n=1185 2.47 (3.28, n=492) 2.20 (3.22, n=693) 
5 years, n=926 2.68 (3.98, n=367) 2.34 (3.66, n=559) 
 
eTable 6: Multivariable logistic regression analysis of association between history of cannabis use at 
presentation with first episode psychosis and clozapine prescription during follow-up period 
Follow-up period Clozapine prescription 
Odds ratio (95% CI, p value) 
1 year, n=2026 0.90 (0.53 to 1.53, p=0.69) 
2 years, n=1738 1.00 (0.66 to 1.49, p=0.98) 
3 years, n=1461 1.32 (0.90 to 1.92, p=0.15) 
4 years, n=1185 0.99 (0.68 to 1.44, p=0.95) 
5 years, n=926 1.14 (0.77 to 1.71, p=0.51) 
Results adjusted for age, gender, ethnicity, marital status and psychotic diagnosis 
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eTable 7: Multivariable negative binomial regression analysis of association between history of 
cannabis use at presentation with first episode psychosis and number of unique antipsychotic 
medications prescribed during follow-up period 
Follow-up period Number of unique antipsychotics prescribed 
Incidence rate ratio (95% CI, p value) 
1 year, n=2026 1.13 (1.05 to 1.21), p=0.001 
2 years, n=1738 1.11 (1.03 to 1.19), p=0.004 
3 years, n=1461 1.15 (1.06 to 1.24), p=0.001 
4 years, n=1185 1.09 (1.00 to 1.19), p=0.05 
5 years, n=926 1.13 (1.02 to 1.25), p=0.02 
Results adjusted for age, gender, ethnicity, marital status and psychotic diagnosis 
Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis 
Online supplementary material – page 4 of 4 
eTable 8: Mediation analysis investigating association of history of cannabis use at presentation with clinical outcomes mediated by number of unique 
antipsychotics prescribed during follow-up period 
Outcome variable Follow-up period Natural direct effect (95% CI, p value) Natural indirect effect (95% CI, p value) Total effect (95% CI, p value) 
Number of admissions 
to hospital 
Incidence rate ratio 
1 year, n=2026 1.33 (1.11 to 1.60, p=0.002) 1.06 (1.03 to 1.09, p=0.001) 1.41 (1.17 to 1.70, p<0.001) 
2 years, n=1738 1.35 (1.14 to 1.60, p<0.001) 1.06 (1.02 to 1.11, p=0.006) 1.44 (1.21 to 1.71, p<0.001) 
3 years, n=1461 1.35 (1.16 to 1.58, p<0.001) 1.10 (1.04 to 1.16, p=0.001) 1.49 (1.26 to 1.76, p<0.001) 
4 years, n=1185 1.42 (1.22 to 1.66, p<0.001) 1.07 (1.00 to 1.14, p-0.07) 1.52 (1.28 to 1.80, p<0.001) 




1 year, n=2026 1.10 (0.75 to 1.62, p=0.63) 1.15 (1.06 to 1.24, p=0.001) 1.26 (0.85 to 1.88, p=0.26) 
2 years, n=1738 1.13 (0.71 to 1.81, p=0.60) 1.15 (1.04 to 1.27, p=0.006) 1.30 (0.80 to 2.12, p=0.29) 
3 years, n=1461 1.42 (0.94 to 2.15, p=0.10) 1.25 (1.09 to 1.43, p=0.002) 1.77 (1.12 to 2.80, p=0.02) 
4 years, n=1185 1.57 (0.89 to 2.77, p=0.12) 1.18 (0.99 to 1.41, p=0.07) 1.85 (1.00 to 3.41, p=0.05) 
5 years, n=926 1.39 (0.68 to 2.83, p=0.37) 1.27 (1.03 to 1.58, p=0.03) 1.76 (0.81 to 3.84, p=0.15) 
Number of days spent 
in hospital 
B coefficient (days) 
1 year, n=2026 0.3 (-3.9 to 4.4, p=0.90) 3.8 (1.7 to 5.9, p<0.001) 4.1 (-0.6 to 8.7, p=0.09) 
2 years, n=1738 2.2 (-5.4 to 9.7, p=0.57) 7.4 (2.2 to 12.5, p=0.005) 9.6 (0.6 to 18.5, p=0.04) 
3 years, n=1461 8.0 (-2.9 to 18.9, p=0.15) 13.6 (5.3 to 21.8, p<0.001) 21.6 (8.4 to 34.8, p<0.001) 
4 years, n=1185 13.2 (-1.3 to 27.7, p=0.07) 10.8 (-0.7 to 22.2, p=0.07) 24.0 (5.9 to 42.1, p=0.009) 
5 years, n=926 17.0 (-1.5 to 35.4, p=0.07) 17.9 (2.4 to 33.4, p=0.02) 34.8 (11.6 to 58.1, p=0.003) 
Natural direct effect: cannabis use  outcome 
Natural indirect effect: cannabis use  number of unique antipsychotics  outcome 













  accepted_date, 
  case 
   when accepted_date between '1 Apr 2006' and '31 Mar 
2007' then '2006-7' 
   when accepted_date between '1 Apr 2007' and '31 Mar 
2008' then '2007-8' 
   when accepted_date between '1 Apr 2008' and '31 Mar 
2009' then '2008-9' 
   when accepted_date between '1 Apr 2009' and '31 Mar 
2010' then '2009-10' 
   when accepted_date between '1 Apr 2010' and '31 Mar 
2011' then '2010-11' 
   when accepted_date between '1 Apr 2011' and '31 Mar 
2012' then '2011-12' 
   when accepted_date between '1 Apr 2012' and '31 Mar 
2013' then '2012-13' 
  end as 'accepted_year', 
  case 
   when accepted_date between '1 Apr 2006' and '31 Mar 
2007' then '1' 
   when accepted_date between '1 Apr 2007' and '31 Mar 
2008' then '2' 
   when accepted_date between '1 Apr 2008' and '31 Mar 
2009' then '3' 
   when accepted_date between '1 Apr 2009' and '31 Mar 
2010' then '4' 
   when accepted_date between '1 Apr 2010' and '31 Mar 
2011' then '5' 
   when accepted_date between '1 Apr 2011' and '31 Mar 
2012' then '6' 
   when accepted_date between '1 Apr 2012' and '31 Mar 
2013' then '7' 
  end as 'accepted_year_recode', 




  case 
   when 
    Location_Name like '%COAST%' or 
    Location_Name like '%Leo%' or 
    Location_Name like '%Lewisham Early%' or 
    Location_Name like 'STEP' 
   then '1' else '0' 
  end as 'EIS', 
  case 
   when 
    Location_Name like '%OASIS%' 
   then '1' else '0' 
  end as 'OASIS', 
  floor((datediff (day, p.cleaneddateofbirth , cast 
(accepted_date as datetime))/365)) age, 
  p.Gender_ID  Gender, 
  p.ethnicitycleaned ethnicity, 
  p.Marital_Status_ID marital_status, 
  p.Employment_ID Employment_status, 
  p.Housing_Status Accommodation_status  
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 select distinct brcid,accepted_date,Location_Name,ROW_NUMBER() 
 over (partition by brcid order by accepted_date) spell 
 from [brhnsql094].[SQLCRIS].[dbo].[Team_episode] r  
 where  
 Accepted_Date between '1 Apr 2006' and '31 Mar 2013' 
 and Referral_Admin_Status_ID not like 'rejected' 
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  Location_Name like '%Leo%' or 
  Location_Name like '%Lewisham Early%' or 
  Location_Name like '%OASIS%' or 
  Location_Name like 'STEP') 
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      ,r.[accepted_date] 
      ,r.[accepted_year] 
      ,r.[accepted_year_recode] 
      ,r.[location_name] 
      ,b.[diagnosis_date] 
      ,b.[primary_diagnosisrecode] 
 ,case 
  when ( 
   b.[primary_diagnosisrecode] like 'F2xSchizophrenia') 




   
  when ( 
   b.[primary_diagnosisrecode] like 'Bipolar') 
  then '2' 
   
  when ( 
   b.[primary_diagnosisrecode] like 
'PsychoticDepression') 
  then '3' 
   
  when ( 
   b.[primary_diagnosisrecode] like 'Schizoaffective') 
  then '4' 
 
  when ( 
   b.[primary_diagnosisrecode] like 'F1x.5DrugPsyc') 
  then '5' 
 
  when ( 
   b.[primary_diagnosisrecode] like 'OtherPsychosis') 
  then '6' 
   
  end as Firstpsychosisdiagnosisrecode2 
      ,r.[EIS] 
      ,r.[OASIS] 
      ,r.[age] 
      ,r.[Gender] 
      ,case 
  when  
   r.Gender like 'Female' 
  then '0' 
 
  when 
   r.Gender like 'Male' 
  then '1' 
 
  when 
   r.Gender like 'Not Known' 
  then '2' 
 
  end as GenderRecode2 
      ,r.[ethnicity] 
      ,case 
  when ( 
   r.ethnicity like 'Irish (B)' or 
   r.ethnicity like 'Any other white background (C)' or 
   r.ethnicity like 'British (A)') 





  when ( 
   r.ethnicity like 'Bangladeshi (K)' or 
   r.ethnicity like 'Pakistani (J)' or 
   r.ethnicity like 'Chinese (R)' or 
   r.ethnicity like 'Indian (H)' or 
   r.ethnicity like 'Any other Asian background (L)') 
  then 'Asian' 
 
  when ( 
   r.ethnicity like 'African (N)') 
  then 'BlackAfrican' 
 
  when ( 
   r.ethnicity like 'Caribbean (M)') 
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  when ( 
   r.ethnicity like 'Any other black background (P)' or 
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  then 'BlackOther' 
 
  when ( 
   r.ethnicity like 'White and Asian (F)' or 
   r.ethnicity like 'Any other mixed background (G)' or 
   r.ethnicity like 'Any other ethnic group (S)' or 
   r.ethnicity like 'Not Stated (Z)' or 
   r.ethnicity like 'None') 
  then 'Other' 
 
  end as ethnicrecode, 
 
      case 
  when ( 
   r.ethnicity like 'Irish (B)' or 
   r.ethnicity like 'Any other white background (C)' or 
   r.ethnicity like 'British (A)') 
  then '1' 
 
  when ( 
   r.ethnicity like 'Bangladeshi (K)' or 
   r.ethnicity like 'Pakistani (J)' or 
   r.ethnicity like 'Chinese (R)' or 
   r.ethnicity like 'Indian (H)' or 
   r.ethnicity like 'Any other Asian background (L)') 
  then '2' 
 
  when ( 
   r.ethnicity like 'African (N)') 





  when ( 
   r.ethnicity like 'Caribbean (M)') 
  then '4' 
 
  when ( 
   r.ethnicity like 'Any other black background (P)' or 
   r.ethnicity like 'White and Black African (E)') 
  then '5' 
 
  when ( 
   r.ethnicity like 'White and Asian (F)' or 
   r.ethnicity like 'Any other mixed background (G)' or 
   r.ethnicity like 'Any other ethnic group (S)' or 
   r.ethnicity like 'Not Stated (Z)' or 
   r.ethnicity like 'None') 
  then '6' 
 
  end as ethnicrecode2 
      ,r.[marital_status] 
      ,case 
  when ( 
   r.marital_status like 'Cohabiting' or 
   r.marital_status like 'Married' or 
   r.marital_status like 'Married/Civil Partner') 
  then 'MarriedCohabiting' 
 
  when ( 
   r.marital_status like 'Divorced' or 
   r.marital_status like 'Divorced/Civil Partnership 
Dissolved' or 
   r.marital_status like 'Separated') 
  then 'DivorcedSeparated' 
 
  when ( 
   r.marital_status like 'Single') 
  then 'Single' 
 
  when ( 
   r.marital_status like 'Widowed' or 
   r.marital_status like 'Widowed/Surviving Civil 
Partner') 
  then 'Widowed' 
 
  when ( 
   r.marital_status like 'Not Disclosed' or 
   r.marital_status like 'Not Known') 
  then 'NotRecorded' 




  end as maritalrecode, 
 
      case 
  when ( 
   r.marital_status like 'Cohabiting' or 
   r.marital_status like 'Married' or 
   r.marital_status like 'Married/Civil Partner') 
  then '1' 
 
  when ( 
   r.marital_status like 'Divorced' or 
   r.marital_status like 'Divorced/Civil Partnership 
Dissolved' or 
   r.marital_status like 'Separated') 
  then '2' 
 
  when ( 
   r.marital_status like 'Single') 
  then '3' 
 
  when ( 
   r.marital_status like 'Widowed' or 
   r.marital_status like 'Widowed/Surviving Civil 
Partner') 
  then '4' 
 
  when ( 
   r.marital_status like 'Not Disclosed' or 
   r.marital_status like 'Not Known') 
  then '5' 
   
  end as maritalrecode2 
      ,r.[Employment_status] 
      ,case 
  when ( 
   r.Employment_status like 'Volunteer' or 
   r.Employment_status like 'Self Employed' or 
   r.Employment_status like 'Part Time Employment' or 
   r.Employment_status like 'Paid Employment') 
  then 'Employed' 
 
  when ( 
   r.Employment_status like 'Govt Training Scheme' or 
   r.Employment_status like 'Full Time Student' or 
   r.Employment_status like 'Full Time Student - School 
age') 
  then 'Student' 
 




   r.Employment_status like 'Retired') 
  then 'Retired' 
 
  when ( 
   r.Employment_status like 'Registered Disabled' or 
   r.Employment_status like 'Unemployed') 
  then 'Unemployed' 
 
  when ( 
   r.Employment_status like 'Other' or 
   r.Employment_status like 'Not Known' or 
   r.Employment_status like 'xNx') 
  then 'NotRecorded' 
   
  end as employmentrecode, 
 
      case 
  when ( 
   r.Employment_status like 'Volunteer' or 
   r.Employment_status like 'Self Employed' or 
   r.Employment_status like 'Part Time Employment' or 
   r.Employment_status like 'Paid Employment') 
  then '1' 
 
  when ( 
   r.Employment_status like 'Govt Training Scheme' or 
   r.Employment_status like 'Full Time Student' or 
   r.Employment_status like 'Full Time Student - School 
age') 
  then '2' 
 
  when ( 
   r.Employment_status like 'Retired') 
  then '3' 
 
  when ( 
   r.Employment_status like 'Registered Disabled' or 
   r.Employment_status like 'Unemployed') 
  then '4' 
 
  when ( 
   r.Employment_status like 'Other' or 
   r.Employment_status like 'Not Known' or 
   r.Employment_status like 'xNx') 
  then '5' 
   
  end as employmentrecode2 
      ,r.[Accommodation_status] 




  when ( 
   r.Accommodation_status like 'Owner') 
  then 'Owner' 
 
  when ( 
   r.Accommodation_status like 'Private Tenant') 
  then 'PrivateTenant' 
 
  when ( 
   r.Accommodation_status like 'Council Tenant') 
  then 'CouncilTenant' 
 
  when ( 
   r.Accommodation_status like 'Trust' or 
   r.Accommodation_status like 'Nursing/Residential') 
  then 'SupportedAccommodation' 
 
  when ( 
   r.Accommodation_status like 'Homeless') 
  then 'Homeless' 
 
  when ( 
   r.Accommodation_status like 'Other') 
  then 'Other' 
 
  when ( 
   r.Accommodation_status like 'Not known' or 
   r.Accommodation_status like 'xNx') 
  then 'NotRecorded' 
   
  end as accommodationrecode, 
 
      case 
  when ( 
   r.Accommodation_status like 'Owner') 
  then '1' 
 
  when ( 
   r.Accommodation_status like 'Private Tenant') 
  then '2' 
 
  when ( 
   r.Accommodation_status like 'Council Tenant') 
  then '3' 
 
  when ( 
   r.Accommodation_status like 'Trust' or 
   r.Accommodation_status like 'Nursing/Residential') 





  when ( 
   r.Accommodation_status like 'Homeless') 
  then '5' 
 
  when ( 
   r.Accommodation_status like 'Other') 
  then '6' 
 
  when ( 
   r.Accommodation_status like 'Not known' or 
   r.Accommodation_status like 'xNx') 
  then '7' 
   
  end as accommodationrecode2 
 ,case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.accepted_date and 
   DATEADD(d,14,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  mhasection2w, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.accepted_date and 
   DATEADD(m,1,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  mhasection1m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.accepted_date and 
   DATEADD(m,3,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  mhasection3m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.accepted_date and 
   DATEADD(m,6,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  mhasection6m, 
 case when ( 




  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.accepted_date and 
   DATEADD(m,12,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  mhasection12m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.accepted_date and 
   DATEADD(m,24,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  mhasection24m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.accepted_date and 
   DATEADD(m,36,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  mhasection36m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.accepted_date and 
   DATEADD(m,48,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  mhasection48m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.mha_section 
  where 
   Start_Date between r.accepted_date and 
   DATEADD(m,60,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  mhasection60m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 
  where 
   admission_Date between r.accepted_date and 
   DATEADD(d,14,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  inpatient2w, 
 case when ( 
  select distinct brcid 




  where 
   admission_Date between r.accepted_date and 
   DATEADD(m,1,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  inpatient1m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 
  where 
   admission_Date between r.accepted_date and 
   DATEADD(m,3,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  inpatient3m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 
  where 
   admission_Date between r.accepted_date and 
   DATEADD(m,6,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  inpatient6m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 
  where 
   admission_Date between r.accepted_date and 
   DATEADD(m,12,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  inpatient12m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 
  where 
   admission_Date between r.accepted_date and 
   DATEADD(m,24,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  inpatient24m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 
  where 
   admission_Date between r.accepted_date and 
   DATEADD(m,36,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  inpatient36m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 




   admission_Date between r.accepted_date and 
   DATEADD(m,48,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  inpatient48m, 
 case when ( 
  select distinct brcid 
  from sqlcris.dbo.inpatient_episode 
  where 
   admission_Date between r.accepted_date and 
   DATEADD(m,60,r.accepted_date) and 
   brcid=r.brcid 
  ) IS  null then 0 else 1 end  inpatient60m, 
  (SELECT  COUNT(*) AS noofadmissions 
   FROM sqlcris.dbo.inpatient_episode 
   WHERE (BrcId = r.brcid) AND 
     (Admission_Date <= 
DATEADD(m,12,r.accepted_date)) AND 
     (Discharge_Date >= r.accepted_date) 
OR 
     (BrcId = r.brcid) AND 
     (Admission_Date <= 
DATEADD(m,12,r.accepted_date)) AND 
     (Discharge_Date = '1 Jan 1900') 
   GROUP BY BrcId) AS noofadmissions_12m, 
  (SELECT  COUNT(*) AS noofadmissions 
   FROM sqlcris.dbo.inpatient_episode 
   WHERE (BrcId = r.brcid) AND 
     (Admission_Date <= 
DATEADD(m,24,r.accepted_date)) AND 
     (Discharge_Date >= r.accepted_date) 
OR 
     (BrcId = r.brcid) AND 
     (Admission_Date <= 
DATEADD(m,24,r.accepted_date)) AND 
     (Discharge_Date = '1 Jan 1900') 
   GROUP BY BrcId) AS noofadmissions_24m, 
  (SELECT  COUNT(*) AS noofadmissions 
   FROM sqlcris.dbo.inpatient_episode 
   WHERE (BrcId = r.brcid) AND 
     (Admission_Date <= 
DATEADD(m,36,r.accepted_date)) AND 
     (Discharge_Date >= r.accepted_date) 
OR 
     (BrcId = r.brcid) AND 
     (Admission_Date <= 
DATEADD(m,36,r.accepted_date)) AND 
     (Discharge_Date = '1 Jan 1900') 
   GROUP BY BrcId) AS noofadmissions_36m, 




   FROM sqlcris.dbo.inpatient_episode 
   WHERE (BrcId = r.brcid) AND 
     (Admission_Date <= 
DATEADD(m,48,r.accepted_date)) AND 
     (Discharge_Date >= r.accepted_date) 
OR 
     (BrcId = r.brcid) AND 
     (Admission_Date <= 
DATEADD(m,48,r.accepted_date)) AND 
     (Discharge_Date = '1 Jan 1900') 
   GROUP BY BrcId) AS noofadmissions_48m, 
  (SELECT  COUNT(*) AS noofadmissions 
   FROM sqlcris.dbo.inpatient_episode 
   WHERE (BrcId = r.brcid) AND 
     (Admission_Date <= 
DATEADD(m,60,r.accepted_date)) AND 
     (Discharge_Date >= r.accepted_date) 
OR 
     (BrcId = r.brcid) AND 
     (Admission_Date <= 
DATEADD(m,60,r.accepted_date)) AND 
     (Discharge_Date = '1 Jan 1900') 
   GROUP BY BrcId) AS noofadmissions_60m, 
  SQLCrisImport.dbo.getlos(accepted_date, DATEADD(m, 12, 
accepted_date), r.brcid) AS los_12m, 
  SQLCrisImport.dbo.getlos(accepted_date, DATEADD(m, 24, 
accepted_date), r.brcid) AS los_24m, 
  SQLCrisImport.dbo.getlos(accepted_date, DATEADD(m, 36, 
accepted_date), r.brcid) AS los_36m, 
  SQLCrisImport.dbo.getlos(accepted_date, DATEADD(m, 48, 
accepted_date), r.brcid) AS los_48m, 
  SQLCrisImport.dbo.getlos(accepted_date, DATEADD(m, 60, 
accepted_date), r.brcid) AS los_60m, 
      case when ( 
  select distinct brcid 
  from 
[GateDB_Cris].[RPatel].[vw_gate_hunter_cannabis_filteredmatch] b 
  where b.prob >0.7524131 and ( 
   b.mlObservation1 like 'positive') 
   and 
   Convert(datetime,b.Document_Date,103) between 
DATEADD(m,-1,r.accepted_date) and DATEADD(m,1,r.accepted_date) 
   and 
   b.brcid=r.brcid 
  ) IS not null then 1 else 0 end Cannabis1m, 
  (select MAX(drugorder) 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 




   Start_Date <= DATEADD(d,14,r.accepted_date) and 
   brcid=r.brcid 
  group by brcid) as antipsychoticcount2w, 
  (select MAX(drugorder) 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,1,r.accepted_date) and 
   brcid=r.brcid 
  group by brcid) as antipsychoticcount1m, 
  (select MAX(drugorder) 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,3,r.accepted_date) and 
   brcid=r.brcid 
  group by brcid) as antipsychoticcount3m, 
  (select MAX(drugorder) 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,6,r.accepted_date) and 
   brcid=r.brcid 
  group by brcid) as antipsychoticcount6m, 
  (select MAX(drugorder) 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,12,r.accepted_date) and 
   brcid=r.brcid 
  group by brcid) as antipsychoticcount12m, 
  (select MAX(drugorder) 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,24,r.accepted_date) and 
   brcid=r.brcid 
  group by brcid) as antipsychoticcount24m, 
  (select MAX(drugorder) 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,36,r.accepted_date) and 
   brcid=r.brcid 
  group by brcid) as antipsychoticcount36m, 
  (select MAX(drugorder) 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 




   Start_Date <= DATEADD(m,48,r.accepted_date) and 
   brcid=r.brcid 
  group by brcid) as antipsychoticcount48m, 
  (select MAX(drugorder) 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,60,r.accepted_date) and 
   brcid=r.brcid 
  group by brcid) as antipsychoticcount60m, 
 case when ( 
  select distinct brcid 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(d,14,r.accepted_date) and 
   drugrecoded like 'Clozapine' and 
   brcid=r.brcid 
  ) IS null then 0 else 1 end Clozapine2w, 
 case when ( 
  select distinct brcid 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,1,r.accepted_date) and 
   drugrecoded like 'Clozapine' and 
   brcid=r.brcid 
  ) IS null then 0 else 1 end Clozapine1m, 
 case when ( 
  select distinct brcid 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,3,r.accepted_date) and 
   drugrecoded like 'Clozapine' and 
   brcid=r.brcid 
  ) IS null then 0 else 1 end Clozapine3m, 
 case when ( 
  select distinct brcid 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,6,r.accepted_date) and 
   drugrecoded like 'Clozapine' and 
   brcid=r.brcid 
  ) IS null then 0 else 1 end Clozapine6m, 
 case when ( 




  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,12,r.accepted_date) and 
   drugrecoded like 'Clozapine' and 
   brcid=r.brcid 
  ) IS null then 0 else 1 end Clozapine12m, 
 case when ( 
  select distinct brcid 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,24,r.accepted_date) and 
   drugrecoded like 'Clozapine' and 
   brcid=r.brcid 
  ) IS null then 0 else 1 end Clozapine24m, 
 case when ( 
  select distinct brcid 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,36,r.accepted_date) and 
   drugrecoded like 'Clozapine' and 
   brcid=r.brcid 
  ) IS null then 0 else 1 end Clozapine36m, 
 case when ( 
  select distinct brcid 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,48,r.accepted_date) and 
   drugrecoded like 'Clozapine' and 
   brcid=r.brcid 
  ) IS null then 0 else 1 end Clozapine48m, 
 case when ( 
  select distinct brcid 
  from 
[SQLCRIS_User].[RPatel].[tbl_rp_EIScohort_Antipsychoticafter_collapsed] 
  where 
   Start_Date <= DATEADD(m,60,r.accepted_date) and 
   drugrecoded like 'Clozapine' and 
   brcid=r.brcid 
  ) IS null then 0 else 1 end Clozapine60m 
  FROM [SQLCRIS_User].[RPatel].[rp_EIScohort] r 


















































      ,[source_table] 
      ,[start_date] 
      ,[drug] 
      ,[drugrecoded] 
      ,[cn_doc_id] 
  FROM [SQLCRIS_User].[RPatel].[rp_EIScohort] a 
  left join 
[SQLCRIS_User].[RPatel].[rp_medication_combined_antipsychotic_recode] b on 
a.brcid=b.brcid 
















      ,ROW_NUMBER() OVER(PARTITION BY brcid ORDER BY start_date ASC) 
drugorder 
      ,[start_date] 
      ,[drugrecoded] 
FROM ( 
  SELECT brcid, 
    start_date, 
    drugrecoded, 
    ROW_NUMBER() OVER(PARTITION BY 
drugrecoded,brcid ORDER BY start_date ASC) rn 
   FROM 
[SQLCRIS_User].[RPatel].[rp_EIScohort_Antipsychoticafter] 
   ) a 
















brcid  start_date  drugrecoded  rn  drugorder 
4568135  02/05/2006  Olanzapine  1  1 
4568135  05/05/2006  Olanzapine  2  1 
4568135  14/07/2006  Risperidone  1  2 
4568135  15/07/2006  Risperidone  2  2 
4568135  19/07/2006  Risperidone  3  2 
4568135  24/07/2006  Risperidone  4  2 
4568135  15/09/2006  Risperidone  5  2 
4568135  18/04/2008  Aripiprazole  1  3 
4568135  24/04/2008  Aripiprazole  2  3 
4568135  26/04/2008  Aripiprazole  3  3 
4568135  30/04/2008  Aripiprazole  4  3 
4568135  02/05/2008  Aripiprazole  5  3 
 
Running the query described above would reduce the output to the following: 
brcid  start_date  drugrecoded  drugorder 
4568135  02/05/2006  Olanzapine  1 
4568135  14/07/2006  Risperidone  2 














      ,[source_table] 
      ,[diagnosis_date] 
      ,[primary_diagnosis] 
      ,[cn_doc_id] 
  FROM [SQLCRIS_User].[RPatel].[rp_EIScohort] a 
  left join [SQLCrisImport].[dbo].[diagnosis_combined] b on a.brcid=b.brcid 
  where diagnosis_date>=a.accepted_date and 
(primary_diagnosis LIKE '%psychotic%' OR 
primary_diagnosis LIKE '%psychosis%' OR 
primary_diagnosis LIKE '%with psyc%' OR 
primary_diagnosis LIKE '%schizophreni%' OR 
primary_diagnosis LIKE '%scizophreni%' OR 
primary_diagnosis LIKE '%schizotyp%' OR 
primary_diagnosis LIKE '%scizotyp%' OR 
primary_diagnosis LIKE '%delusion%' OR 
primary_diagnosis LIKE '%hallucin%' OR 
primary_diagnosis LIKE '%thought disorder%' OR 
primary_diagnosis LIKE '%first rank%' OR 
primary_diagnosis LIKE '%schizoaffect%' OR 
primary_diagnosis LIKE '%scizoaffect%' OR 
primary_diagnosis LIKE '%mania%' OR 
primary_diagnosis LIKE '%manic%' OR 
primary_diagnosis LIKE '%f20%' OR 
primary_diagnosis LIKE '%f21%' OR 
primary_diagnosis LIKE '%f22%' OR 
primary_diagnosis LIKE '%f23%' OR 
primary_diagnosis LIKE '%f24%' OR 
primary_diagnosis LIKE '%f25%' OR 
primary_diagnosis LIKE '%f28%' OR 
primary_diagnosis LIKE '%f29%' OR 
primary_diagnosis LIKE '%f30%' OR 




primary_diagnosis LIKE '%f32.3%' OR 
primary_diagnosis LIKE '%f33.3%') AND 
primary_diagnosis NOT LIKE '%without psyc%' AND 
primary_diagnosis NOT LIKE '%personality%' AND 
primary_diagnosis NOT LIKE '%trichotil%' AND 
primary_diagnosis NOT LIKE '%kleptomani%' AND 














    [diagnosis_date], 
    [primary_diagnosis] primary_diagnosisraw, 
    [cn_doc_id], 
 case 
  when ( 
   primary_diagnosis like '%schizophreni%' or 
   primary_diagnosis like '%scizophreni%' or 
   primary_diagnosis like '%schizotyp%' or 
   primary_diagnosis like '%scizotyp%' or 
   primary_diagnosis like '%f20%' or 
   primary_diagnosis like '%f21%' or 
   primary_diagnosis like '%f22%' or 
   primary_diagnosis like '%f23%' or 
   primary_diagnosis like '%f24%' or 
   primary_diagnosis like '%f28%' or 
   primary_diagnosis like '%f29%') 





  when ( 
   primary_diagnosis like '%schizoaffect%' or 
   primary_diagnosis like '%scizoaffect%' or 
   primary_diagnosis like '%f25%') 
  then 'Schizoaffective' 
 
  when ( 
   primary_diagnosis like '%f30%' or 
   primary_diagnosis like '%f31%' or 
   primary_diagnosis like '%manic%' or 
   primary_diagnosis like '%mania%' or 
   primary_diagnosis like '%bipolar%' or 
   primary_diagnosis like '%bpad%' or 
   primary_diagnosis like '%affective disorder%' or 
   primary_diagnosis like '%mixed affective%') and 
   primary_diagnosis not like '%trichotillomania%' and 
   primary_diagnosis not like '%kleptomania%' 
  then 'Bipolar' 
 
  when ( 
   primary_diagnosis like '%psychosis%' or 
   primary_diagnosis like '%psychotic%' or 
   primary_diagnosis like '%with psyc%' or 
   primary_diagnosis like '%f32.3%' or 
   primary_diagnosis like '%f33.3%') and 
   (primary_diagnosis like '%depress%' or 
   primary_diagnosis like '%f32%' or 
   primary_diagnosis like '%f33%') and 
   primary_diagnosis not like '%without%' 
  then 'PsychoticDepression' 
 
  when ( 
   primary_diagnosis like '%drug%' or 
   primary_diagnosis like '%alcohol%' or 
   primary_diagnosis like '%opioid%' or 
   primary_diagnosis like '%opiate%' or 
   primary_diagnosis like '%cannabi%' or 
   primary_diagnosis like '%benzo%' or 
   primary_diagnosis like '%hallucinogen%' or 
   primary_diagnosis like '%cocaine%' or 
   primary_diagnosis like '%cannabis%' or 
   primary_diagnosis like '%f10%' or 
   primary_diagnosis like '%f11%' or 
   primary_diagnosis like '%f12%' or 
   primary_diagnosis like '%f13%' or 
   primary_diagnosis like '%f14%' or 
   primary_diagnosis like '%f15%' or 
   primary_diagnosis like '%f16%' or 




   primary_diagnosis like '%f18%' or 
   primary_diagnosis like '%f19%') 
  then 'F1x.5DrugPsyc' 
  else 'OtherPsychosis' 
  end as primary_diagnosisrecode 










      diagnosis_date, 
      primary_diagnosisrecode 
FROM ( 
  SELECT brcid, 
    diagnosis_date, 
    primary_diagnosisrecode, 
    ROW_NUMBER() OVER(PARTITION BY brcid ORDER 
BY diagnosis_date ASC) rn 
   FROM RPatel.rp_EIScohort_diagafter_recode 
   ) a 
 
WHERE rn = 1 

























SET ANSI_NULLS ON 
GO 
SET QUOTED_IDENTIFIER ON 
GO 
CREATE view [RPatel].[vw_gate_hunter_cannabis_filteredmatch] as 
SELECT * 
  FROM [GateDB_Cris].[RPatel].[gate_hunter_cannabis_new] 
  where 
  match not like 'Hospice' and   
  match not like 'Spicer' and   
  match not like 'Gillgrass' and   
  match not like 'Hashim' and   
  match not like 'HEALTHCARE' and   
  match not like 'weeding' and   
  match not like 'Marije' and   
  match not like 'Hashmi' and   




  match not like 'Gilgrass' and   
  match not like 'Rozemarijn' and   
  match not like 'FORTHCOMING' and   
  match not like 'Tweed' and   
  match not like 'Nathasha' and   
  match not like 'incresing' and   
  match not like 'grassing' and   
  match not like 'Marija' and   
  match not like 'incresingly' and   
  match not like 'Hashemi' and   
  match not like 'expresing' and   
  match not like 'Tweedy' and   
  match not like 'Ingrassia' and   
  match not like 'hashimoto' and   
  match not like 'Hashieka' and   
  match not like 'resinded' and   
  match not like 'Takahashi-' and   
  match not like 'weeded' and   
  match not like 'spiced' and   
  match not like 'weedkiller' and   
  match not like 'Gringrass' and   
  match not like 'Shasha' and   
  match not like 'grassy' and   
  match not like 'Shashi' and   
  match not like 'distresing' and   
  match not like 'dresing' and   
  match not like 'Marijke' and   
  match not like 'Hashad' and   
  match not like 'Sweeden' and   
  match not like 'Hashimi' and   
  match not like 'Weedon' and   
  match not like 'hospices' and   
  match not like 'Hashima' and   
  match not like 'trinityhospice' and   
  match not like 'Grassmere' and   
  match not like 'spicey' and   
  match not like 'resing' and   
  match not like 'resind' and   
  match not like 'Depresin' and   
  match not like 'Rehashed' and   
  match not like 'Shash' and   
  match not like 'gjithashtu' and   
  match not like 'Hashimotos' and   
  match not like 'seaweed' and   
  match not like 'presing' and   
  match not like 'Revieweed' and   
  match not like 'progresing' and   
  match not like 'Saruhashi' and   




  match not like 'grasshopper' and   
  match not like 'Subhash' and   
  match not like 'addresing' and   
  match not like 'weedy' and   
  match not like 'Hashi' and   
  match not like 'aggrassive' and   
  match not like 'Takahashi' and   
  match not like 'Marijia' and   
  match not like 'rehashing' and   
  match not like 'jDspicer' and   
  match not like 'Showeed' and   
  match not like 'rehash' and   
  match not like 'decresing' and   
  match not like 'Weednesday' and   
  match not like 'Hashtroudi' and   
  match not like 'Hasheem' and   
  match not like 'Hashi-' and   
  match not like 'Manjubhashini' and   
  match not like 'Gharghasht' and   
  match not like 'Snodgrass' and   
  match not like 'Hashir' and   
  match not like 'Hashes' and   
  match not like 'alloweed' and   
  match not like 'Desmopresin' and   
  match not like 'Grassarah' and   
  match not like 'Capgrass' and   
  match not like 'Grassby' and   
  match not like 'Hashtrodi' and   
  match not like 'Grassa' and   
  match not like 'Ambresin' and   
  match not like 'cannabalism' and   
  match not like 'reviweed' and   
  match not like 'dhashay' and   
  match not like 'sweedish' and   
  match not like 'resinstated' and   
  match not like 'auspice' and   
  match not like 'Kinshasha' and   
  match not like 'Marijka' and   
  match not like 'Lanchashire' and   
  match not like 'spicemen' and   
  match not like 'Amarijit' and   
  match not like 'Weeder' and   
  match not like 'followeed' and   
  match not like 'Dishashi' and   
  match not like 'weedend' and   
  match not like 'Hashma' and   
  match not like 'grasshoppers' and   
  match not like 'resinding' and   




  match not like 'diuresing' and   
  match not like 'Gingrass' and   
  match not like 'grassland' and   
  match not like 'Shashee' and   
  match not like 'Tweedie' and   
  match not like 'Lemongrass' and   
  match not like 'Tweedlie' and   
  match not like 'Kamishasherene' and   
  match not like 'EALTHCARE' and   
  match not like 'Hasher' and   
  match not like 'Grasso' and   
  match not like 'Hashmita' and   
  match not like 'resinstate' and   
  match not like 'HEATHCOTE' and   
  match not like 'Tweedle' and   
  match not like 'Elaweed' and   
  match not like 'Grassroots' and   
  match not like 'resined' and   
  match not like 'thashe' and   
  match not like 'hashed' and   
  match not like 'answeed' and   
  match not like 'Desmopresine' and   
  match not like 'csnodgrass' and   
  match not like 'Resinente' and   
  match not like 'Tweedale' and   
  match not like 'Marijah' and   
  match not like 'resindment' and   
  match not like 'Hairdresing' and   
  match not like 'Hashard' and   
























**Recoding demographic variables to deal with missing data and regrouping 
categories** 
gen agegp=age 
recode agegp min/15=1 16/25=2 26/35=3 36/max=4 
gen ethnicrecode3 = ethnicrecode2 
recode ethnicrecode3 1=1 2=2 3=3 4=3 5=3 6=4 7=5 
gen ethnicrecode3b = ethnicrecode3 
recode ethnicrecode3b 5=. 
gen maritalrecode3 = maritalrecode2 
recode maritalrecode3 1=1 2=2 3=3 4=3 5=4 
gen maritalrecode3b = maritalrecode3 
recode maritalrecode3b 4=. 
gen employmentrecode3 = employmentrecode2 
recode employmentrecode3 1=1 2=2 3=3 4=3 5=4 
gen employmentrecode3b = employmentrecode3 
recode employmentrecode3b 4=. 
gen accommodationrecode3 = accommodationrecode2 
recode accommodationrecode3 7=6 
gen accommodationrecode3b = accommodationrecode2 
recode accommodationrecode3b 7=. 
gen fullcovariate1 = 1 
replace fullcovariate1 = 0 if ethnicrecode3b==.|maritalrecode3b==. 
gen fullcovariate2 = 1 








label define Firstpsychosisdiagnosisrecode2 1 "F2xSchizophrenia" 2 
"Bipolar" 3 "PsychoticDepression" 4 "Schizoaffective" 5 "F1x.5DrugPsyc" 6 
"OtherPsychosis" 
label define agegp 1 "<16" 2 "16-25" 3 "26-35" 4 ">35" 
label define AgeRecode2 1 "<16" 2 "16-24" 3 "24-49" 4 "50-64" 5 ">64" 
label define GenderRecode2 0 "Female" 1 "Male" 2 "NotRecorded" 
label define ethnicrecode2 1 "White" 2 "Asian" 3 "BlackAfrican" 4 
"BlackCaribbean" 5 "BlackOther" 6 "Other" 7 "NotRecorded" 
label define ethnicrecode3 1 "White" 2 "Asian" 3 "Black" 4 "Other" 5 
"NotRecorded" 
label define ethnicrecode3b 1 "White" 2 "Asian" 3 "Black" 4 "Other" 
label define maritalrecode2 1 "MarriedCohabiting" 2 "DivorcedSeparated" 3 
"Single" 4 "Widowed" 5 "NotRecorded" 
label define maritalrecode3 1 "MarriedCohabiting" 2 "DivorcedSeparated" 3 
"Single" 4 "NotRecorded" 
label define maritalrecode3b 1 "MarriedCohabiting" 2 "DivorcedSeparated" 3 
"Single" 
label define employmentrecode2 1 "Employed" 2 "Student" 3 "Retired" 4 
"Unemployed" 5 "NotRecorded" 
label define employmentrecode3 1 "Employed" 2 "Student" 3 "Unemployed" 4 
"NotRecorded" 
label define employmentrecode3b 1 "Employed" 2 "Student" 3 "Unemployed" 
label define accommodationrecode2 1 "Owner" 2 "PrivateTenant" 3 
"CouncilTenant" 4 "SupportedAccomodation" 5 "Homeless" 6 "Other" 7 
"NotRecorded" 
label define accommodationrecode3 1 "Owner" 2 "PrivateTenant" 3 
"CouncilTenant" 4 "SupportedAccomodation" 5 "Homeless" 6 "Other" 
label define accommodationrecode3b 1 "Owner" 2 "PrivateTenant" 3 
"CouncilTenant" 4 "SupportedAccomodation" 5 "Homeless" 6 "Other" 
label define accepted_year_recode 1 "2006-7" 2 "2007-8" 3 "2008-9" 4 "2009-
10" 5 "2010-11" 6 "2011-12" 7 "2012-13" 
label values Firstpsychosisdiagnosisrecode2 Firstpsychosisdiagnosisrecode2 
label values agegp agegp 
label values AgeRecode2 AgeRecode2 
label values GenderRecode2 GenderRecode2 
label values ethnicrecode2 ethnicrecode2 
label values ethnicrecode3 ethnicrecode3 
label values ethnicrecode3b ethnicrecode3b 
label values maritalrecode2 maritalrecode2 
label values maritalrecode3 maritalrecode3 
label values maritalrecode3b maritalrecode3b 
label values employmentrecode2 employmentrecode2 
label values employmentrecode3 employmentrecode3 
label values employmentrecode3b employmentrecode3b 
label values accommodationrecode2 accommodationrecode2 
label values accommodationrecode3 accommodationrecode3 
label values accommodationrecode3b accommodationrecode3b 









summ age, detail 
summ age if Cannabis1m==0, detail 
summ age if Cannabis1m==1, detail 
ksmirnov age, by(Cannabis1m) 
ranksum age, by(Cannabis1m) 
tab Cannabis1m Firstpsychosisdiagnosisrecode2, row chi2 
**tab Cannabis1m Firstpsychosisdiagnosisrecode2, row exact** 
tab Cannabis1m Secondpsydiagnosisrecode2, row chi2 
**tab Cannabis1m Secondpsydiagnosisrecode2, row exact** 
tab Firstpsychosisdiagnosisrecode2 Secondpsydiagnosisrecode2, row chi2 
**tab Firstpsychosisdiagnosisrecode2 Secondpsydiagnosisrecode2, row exact** 
tab Cannabis1m agegp, row chi2 
tab Cannabis1m agegp, row exact 
tab Cannabis1m GenderRecode2, row chi2 
tab Cannabis1m GenderRecode2, row exact 
tab Cannabis1m ethnicrecode3b, row chi2 
tab Cannabis1m ethnicrecode3b, row exact 
tab Cannabis1m maritalrecode3b, row chi2 
tab Cannabis1m maritalrecode3b, row exact 
 
**Demographic variables including missing data** 
tab Cannabis1m maritalrecode3, row chi2 
tab Cannabis1m maritalrecode3, row exact 
 
**Demographic variables logistic regression** 
logistic Cannabis1m i.Firstpsychosisdiagnosisrecode2 
logistic Cannabis1m i.Secondpsydiagnosisrecode2 
logistic Cannabis1m ib2.agegp 
logistic Cannabis1m ib1.GenderRecode2 
logistic Cannabis1m ib3.ethnicrecode3 
logistic Cannabis1m ib3.maritalrecode3b 
logistic Cannabis1m i.Firstpsychosisdiagnosisrecode2 ib2.agegp 
ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3b 
 
**Demographic variables logistic regression including missing** 
logistic Cannabis1m ib3.maritalrecode3 
logistic Cannabis1m i.Firstpsychosisdiagnosisrecode2 ib2.agegp 
ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 
 
**MHA Section** 
tab Cannabis1m mhasection12m, row 
tab Cannabis1m mhasection24m if accepted_year_recode<=6, row 
tab Cannabis1m mhasection36m if accepted_year_recode<=5, row 
tab Cannabis1m mhasection48m if accepted_year_recode<=4, row 






summ antipsychoticcount12m if Cannabis1m==0, detail 
summ antipsychoticcount12m if Cannabis1m==1, detail 
summ antipsychoticcount24m if Cannabis1m==0 & accepted_year_recode<=6, 
detail 
summ antipsychoticcount24m if Cannabis1m==1 & accepted_year_recode<=6, 
detail 
summ antipsychoticcount36m if Cannabis1m==0 & accepted_year_recode<=5, 
detail 
summ antipsychoticcount36m if Cannabis1m==1 & accepted_year_recode<=5, 
detail 
summ antipsychoticcount48m if Cannabis1m==0 & accepted_year_recode<=4, 
detail 
summ antipsychoticcount48m if Cannabis1m==1 & accepted_year_recode<=4, 
detail 
summ antipsychoticcount60m if Cannabis1m==0 & accepted_year_recode<=3, 
detail 




tab Cannabis1m Clozapine12m, row 
tab Cannabis1m Clozapine24m if accepted_year_recode<=6, row 
tab Cannabis1m Clozapine36m if accepted_year_recode<=5, row 
tab Cannabis1m Clozapine48m if accepted_year_recode<=4, row 
tab Cannabis1m Clozapine60m if accepted_year_recode<=3, row 
 
**Number of admissions** 
summ noofadmissions_12m if Cannabis1m==0, detail 
summ noofadmissions_12m if Cannabis1m==1, detail 
summ noofadmissions_24m if Cannabis1m==0 & accepted_year_recode<=6, detail 
summ noofadmissions_24m if Cannabis1m==1 & accepted_year_recode<=6, detail 
summ noofadmissions_36m if Cannabis1m==0 & accepted_year_recode<=5, detail 
summ noofadmissions_36m if Cannabis1m==1 & accepted_year_recode<=5, detail 
summ noofadmissions_48m if Cannabis1m==0 & accepted_year_recode<=4, detail 
summ noofadmissions_48m if Cannabis1m==1 & accepted_year_recode<=4, detail 
summ noofadmissions_60m if Cannabis1m==0 & accepted_year_recode<=3, detail 
summ noofadmissions_60m if Cannabis1m==1 & accepted_year_recode<=3, detail 
 
**Number of inpatient days** 
summ los_12m if Cannabis1m==0, detail 
summ los_12m if Cannabis1m==1, detail 
summ los_24m if Cannabis1m==0 & accepted_year_recode<=6, detail 
summ los_24m if Cannabis1m==1 & accepted_year_recode<=6, detail 
summ los_36m if Cannabis1m==0 & accepted_year_recode<=5, detail 
summ los_36m if Cannabis1m==1 & accepted_year_recode<=5, detail 
summ los_48m if Cannabis1m==0 & accepted_year_recode<=4, detail 




summ los_60m if Cannabis1m==0 & accepted_year_recode<=3, detail 
summ los_60m if Cannabis1m==1 & accepted_year_recode<=3, detail 
 
**Multivariable analyses with missing data included** 
 
**MHA section** 
logistic mhasection12m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 
logistic mhasection24m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=6 
logistic mhasection36m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=5 
logistic mhasection48m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=4 
logistic mhasection60m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=3 
 
**Antipsychotic count - nbreg** 
nbreg antipsychoticcount12m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3, irr 
nbreg antipsychoticcount24m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=6, irr 
nbreg antipsychoticcount36m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=5, irr 
nbreg antipsychoticcount48m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=4, irr 
nbreg antipsychoticcount60m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=3, irr 
 
**Number of admissions - nbreg** 
nbreg noofadmissions_12m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3, irr 
nbreg noofadmissions_24m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=6, irr 
nbreg noofadmissions_36m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=5, irr 
nbreg noofadmissions_48m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 





nbreg noofadmissions_60m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 




regress los_12m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 ib2.agegp 
ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 
regress los_24m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 ib2.agegp 
ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=6 
regress los_36m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 ib2.agegp 
ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=5 
regress los_48m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 ib2.agegp 
ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=4 
regress los_60m i.Cannabis1m i.Firstpsychosisdiagnosisrecode2 ib2.agegp 





**Antipsychotic count predictor** 
logistic mhasection12m antipsychoticcount12m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 
logistic mhasection24m antipsychoticcount24m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 
logistic mhasection36m antipsychoticcount36m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 
logistic mhasection48m antipsychoticcount48m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 
logistic mhasection60m antipsychoticcount60m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 
 
nbreg noofadmissions_12m antipsychoticcount12m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3, irr 
nbreg noofadmissions_24m antipsychoticcount24m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 if accepted_year_recode<=6, irr 
nbreg noofadmissions_36m antipsychoticcount36m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 




nbreg noofadmissions_48m antipsychoticcount48m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 if accepted_year_recode<=4, irr 
nbreg noofadmissions_60m antipsychoticcount60m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 if accepted_year_recode<=3, irr 
 
regress los_12m antipsychoticcount12m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 
regress los_24m antipsychoticcount24m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=6 
regress los_36m antipsychoticcount36m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=5 
regress los_48m antipsychoticcount48m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=4 
regress los_60m antipsychoticcount60m i.Firstpsychosisdiagnosisrecode2 
ib2.agegp ib1.GenderRecode2 ib3.ethnicrecode3 ib3.maritalrecode3 if 
accepted_year_recode<=3 
 
**Adding in antipsychoticcount as covariate** 
logistic mhasection12m i.Cannabis1m antipsychoticcount12m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 
logistic mhasection24m i.Cannabis1m antipsychoticcount24m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 
logistic mhasection36m i.Cannabis1m antipsychoticcount36m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 
logistic mhasection48m i.Cannabis1m antipsychoticcount48m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 
logistic mhasection60m i.Cannabis1m antipsychoticcount60m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 
 
nbreg noofadmissions_12m i.Cannabis1m antipsychoticcount12m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3, irr 
nbreg noofadmissions_24m i.Cannabis1m antipsychoticcount24m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 if accepted_year_recode<=6, irr 
nbreg noofadmissions_36m i.Cannabis1m antipsychoticcount36m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 




nbreg noofadmissions_48m i.Cannabis1m antipsychoticcount48m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 if accepted_year_recode<=4, irr 
nbreg noofadmissions_60m i.Cannabis1m antipsychoticcount60m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 if accepted_year_recode<=3, irr 
 
regress los_12m i.Cannabis1m antipsychoticcount12m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 
regress los_24m i.Cannabis1m antipsychoticcount24m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 if accepted_year_recode<=6 
regress los_36m i.Cannabis1m antipsychoticcount36m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 if accepted_year_recode<=5 
regress los_48m i.Cannabis1m antipsychoticcount48m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 if accepted_year_recode<=4 
regress los_60m i.Cannabis1m antipsychoticcount60m 
i.Firstpsychosisdiagnosisrecode2 ib2.agegp ib1.GenderRecode2 
ib3.ethnicrecode3 ib3.maritalrecode3 if accepted_year_recode<=3 
 
**Generate shorter variable names and dummy variables** 
gen antipsy2w = antipsychoticcount2w 
gen antipsy1m = antipsychoticcount1m 
gen antipsy3m = antipsychoticcount3m 
gen antipsy6m = antipsychoticcount6m 
gen antipsy12m = antipsychoticcount12m 
gen antipsy24m = antipsychoticcount24m 
gen antipsy36m = antipsychoticcount36m 
gen antipsy48m = antipsychoticcount48m 
gen antipsy60m = antipsychoticcount60m 
xi i.agegp i.GenderRecode2 
 
**Mediation analysis - paramed** 
**N.B. paramed cannot use "if"* 
 
paramed noofadmissions_12m, avar(Cannabis1m) mvar(antipsy12m) a0(0) a1(1) 
m(0) yreg(negbin) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 
_IGenderRec_1 _IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 
_IFirstpsyc_6 _Iethnicrec_2 _Iethnicrec_3 _Iethnicrec_4 _Imaritalre_2 
_Imaritalre_3 _Imaritalre_4) 
paramed mhasection12m, avar(Cannabis1m) mvar(antipsy12m) a0(0) a1(1) m(0) 
yreg(logistic) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 
_IGenderRec_1 _IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 





paramed los_12m, avar(Cannabis1m) mvar(antipsy12m) a0(0) a1(1) m(0) 
yreg(linear) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 _IGenderRec_1 
_IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 _IFirstpsyc_6 
_Iethnicrec_2 _Iethnicrec_3 _Iethnicrec_4 _Imaritalre_2 _Imaritalre_3 
_Imaritalre_4) 
 
drop if accepted_year_recode>=7 
paramed noofadmissions_24m, avar(Cannabis1m) mvar(antipsy24m) a0(0) a1(1) 
m(0) yreg(negbin) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 
_IGenderRec_1 _IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 
_IFirstpsyc_6 _Iethnicrec_2 _Iethnicrec_3 _Iethnicrec_4 _Imaritalre_2 
_Imaritalre_3 _Imaritalre_4) 
paramed mhasection24m, avar(Cannabis1m) mvar(antipsy24m) a0(0) a1(1) m(0) 
yreg(logistic) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 
_IGenderRec_1 _IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 
_IFirstpsyc_6 _Iethnicrec_2 _Iethnicrec_3 _Iethnicrec_4 _Imaritalre_2 
_Imaritalre_3 _Imaritalre_4) 
paramed los_24m, avar(Cannabis1m) mvar(antipsy24m) a0(0) a1(1) m(0) 
yreg(linear) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 _IGenderRec_1 
_IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 _IFirstpsyc_6 
_Iethnicrec_2 _Iethnicrec_3 _Iethnicrec_4 _Imaritalre_2 _Imaritalre_3 
_Imaritalre_4) 
 
drop if accepted_year_recode>=6 
paramed noofadmissions_36m, avar(Cannabis1m) mvar(antipsy36m) a0(0) a1(1) 
m(0) yreg(negbin) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 
_IGenderRec_1 _IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 
_IFirstpsyc_6 _Iethnicrec_2 _Iethnicrec_3 _Iethnicrec_4 _Imaritalre_2 
_Imaritalre_3 _Imaritalre_4) 
paramed mhasection36m, avar(Cannabis1m) mvar(antipsy36m) a0(0) a1(1) m(0) 
yreg(logistic) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 
_IGenderRec_1 _IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 
_IFirstpsyc_6 _Iethnicrec_2 _Iethnicrec_3 _Iethnicrec_4 _Imaritalre_2 
_Imaritalre_3 _Imaritalre_4) 
paramed los_36m, avar(Cannabis1m) mvar(antipsy36m) a0(0) a1(1) m(0) 
yreg(linear) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 _IGenderRec_1 
_IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 _IFirstpsyc_6 
_Iethnicrec_2 _Iethnicrec_3 _Iethnicrec_4 _Imaritalre_2 _Imaritalre_3 
_Imaritalre_4) 
 
drop if accepted_year_recode>=5 
paramed noofadmissions_48m, avar(Cannabis1m) mvar(antipsy48m) a0(0) a1(1) 
m(0) yreg(negbin) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 
_IGenderRec_1 _IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 
_IFirstpsyc_6 _Iethnicrec_2 _Iethnicrec_3 _Iethnicrec_4 _Imaritalre_2 
_Imaritalre_3 _Imaritalre_4) 
paramed mhasection48m, avar(Cannabis1m) mvar(antipsy48m) a0(0) a1(1) m(0) 
yreg(logistic) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 




_IFirstpsyc_6 _Iethnicrec_2 _Iethnicrec_3 _Iethnicrec_4 _Imaritalre_2 
_Imaritalre_3 _Imaritalre_4) 
paramed los_48m, avar(Cannabis1m) mvar(antipsy48m) a0(0) a1(1) m(0) 
yreg(linear) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 _IGenderRec_1 
_IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 _IFirstpsyc_6 
_Iethnicrec_2 _Iethnicrec_3 _Iethnicrec_4 _Imaritalre_2 _Imaritalre_3 
_Imaritalre_4) 
 
drop if accepted_year_recode>=4 
paramed noofadmissions_60m, avar(Cannabis1m) mvar(antipsy60m) a0(0) a1(1) 
m(0) yreg(negbin) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 
_IGenderRec_1 _IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 
_IFirstpsyc_6 _Iethnicrec_2 _Iethnicrec_3 _Iethnicrec_4 _Imaritalre_2 
_Imaritalre_3 _Imaritalre_4) 
paramed mhasection60m, avar(Cannabis1m) mvar(antipsy60m) a0(0) a1(1) m(0) 
yreg(logistic) mreg(linear) cvars(_Iagegp_2 _Iagegp_3 _Iagegp_4 
_IGenderRec_1 _IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 
_IFirstpsyc_6 _Iethnicrec_2 _Iethnicrec_3 _Iethnicrec_4 _Imaritalre_2 
_Imaritalre_3 _Imaritalre_4) 
paramed los_60m, avar(Cannabis1m) mvar(antipsy60m) a0(0) a1(1) m(0) 
yreg(linear) mreg(linear) cvars_Iagegp_2 _Iagegp_3 _Iagegp_4 _IGenderRec_1 
_IFirstpsyc_2 _IFirstpsyc_3 _IFirstpsyc_4 _IFirstpsyc_5 _IFirstpsyc_6 
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Objectives: To identify negative symptoms in the
clinical records of a large sample of patients with
schizophrenia using natural language processing and
assess their relationship with clinical outcomes.
Design: Observational study using an anonymised
electronic health record case register.
Setting: South London and Maudsley NHS Trust
(SLaM), a large provider of inpatient and community
mental healthcare in the UK.
Participants: 7678 patients with schizophrenia
receiving care during 2011.
Main outcome measures: Hospital admission,
readmission and duration of admission.
Results: 10 different negative symptoms were
ascertained with precision statistics above 0.80. 41%
of patients had 2 or more negative symptoms. Negative
symptoms were associated with younger age, male
gender and single marital status, and with increased
likelihood of hospital admission (OR 1.24, 95% CI
1.10 to 1.39), longer duration of admission
(β-coefficient 20.5 days, 7.6–33.5), and increased
likelihood of readmission following discharge
(OR 1.58, 1.28 to 1.95).
Conclusions: Negative symptoms were common and
associated with adverse clinical outcomes, consistent
with evidence that these symptoms account for much
of the disability associated with schizophrenia. Natural
language processing provides a means of conducting
research in large representative samples of patients,
using data recorded during routine clinical practice.
INTRODUCTION
Negative symptoms, which include amotiva-
tion, a ﬂattening of emotional responses, a
reduction in speech and activity, and social
withdrawal,1 contribute to much of the dis-
ability associated with schizophrenia.2 These
symptoms are also associated with poor
psychosocial functioning3 and a reduced like-
lihood of remission.4–9 The aetiology and
pathophysiology of negative symptoms are
unknown, and there are no effective
treatments.10 11
A number of excellent rating scales have
been developed to assess negative symp-
toms.12–14 However, these are relatively
detailed, require a trained rater, and are not
routinely applied in clinical practice. As a
result, much of our knowledge of negative
symptoms is derived from studies in relatively
small samples of patients, who may have
been selected for inclusion because they had
particularly severe symptoms. The ﬁndings
Strengths and limitations of this study
▪ This is the largest known study (over 7000 parti-
cipants) to investigate the relationship of nega-
tive symptoms with clinical outcomes in people
with schizophrenia. Our findings demonstrate
that negative symptoms are present in a substan-
tial number of people with schizophrenia and are
associated with increased hospital admission,
readmission and duration of inpatient stay.
▪ To our knowledge, this is the first published
study to use an automated information extraction
method to acquire data on negative symptoms
from electronic health records. This approach
permits rapid acquisition of negative symptom
data which is representative of everyday clinical
practice in secondary mental healthcare.
▪ Our findings are based on data recorded by clini-
cians delivering routine mental healthcare who
were not specifically ascertaining negative symp-
toms. It is therefore possible that negative symp-
toms were not comprehensively documented in
the electronic health records from which they
were identified leading to an inaccurate estimate
of their prevalence in the analysed sample.
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from these samples may not therefore be representative
of negative symptoms in the overall population of
patients with schizophrenia.
Clinical information is increasingly recorded electron-
ically, facilitating access of rich clinical data, including
presence or absence of symptoms,15 from routine
medical records. In the present study, we used a novel
information extraction tool to identify negative symp-
tomatology in a large body of electronic records
collected from individuals with schizophrenia.16–18 We
then examined the relationship between negative symp-
toms and clinical outcomes. We tested the hypothesis
that negative symptoms are common in patients with
schizophrenia, and are associated with poor clinical
outcome, as indexed by the frequency and duration of
hospital admissions.
METHODS
Participants and clinical data
The study was carried out using the South London and
Maudsley NHS Foundation Trust (SLaM) Biomedical
Research Centre (BRC) Case Register, comprising elec-
tronic health record data dating back to April 2006 from
a large mental healthcare provider to 1.2 million resi-
dents of southeast London (UK). The data were interro-
gated using the Clinical Record Interactive Search
(CRIS) application,19 with a robust anonymisation
process and patient-led oversight.20 Three samples were
identiﬁed for analysis:
I. Sample A (n=7678): patients with schizophrenia
(International Classiﬁcation of Diseases (ICD)-10
F20.XX) aged 16 years and over who had used
SLaM services during 2011. This sample was used to
investigate: (1) the relationship between negative
symptoms, documented at any point in the elec-
tronic health record, and demographic and other
clinical measures (described below); (2) the rela-
tionship between negative symptoms documented
prior to 1 January 2011 and the risk of hospital
admission during 2011. This year was chosen for
analysis because it maximised the duration of time
over which text would be available for measurement
development, while allowing at least 12 months
follow-up in all instances.
II. Sample B (n=1612): the subset of patients from
sample A who had been discharged from SLaM
inpatient care during 2011. This sample was used
to investigate the relationship between negative
symptoms documented prior to 2011 and the risk
of readmission in the 12 months following
discharge.
III. Sample C (n=1609): the subset of patients from
sample A who received SLaM inpatient care during
2011. This sample was used to investigate the rela-
tionship between negative symptoms documented
prior to 2011 and the length of the ﬁrst hospital
admission during 2011.
Measurement development
Natural language processing (NLP) information extrac-
tion allows structured information to be obtained from
unstructured text records. We used NLP to detect state-
ments in the correspondence ﬁelds of clinical records to
determine references to prespeciﬁed negative symptoms.
Full details of the NLP method are described in a previ-
ous paper.16 In summary, a putative training data set was
selected which contained broad dictionary terms rele-
vant to the negative symptoms of interest (described
below). A detailed review of the training data set was
undertaken by two psychiatrists (RP and RS) to identify
and annotate key phrases within the records that were
either relevant or irrelevant for keywords related to each
symptom. Inter-rater reliability was tested between the
two annotators resulting in percentage agreement of
93.0% (Cohen’s κ 0.85). This training data set was used
to construct an application (CRIS Negative Symptoms
Scale, CRIS-NSS) using a hybrid classiﬁcation model
consisting of a support vector machine (SVM) learning
algorithm21 and rule-based text matching, using the
Generalised Architecture for Text Engineering (GATE)
software package.17 The SVM algorithm was applied
using a ‘bag-of-words’ approach to take into account the
context of negative symptoms within the sentence in
which they were documented, thereby allowing ascer-
tainment of negative symptoms experienced speciﬁcally
by the patient as well as distinguishing between positive
instances and negated instances.16 Once developed,
CRIS-NSS was subsequently used to determine the pres-
ence of negative symptoms within the clinical sample.
The accuracy of CRIS-NSS was evaluated using precision
and recall statistics which were generated through
internal ﬁvefold cross-validation:21 precision, represent-
ing the proportion of text instances identiﬁed by the
tool which were found to be correct in terms of identify-
ing the negative symptom of interest (equivalent to posi-
tive predictive value); and recall, measuring the
proportion of text instances recording a given negative
symptoms which were correctly identiﬁed as such by the
tool (equivalent to sensitivity).
Details of the criteria for ascertaining the negative
symptoms in the CRIS-NSS application are described in
further detail elsewhere;16 brieﬂy, applications were
developed for 10 items: poor motivation, blunted or ﬂat-
tened affect, poor eye contact, emotional withdrawal,
poor rapport, social withdrawal, poverty of speech,
mutism, apathy and concrete thinking. Each of these
symptoms was deﬁned as a binary variable on the basis
of being present at any point in the record within the
deﬁned time period, and a composite scale (range
0–10) was constructed by summing these variables,
followed by Cronbach α score calculation (a measure of
intercorrelation between individual scale items) to esti-
mate its internal consistency. A threshold score of at
least 2 (ie, two or more negative symptoms documented)
was applied a priori to determine the presence or
absence of negative symptoms for analysis as a binary
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variable, as well as treating the scale score as an ordinal
variable.
Clinical outcome measures and covariates
The following clinical and demographic variables were
obtained as covariates from the data set: age (on 1
January 2011), gender, marital status, employment
status, and admission and discharge dates for inpatient
care episodes. Using structured data derived from the
Health of the Nation Outcome Scale (HoNOS),22 rou-
tinely completed in SLaM patients, the following sub-
scales (scored 0–4) were used as covariates: activities of
daily living (ADL) impairment, problems with relation-
ships (social impairment), presence of hallucinations or
delusions (a measure of positive symptoms) and depres-
sive symptoms. For all of these HoNOS subscales, binary
variables were deﬁned on the basis of a score of 2 or
more indicating the presence of each construct at levels
judged to be clinically signiﬁcant. In cases with multiple
data points, all covariates were deﬁned as those recorded
closest to 1 January 2011.
Statistical analysis
STATA (V.11) software was used. Estimates of prevalence
of negative symptoms by demographic factors were
obtained as the proportion of patients within each
group with two or more negative symptoms. After
describing the distribution of negative symptoms and
the psychometric properties of the CRIS-NSS, further
analyses were performed to investigate the associations
between the clinical outcomes described above and (1)
the presence of negative symptoms, using binary logistic
regression; and (2) CRIS-NSS scores, using ordinal logis-
tic regression. Reference groups for categorical variables
were generally deﬁned as the most prevalent category,
apart from age group where the youngest group of sufﬁ-
cient size was assigned as the reference. Associations
between negative symptomatology and hospital admis-
sion and readmission were analysed using logistic regres-
sion, while those with length of inpatient stay were
analysed using linear regression—again, estimating asso-
ciations with both the binary and ordinal CRIS-NSS
exposure. For the analyses with hospitalisation outcomes
in/following 2011, CRIS-NSS was generated restricting
information extraction to electronic health records prior
to 2011. Where data were missing on individual covari-
ates (in 2362 participants), this was indicated in the
regression models as a separate category, supplemented
by sensitivity analyses performed on the sample with
complete data on all covariates to check the consistency
of ﬁndings. A further supplementary analysis was per-
formed to test the hypothesis that the association
between negative symptoms and clinical outcomes varies
with age. For this analysis, the previous analyses were
repeated within the subgroups of those aged under the
age of 40 years and those over the age of 40 years and
including an interaction term of age under or over 40
and binary CRIS-NSS exposure. Finally, secondary
analyses were undertaken to investigate and compare
the relationships of individual CRIS-NSS symptoms with
risk of readmission and length of stay using binary logis-
tic and linear regression, respectively.
RESULTS
Performance of CRIS-NSS
Table 1 illustrates results from ﬁvefold cross-validation of
the CRIS-NSS tool. Precision coefﬁcients ranged
between 0.80 and 0.99 and recall between 0.62 and 0.97.
For the composite 10-point scale, the Cronbach α value
was 0.78 indicating a good level of internal consistency.
Prevalence and distribution of negative symptoms
Of the 7678 patients with schizophrenia, 3149 (41.0%)
had at least two negative symptoms documented. Table 1
displays prevalences for each of the symptoms classiﬁed
by the tool. The most frequently recorded symptoms
were poor motivation (30.5%), blunted or ﬂattened
affect (27.4%), poor eye contact (26.0%) and emotional
withdrawal (23.5%). The prevalences by number of symp-
toms were as follows: one symptom 14.6%, two symptoms
12.7%, three symptoms 9.3%, four symptoms 6.4%, ﬁve
symptoms 5.0%, six or more symptoms 7.6%.
Binary logistic regression analyses (table 2) revealed
that patients with two or more negative symptoms were
most likely to be 20–29 years old, male and single. Two
or more negative symptoms were also associated with
ADL impairment, whereas patients who were employed
were less likely to have negative symptoms compared
with those unemployed. Ordinal logistic regression ana-
lysis (etable 1) revealed similar ﬁndings for CRIS-NSS
score as an exposure, and sensitivity analyses limited to
those with full data on all covariates (etable 2) were also
consistent.
Table 1 Performance of Clinical Record Interactive
Search Negative Symptoms Scale (CRIS-NSS) information











Poor motivation 0.87/0.62 30.5
Blunted or flattened affect 0.93/0.83 27.4
Poor eye contact 0.95/0.79 26.0
Emotional withdrawal 0.85/0.74 23.5
Poor rapport 0.91/0.77 16.3
Social withdrawal 0.94/0.96 12.7
Poverty of speech 0.80/0.73 12.4
Mute 0.99/0.94 8.1
Apathy 0.88/0.97 7.7
Concrete thinking 0.91/0.72 5.7
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Hospital admission, length of stay and readmission
Figure 1 summarises the association of negative symptoms
recorded prior to 2011 with mental health admission
(etable 3) and readmission (etable 4) in 2011. Figure 2
summarises length of hospitalisation for inpatients during
2011 (etable 5). Logistic and linear regression analyses
(table 3) conﬁrmed that negative symptoms were asso-
ciated with a higher likelihood of admission, readmission
and a longer duration of hospitalisation. Speciﬁcally, after
full adjustment (table 3, model 3), patients with two or
more negative symptoms before 2011 had a 24% greater
likelihood of admission during 2011. Moreover, each of
their admissions was, on average, an extra 21 days in
duration, and when they were discharged, they had a 58%
higher risk of readmission within 12 months. All of these
associations remained independent and largely unaltered
following adjustment for intensity of delusions/hallucina-
tions among other covariates. Further analysis (etable 6)
comparing patients aged under and over 40 years showed
that the effects of negative symptoms on inpatient admis-
sion were broadly similar for both groups but with a slight
increase in risk of readmission and reduced duration of
admission in relation to negative symptoms for those
under 40 compared with those over 40. However, the age ×
negative symptoms interaction term remained a non-
signiﬁcant factor (p>0.05) for all models.
Figure 1 Percentage of patients admitted to hospital or readmitted to hospital following discharge in 2011 by number of
negative symptoms.
Figure 2 Median duration of admission among mental health inpatients with schizophrenia in 2011 by number of negative
symptoms (n=1609).
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Finally, logistic and linear regression analyses were per-
formed to examine the relationship between individual
negative symptoms and the frequency and duration of
admission (table 4). Poor eye contact and poor rapport
were associated with increased risk of readmission, while
apathy was associated with increased duration of admis-
sion. Emotional withdrawal and mutism were associated
with both the risk of readmission and the duration of
admission.
DISCUSSION
Using an SVM learning method with an NLP tool, we
were able successfully to extract data on negative symp-
toms from the electronic mental health records of a
large clinical sample of patients with schizophrenia. This
approach did not require any specialised training or
extra clinical assessments, and was able to generate a
scale with robust construct and predictive validity from
data recorded as part of routine clinical care.
The results suggest that negative symptoms are docu-
mented in the electronic health records of a sizeable
proportion of patients with schizophrenia, particularly
in those who are relatively young, male and not in a rela-
tionship, consistent with ﬁndings from studies that
assessed negative symptoms using quite different
methods.23 24 Our ﬁndings were based on the
unprompted documentation of negative symptoms in
the context of routine clinical care by staff who were not
speciﬁcally trained in their assessment. Previous ﬁndings
have usually been based on systematic ratings by a
researcher using a dedicated rating scale. Negative symp-
toms are relatively difﬁcult to detect and assess,1 2 and
may be less frequently documented than positive symp-
toms, such as delusions and hallucinations, because they
are less clinically obvious. In addition, mental health
services in the UK are often orientated towards the man-
agement of acute crises, and hence the treatment of
positive symptoms.25 It is thus possible that the ﬁgures
for the prevalence and the severity of negative symptoms
derived from our approach are lower than would have
been obtained from a trained assessor using a standar-
dised instrument. In addition, our method may be more
likely to identify the types of negative symptoms (eg,
poverty of speech) whose detection does not require
specialised training.
We found that a substantial proportion (41%) of the
sample had at least two negative symptoms. Although we
deﬁned and assessed negative symptoms in different
ways to previous studies, this ﬁgure is comparable to that
described in other samples of patients with schizophre-
nia ( Jager et al4: 44%; Bobes et al23: 58%; Cohen et al24:
40%). Taken together, these ﬁndings suggest that nega-
tive symptoms are a relatively common feature of schizo-
phrenia, rather than being limited to a subgroup of
patients with a chronic, unremitting illness.26
As predicted, we found a clear association between
negative symptoms and poor clinical outcomes, as
indexed by impairments in daily living, increased risk of
admission, increased duration of admission and
increased risk of readmission. Hospital admissions are
the main drivers of cost in the care of patients with
schizophrenia,27 but have traditionally been linked to
the severity of positive psychotic symptoms.28 Our data
indicate that negative symptoms are an equally import-
ant factor, and suggest that a greater emphasis on asses-
sing and treating these features of schizophrenia may
have signiﬁcant health economic beneﬁts. However, as
our ﬁndings are drawn from observational data, it would
be necessary to perform interventional clinical studies to
determine whether an effective treatment for negative
symptoms would lead to better clinical outcomes.
Table 3 Association between number of negative symptoms ascertained prior to 2011 and mental health hospital admission,
readmission and duration of admission in 2011
Inpatient admission









Associations with 2 or more negative symptoms (binary variable)
Unadjusted 1.47 (1.32 to 1.63) 1.73 (1.41 to 2.12) 23.9 (11.2 to 36.7)
1. Age and sex 1.37 (1.23 to 1.53) 1.70 (1.38 to 2.09) 24.1 (11.3 to 36.9)
2. Model 1 plus marital status and employment 1.27 (1.13 to 1.42) 1.58 (1.28 to 1.96) 20.1 (7.1 to 33.1)
3. Model 2 plus delusions/hallucinations, and
depression
1.24 (1.10 to 1.39) 1.58 (1.28 to 1.95) 20.5 (7.6 to 33.5)
Associations with incremental number of negative symptoms (10-point scale ordinal variable)‡
Unadjusted 1.12 (1.09 to 1.15) 1.12 (1.07 to 1.17) 6.5 (3.5 to 9.4)
1. Age and sex 1.09 (1.06 to 1.12) 1.11 (1.06 to 1.16) 6.3 (3.3 to 9.2)
2. Model 1 plus marital status and employment 1.07 (1.04 to 1.10) 1.09 (1.04 to 1.14) 5.4 (2.4 to 8.4)
3. Model 2 plus delusions/hallucinations, and
depression
1.07 (1.04 to 1.10) 1.09 (1.04 to 1.14) 5.6 (2.6 to 8.6)
*Logistic regression.
†Linear regression.
‡ORs and β-coefficients are per one unit increase on the 10-point scale.
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A key strength of our study was the large size of the
patient sample, and that it was representative of the
overall clinical population of people with schizophrenia
in a deﬁned geographic area. Previous studies of negative
symptoms have usually involved smaller patient samples
that were recruited to a research project.4 23 24 Focusing
the information extraction process on text from corres-
pondence maximises the generalisability of our
approach, as letters to primary care physicians (which
accounted for a large portion of the correspondence
text) are unlikely to vary substantially between mental
health services with respect to the language used to
describe the symptoms of interest. In the present study,
we examined the patient’s entire record rather than dis-
crete periods of illness, and it was not possible to delin-
eate the timing or duration of individual negative
symptoms, or whether they were primary (ie, a direct con-
sequence of illness) or secondary (eg, side effects of treat-
ment) as these measures were not routinely documented
in electronic health records. Although we investigated
the association of negative symptoms in clinical docu-
ments prior to 1 January 2011 with outcomes occurring
after 1 January 2011 (to ensure that negative symptoms
were always ascertained prior to outcomes), if negative
symptoms were identiﬁed prior to 1 January 2011, it was
not possible to ascertain when they occurred prior to this
date, or their temporal relationships to subsequent clin-
ical outcomes. The ﬁndings were thus derived from
assessments made over a period that was not standar-
dised, but was generally relatively long. In contrast, most
assessments of negative symptoms in the literature are
derived from a single cross-sectional measurement.29 30
A further limitation of our analysis was the extent to
which individual negative symptoms could be considered
as having equal weight in a composite score. Weighting
the 10 negative symptom applications equally resulted in
a composite score (from 0 to 10) with a reasonable
degree of internal consistency, as demonstrated by a
Cronbach α value of 0.78. However, analysing the associ-
ation of each negative symptom with clinical outcomes
revealed varying degrees of association with poor clinical
outcomes for different negative symptoms. Future
studies are necessary to examine the propensity for dif-
ferent negative symptoms to co-occur in individual
patients and the extent to which different clusters of
symptoms are associated with clinical outcomes, particu-
larly in the light of previous research which suggests that
negative symptoms segregate into two subdomains relat-
ing to amotivation and reduced emotional expression.31
The application of NLP to clinical records is unlikely
to identify negative symptoms as accurately as a direct
assessment using a specialised psychopathological rating
scale. However, automated tools could be used to screen
individuals and identify those with negative symptoms
who would then beneﬁt from comprehensive assessment
using a standardised instrument. In this way, automated
methods could be used to complement standardised
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could also be developed to identify other clinical para-
meters from electronic health records in order to
support real-time clinical decision-making. These possi-
bilities could be explored in future research.
In summary, our data suggest that negative symptoms
can be identiﬁed in clinical records using automated
methods, are common in patients with schizophrenia
and are associated with poor clinical outcomes. The
ﬁndings highlight the potential of automated informa-
tion extraction tools in mental health research and clin-
ical practice, and the importance of developing effective
treatments for negative symptoms.
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eTable 1 - Multivariable ordinal logistic regression analysis of factors associated with negative symptoms in patients with 
schizophrenia 






Unadjusted Adjusted model (n=7676)* 
Odds ratio (95% CI) P value Odds ratio (95% CI) P value 
Age (years) 16-19 203 1.28 2.15 0.30 (0.22-0.40) <0.001 0.46 (0.33-0.64) <0.001 
20-29 1337 2.45 2.64 Reference  Reference  
30-39 1775 1.97 2.21 0.77 (0.67-0.87) <0.001 0.78 (0.68-0.89) <0.001 
40-49 1983 1.66 1.95 0.62 (0.55-0.71) <0.001 0.62 (0.55-0.71) <0.001 
50-59 1137 1.43 1.79 0.53 (0.46-0.61) <0.001 0.52 (0.45-0.61) <0.001 
60-69 654 1.07 1.53 0.37 (0.31-0.44) <0.001 0.36 (0.30-0.44) <0.001 
70+ 589 0.72 1.19 0.25 (0.21-0.30) <0.001 0.25 (0.20-0.31) <0.001 
Gender Male 4592 1.90 2.22 Reference  Reference  
Female 3084 1.41 1.91 0.66 (0.60-0.71) <0.001 0.79 (0.72-0.86) <0.001 
Marital status 
(most recent) 
Single 5795 1.88 2.20 Reference  Reference  
Married/cohabiting 785 1.16 1.61 0.57 (0.50-0.66) <0.001 0.74 (0.64-0.86) <0.001 
Divorced/separated 776 1.35 1.86 0.64 (0.56-0.74) <0.001 0.86 (0.74-0.99) 0.040 
Widowed 208 0.85 1.39 0.40 (0.31-0.52) <0.001 0.81 (0.60-1.09) 0.160 
Employment (most 
recent) 
Unemployed 4956 2.03 2.23 Reference  Reference  
Employed 341 1.51 1.87 0.68 (0.56-0.83) <0.001 0.64 (0.52-0.78) <0.001 
In education 311 1.64 2.10 0.70 (0.57-0.86) 0.001 0.78 (0.63-0.97) 0.026 
Retired 7 0.57 0.79 0.33 (0.08-1.29) 0.110 0.68 (0.16-2.87) 0.599 
ADL impairment Absent 4700 1.73 2.09 Reference  Reference  
Present 2283 1.97 2.23 1.21 (1.11-1.33) <0.001 1.35 (1.22-1.49) <0.001 
Social impairment Absent 4432 1.76 2.10 Reference  Reference  
Present 2533 1.88 2.20 1.07 (0.98-1.17) 0.108 0.95 (0.86-1.05) 0.292 
Delusions / 
hallucinations  
Absent 3904 1.77 2.17 Reference  Reference  
Present 3077 1.85 2.11 1.14 (1.05-1.24) 0.003 1.19 (1.09-1.30) <0.001 
Depression Absent 4976 1.90 2.16 Reference  Reference  
Present 2014 1.59 2.08 0.71 (0.65-0.79) <0.001 0.69 (0.62-0.76) <0.001 




eTable 2 - Multivariable binary logistic regression analysis of factors associated with negative symptoms in patients with 
schizophrenia including cases with full covariate data only 
Factor Group Number in 
sample 
Prevalence of two or more 
negative symptoms (%) 
Association with two or more negative symptoms: odds ratio (95% CI), p-
value 
Unadjusted Adjusted model (n=5316)* 
Age (years) 16-19 203 27.6 0.35 (0.25-0.49) <0.001 0.44 (0.29-0.68) <0.001 
20-29 1337 52.0 Reference  Reference  
30-39 1775 47.0 0.82 (0.71-0.94) 0.006 0.80 (0.67-0.95) 0.012 
40-49 1983 42.6 0.69 (0.60-0.79) <0.001 0.64 (0.54-0.76) <0.001 
50-59 1137 37.2 0.55 (0.47-0.64) <0.001 0.45 (0.37-0.55) <0.001 
60-69 654 29.1 0.38 (0.31-0.46) <0.001 0.32 (0.25-0.41) <0.001 
70+ 589 18.0 0.20 (0.16-0.26) <0.001 0.13 (0.09-0.18) <0.001 
Gender Male 4592 45.3 Reference  Reference  
Female 3083 34.7 0.64 (0.59-0.71) <0.001 0.74 (0.65-0.83) <0.001 
Marital status 
(most recent) 
Single 5795 44.6 Reference  Reference  
Married/cohabiting 785 31.6 0.57 (0.49-0.67) <0.001 0.77 (0.63-0.94) 0.012 
Divorced/separated 776 33.4 0.62 (0.53-0.73) <0.001 0.91 (0.75-1.12) 0.376 
Widowed 208 21.2 0.33 (0.24-0.47) <0.001 0.85 (0.54-1.32) 0.466 
Employment (most 
recent) 
Unemployed 4956 47.9 Reference  Reference  
Employed 341 39.6 0.71 (0.57-0.89) 0.003 0.65 (0.51-0.83) <0.001 
In education 311 39.6 0.71 (0.56-0.90) 0.004 0.78 (0.61-1.02) 0.065 
Retired 7 14.3 0.18 (0.02-1.51) 0.114 0.51 (0.06-4.65) 0.547 
ADL impairment Absent 4700 41.9 Reference  Reference  
Present 2283 46.3 1.20 (1.08-1.32) <0.001 1.29 (1.13-1.47) <0.001 
Social impairment Absent 4432 42.7 Reference  Reference  
Present 2533 44.4 1.07 (0.97-1.18) 0.158 0.93 (0.82-1.05) 0.258 
Delusions / 
hallucinations  
Absent 3904 41.9 Reference  Reference  
Present 3077 45.0 1.14 (1.03-1.25) 0.009 1.23 (1.10-1.38) <0.001 
Depression Absent 4976 45.2 Reference  Reference  
Present 2014 38.8 0.77 (0.69-0.85) <0.001 0.69 (0.61-0.78) <0.001 




















eTable 3 - Percentage of patients admitted to hospital in 
2011 by number of negative symptoms (n=7678) 




Percentage admitted to 
hospital in 2011 (%) 
0 3408 21.7 
1 1121 18.9 
2 974 22.7 
3 717 27.2 
4 492 28.1 
5 382 32.5 
6 or more 584 36.8 
eTable 4 - Percentage of patients readmitted to hospital following 
discharge in 2011 by number of negative symptoms (n=1612) 




Percentage admitted to hospital in 2011 (%) 
0 612 29.9 
1 195 34.4 
2 213 40.4 
3 176 44.9 
4 131 43.5 
5 119 47.1 











eTable 5 - Median duration of admission amongst mental health inpatients 






0 696 30.0 
1 200 37.5 
2 194 46.0 
3 165 40.0 
4 116 48.0 
5 110 51.5 
6 or more 128 56.5 
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eTable 6 - Association between number of negative symptoms ascertained prior to 2011 and mental health hospital 
admission, re-admission and duration of admission in 2011 in patients aged under 40 years and patients aged over 40 
years 
 Inpatient admission 
(odds ratio, 95% 
CI)*  
Re-admission within 12 
months of inpatient 
admission (odds ratio, 
95% CI)* 
Duration of inpatient 
admission (days; B-
coefficient, 95% CI)** 
Associations with 2 or more negative symptoms (binary variable) in 
patients aged between 16 and 39 years. n=3315 n=792 n=785 
Unadjusted 1.36 (1.17-1.59) 1.82 (1.36-2.43) 25.4 (6.2, 44.6) 
1. Age and sex 1.40 (1.20-1.63) 1.88 (1.40-2.54) 20.8 (1.5, 40.1) 
2. Model 1 plus marital status and employment 1.25 (1.06-1.46) 1.70 (1.24-2.31) 15.0 (-4.9, 34.9) 
3. Model 2 plus delusions / hallucinations, and depression 1.22 (1.03-1.43) 1.68 (1.23-2.29) 14.5 (-5.5, 34.5) 
Associations with 2 or more negative symptoms (binary variable) in 
patients aged over 40 years. n=4361 n=820 n=805 
Unadjusted 1.41 (1.20-1.65) 1.61 (1.21-2.16) 22.1 (5.2, 39.1) 
1. Age and sex 1.33 (1.13-1.56) 1.56 (1.16-2.08) 26.7 (9.8, 43.6) 
2. Model 1 plus marital status and employment 1.26 (1.07-1.49) 1.48 (1.10-1.99) 24.3 (7.2, 41.4) 
3. Model 2 plus delusions / hallucinations, and depression 1.24 (1.05-1.45) 1.48 (1.10-1.99) 24.4 (7.5, 41.4) 
 
*Logistic regression; **Linear regression 




















,case when emp1.Assessed_Date is not null then case when emp.Assessed_Date 
is not null then case when  
      abs(datediff(d,emp.Assessed_Date,'1-Jan-2011'))>=abs(datediff(d,'1-
Jan-2011',emp1.Assessed_Date)) 
      then emp1.PSA_Employment_Status_ID 
      else emp.PSA_Employment_Status_ID end  
      else emp1.PSA_Employment_Status_ID end  
      else case when emp.PSA_Employment_Status_ID is not null then  
      emp.PSA_Employment_Status_ID 
      else null end end as Employment 
,case when emp1.Assessed_Date is not null then case when emp.Assessed_Date 
is not null then case when  
      abs(datediff(d,emp.Assessed_Date,'1-Jan-2011'))>=abs(datediff(d,'1-
Jan-2011',emp1.Assessed_Date)) 
      then emp1.Assessed_Date 
      else emp.Assessed_Date end  
      else emp1.Assessed_Date end  
      else case when emp.Assessed_Date is not null then  
      emp.Assessed_Date 




,case when honos1.rating_date is not null then case when honos.rating_date 
is not null then case when  
      abs(datediff(d,honos.rating_date,'1-Jan-2011'))>=abs(datediff(d,'1-
Jan-2011',honos1.rating_date)) 
      then honos1.HONOSTYPE  
      else honos.HONOSTYPE end  
      else honos1.HONOSTYPE end  
      else case when honos.rating_date is not null then  
      honos.HONOSTYPE 
      else null end end as honostype 
,case when honos1.rating_date is not null then case when honos.rating_date 
is not null then case when 
      abs(datediff(d,honos.rating_date,'1-Jan-2011'))>=abs(datediff(d,'1-
Jan-2011',honos1.rating_date)) 
      then honos1.Rating_Date  
      else honos.Rating_Date end  
      else honos1.Rating_Date end  
      else case when honos.rating_date is not null then  
      honos.Rating_Date 
      else null end end as [Rating_Date] 
,case when honos1.rating_date is not null then case when honos.rating_date 
is not null then case when 
      abs(datediff(d,honos.rating_date,'1-Jan-2011'))>=abs(datediff(d,'1-
Jan-2011',honos1.rating_date)) 
      then honos1.Hallucinations_Score_ID  
      else honos.Hallucinations_Score_ID end  
      else honos1.Hallucinations_Score_ID end  
      else case when honos.rating_date is not null then  
      honos.Hallucinations_Score_ID 
      else null end end as Hallucinations_Score_ID 
,case when honos1.rating_date is not null then case when honos.rating_date 
is not null then case when 
      abs(datediff(d,honos.rating_date,'1-Jan-2011'))>=abs(datediff(d,'1-
Jan-2011',honos1.rating_date)) 
      then honos1.Depressed_Mood_Score_ID  
      else honos.Depressed_Mood_Score_ID end  
      else honos1.Depressed_Mood_Score_ID end  
      else case when honos.rating_date is not null then  
      honos.Depressed_Mood_Score_ID 
      else null end end  as Depressed_Mood_Score_ID 
,case when honos1.rating_date is not null then case when honos.rating_date 
is not null then case when 
      abs(datediff(d,honos.rating_date,'1-Jan-2011'))>=abs(datediff(d,'1-
Jan-2011',honos1.rating_date)) 
      then honos1.Relationship_Problems_Score_ID 
      else honos.Relationship_Problems_Score_ID end  
      else honos1.Relationship_Problems_Score_ID end  
      else case when honos.rating_date is not null then  




      else null end end as Relationship_Problems_Score_ID 
,case when honos1.rating_date is not null then case when honos.rating_date 
is not null then case when 
      abs(datediff(d,honos.rating_date,'1-Jan-2011'))>=abs(datediff(d,'1-
Jan-2011',honos1.rating_date)) 
      then honos1.Daily_Living_Problems_Score_ID 
      else honos.Daily_Living_Problems_Score_ID end  
      else honos1.Daily_Living_Problems_Score_ID end  
      else case when honos.rating_date is not null then  
      honos.Daily_Living_Problems_Score_ID 
      else null end end  as Daily_Living_Problems_Score_ID 
,Inpatientin2011 = case when wsperiod.brcid is not null then 'Yes' else 
'No' end 
,case when Dep.brcid is not null then 'Yes' else 'No' end Depression 
from 
      (select 
      distinct brcid 
      from sqlcris.dbo.Referral r 
      where Accepted_Date between '01-jan-1999' and '31-dec-2011' and 
      (Discharge_Date >= '01-jan-2011' or Discharge_Date = '01-jan-1900') 
and 
      Referral_Status_ID not like 'rejected' and 
      exists(select * from tbl_rs_f20count1 where brcid=r.brcid) 
      ) ds1 
join SQLCRIS.dbo.epr_form patient on ds1.BrcId=patient.brcid 
left join [SQLCrisImport].[dbo].[vw_honos_source] honos with (nolock) on 
      honos.cn_doc_id=(select top 1 cn_doc_id from 
[SQLCrisImport].[dbo].[vw_honos_source] with (nolock) 
      where  brcid=ds1.brcid and rating_date<='1-Jan-2011' and 
Invalid_Flag_ID<>'Yes' order by rating_date desc,CN_Doc_ID desc) 
left join [SQLCrisImport].[dbo].[vw_honos_source] honos1 with (nolock) on 
      honos1.cn_doc_id=(select top 1 cn_doc_id from 
[SQLCrisImport].[dbo].[vw_honos_source] with (nolock) 
      where  brcid=ds1.brcid and rating_date>'1-Jan-2011' and  
Invalid_Flag_ID<>'Yes' order by rating_date asc,CN_Doc_ID desc) 
left join [SQLCris].[dbo].[Summary_of_Need] emp with (nolock) on 
      emp.cn_doc_id=(select top 1 cn_doc_id from 
[SQLCris].[dbo].[Summary_of_Need] with (nolock) 
      where brcid=ds1.brcid and Assessed_Date<='1-Jan-2011' and 
Invalid_Flag_ID<>'Yes' order by Assessed_Date desc,CN_Doc_ID desc) 
left join [SQLCris].[dbo].[Summary_of_Need]  emp1 with (nolock) on 
      emp1.cn_doc_id=(select top 1 cn_doc_id from 
[SQLCris].[dbo].[Summary_of_Need] with (nolock) 
      where brcid=ds1.brcid and Assessed_Date>'1-Jan-2011' and 
Invalid_Flag_ID<>'Yes' order by Assessed_Date asc,CN_Doc_ID desc) 
left join (select distinct BrcId from  sqlcris.dbo.ward_stay a 
      where ((a.Current_Ward_Stay_Status_ID like 'closed' or 
      a.Current_Ward_Stay_Status_ID like '%occupied%') and 




      Actual_Start_Date > '01-jan-1900' and 
      ('1-jan-2011' between actual_start_date and case when 
actual_end_date='1-jan-1900' then GETDATE() else actual_end_date end)) 
      ) ws on ws.BrcId =ds1.BrcId 
left join (select  distinct brcid from  sqlcris.dbo.ward_stay a 
      where ((a.Current_Ward_Stay_Status_ID like 'closed' or 
      a.Current_Ward_Stay_Status_ID like '%occupied%') and 
location_name<>'Test Ward' and 
      ((Actual_Start_Date > '01-jan-1900' and  Actual_Start_Date <= '31-
dec-2011') and 
      (Actual_End_Date >= '01-jan-2011' or Actual_End_Date = '01-jan-
1900'))) 
      ) wsperiod on ds1.BrcId =wsperiod.brcid 





























      , 
     abstract_think_concrete, 
     abstract_think_concrete_high_prob 
    ,Affect_abnormal 
    ,Affect_blunted 
    ,Affect_flat 
    ,Affect_reactive 
    ,Apathy_apathetic 
    ,EW_withdrawn 
    ,Eye_contact_good 
    ,Eye_contact_intermediate 
    ,Eye_contact_poor 
    ,POS_abnormal 
    ,POS_normal 
    ,POS_poverty 
    ,Rapport_good 
    ,Rapport_poor 
    ,SW_socially_withdrawn 
    ,motivation 
    ,mutism 
    ,neg_symptoms 
    ,neg_symptoms_high_prob 
       





  FROM  
  [GateDB_Cris].[dbo].[gate_abstract_thinking_current] 
  where convert (datetime, document_date, 103) < '01-jan-2012' 









  FROM  
  [GateDB_Cris].[dbo].[gate_abstract_thinking_current] 
  where convert (datetime, document_date, 103) < '01-jan-2012' 
  and 
  convert (real, [prob]) >= '0.7' 
  group by BrcId) atc1 on a.brcid=atc1.brcid 




COUNT(*) Affect_abnormal    
  FROM GateDB_Cris.dbo.gate_affect_current 
  where affect = 'abnormal' 
  and convert (datetime, document_date, 103) < '01-jan-2012' 






  FROM GateDB_Cris.dbo.gate_affect_current 
  where affect = 'blunted' 
  and convert (datetime, document_date, 103) < '01-jan-2012' 





COUNT(*) Affect_flat    
  FROM GateDB_Cris.dbo.gate_affect_current 
  where affect = 'flat' 
  and convert (datetime, document_date, 103) < '01-jan-2012' 






  FROM GateDB_Cris.dbo.gate_affect_current 
  where affect = 'reactive' 
  and convert (datetime, document_date, 103) < '01-jan-2012' 





COUNT(*) Apathy_apathetic    




  where convert (datetime, document_date, 103) < '01-jan-2012' 





COUNT(*) EW_withdrawn     
  FROM GateDB_Cris.dbo.gate_emotional_withdrawal_current 
  where convert (datetime, document_date, 103) < '01-jan-2012' 





COUNT(*) Eye_contact_good     
  FROM GateDB_Cris.dbo.gate_eye_contact_current 
  where eye_contact = 'good' 
  and convert (datetime, document_date, 103) < '01-jan-2012' 






  FROM GateDB_Cris.dbo.gate_eye_contact_current 
  where eye_contact = 'intermediate' 
  and convert (datetime, document_date, 103) < '01-jan-2012' 





COUNT(*) Eye_contact_poor      
  FROM GateDB_Cris.dbo.gate_eye_contact_current 
  where eye_contact = 'poor' 
  and convert (datetime, document_date, 103) < '01-jan-2012' 





COUNT(*) POS_abnormal       
  FROM GateDB_Cris.dbo.gate_poverty_of_speech_current 
  where poverty_of_speech = 'abnormal' 
  and convert (datetime, document_date, 103) < '01-jan-2012' 








COUNT(*) POS_normal      
  FROM GateDB_Cris.dbo.gate_poverty_of_speech_current 
  where poverty_of_speech = 'normal' 
  and convert (datetime, document_date, 103) < '01-jan-2012' 





COUNT(*) POS_poverty      
  FROM GateDB_Cris.dbo.gate_poverty_of_speech_current 
  where poverty_of_speech = 'poverty' 
  and convert (datetime, document_date, 103) < '01-jan-2012' 





COUNT(*) Rapport_good      
  FROM GateDB_Cris.dbo.gate_rapport_current 
  where rapport = 'good' 
  and convert (datetime, document_date, 103) < '01-jan-2012' 





COUNT(*) Rapport_poor      
  FROM GateDB_Cris.dbo.gate_rapport_current 
  where rapport = 'poor' 
  and convert (datetime, document_date, 103) < '01-jan-2012' 





COUNT(*) SW_socially_withdrawn      
  FROM GateDB_Cris.dbo.gate_social_withdrawal_current 
  where convert (datetime, document_date, 103) < '01-jan-2012' 





COUNT(*) motivation      
  FROM GateDB_Cris.dbo.gate_motivation_current 
  where convert (datetime, document_date, 103) < '01-jan-2012' 









  FROM GateDB_Cris.dbo.gate_mutism_current 
  where convert (datetime, document_date, 103) < '01-jan-2012' 






  FROM GateDB_Cris.dbo.gate_negative_symptoms_current 
  where convert (datetime, document_date, 103) < '01-jan-2012' 






  FROM GateDB_Cris.dbo.gate_negative_symptoms_current 
  where convert (datetime, document_date, 103) < '01-jan-2012' 
  and convert (real, [prob]) >= '0.9' 
















































































*Recoding GATE symptoms* 
 
gen new_concrete = abstract_think_concrete 
replace new_concrete="0" if abstract_think_concrete=="NULL" 
destring new_concrete, replace 
 
gen new_aff_abn = affect_abnormal 
replace new_aff_abn = "0" if affect_abnormal=="NULL" 
destring new_aff_abn, replace 
 
gen new_aff_blunt = affect_blunted 
replace new_aff_blunt = "0" if affect_blunted=="NULL" 
destring new_aff_blunt, replace 
 
gen new_aff_flat = affect_flat 
replace new_aff_flat = "0" if affect_flat=="NULL" 
destring new_aff_flat, replace 
 
gen new_aff_react = affect_reactive 
replace new_aff_react = "0" if affect_reactive=="NULL" 
destring new_aff_react, replace 
 
gen new_apathy = apathy_apathetic 
replace new_apathy = "0" if apathy_apathetic=="NULL" 
destring new_apathy, replace 
 
gen new_ew = ew_withdrawn 
replace new_ew = "0" if ew_withdrawn=="NULL" 





gen new_ec_good = eye_contact_good 
replace new_ec_good = "0" if eye_contact_good=="NULL" 
destring new_ec_good, replace 
 
gen new_ec_int = eye_contact_intermediate 
replace new_ec_int = "0" if eye_contact_intermediate=="NULL" 
destring new_ec_int, replace 
 
gen new_ec_poor = eye_contact_poor 
replace new_ec_poor = "0" if eye_contact_poor=="NULL" 
destring new_ec_poor, replace 
 
gen new_speech_abn = pos_abnormal 
replace new_speech_abn = "0" if pos_abnormal=="NULL" 
destring new_speech_abn, replace 
 
gen new_speech_norm = pos_normal 
replace new_speech_norm = "0" if pos_normal=="NULL" 
destring new_speech_norm, replace 
 
gen new_speech_poor = pos_poverty 
replace new_speech_poor = "0" if pos_poverty=="NULL" 
destring new_speech_poor, replace 
 
gen new_rapp_good = rapport_good 
replace new_rapp_good = "0" if rapport_good=="NULL" 
destring new_rapp_good, replace 
 
gen new_rapp_poor = rapport_poor 
replace new_rapp_poor = "0" if rapport_poor=="NULL" 
destring new_rapp_poor, replace 
 
gen new_sw = sw_socially_withdrawn 
replace new_sw = "0" if sw_socially_withdrawn=="NULL" 
destring new_sw, replace 
 
gen new_amotiv = motivation 
replace new_amotiv = "0" if motivation=="NULL" 
destring new_amotiv, replace 
 
gen new_mute = mutism 
replace new_mute = "0" if mutism=="NULL" 
destring new_mute, replace 
 
gen new_neg1 = neg_symptoms 
replace new_neg1 = "0" if neg_symptoms=="NULL" 
destring new_neg1, replace 
 




replace new_neg2 = "0" if neg_symptoms_high_prob=="NULL" 




gen GATEn1a = new_aff_blunt 
recode GATEn1a 1/max=1 
 
gen GATEn2a = new_aff_flat 
recode GATEn2a 1/max=1 
 
gen GATEn1a2a = (new_aff_blunt + new_aff_flat) 
recode GATEn1a2a 1/max=1 
 
gen GATEn3a = new_ew 
recode GATEn3a 1/max=1 
 
gen GATEn4a = new_ec_int 
recode GATEn4a 1/max=1 
 
gen GATEn5a = new_ec_poor 
recode GATEn5a 1/max=1 
 
gen GATEn4a5a = (new_ec_int + new_ec_poor) 
recode GATEn4a5a 1/max=1 
 
gen GATEn6a = new_rapp_poor 
recode GATEn6a 1/max=1 
 
gen GATEn7a = new_apathy 
recode GATEn7a 1/max=1 
 
gen GATEn8a = new_sw 
recode GATEn8a 1/max=1 
 
gen GATEn9a = new_amotiv 
recode GATEn9a 1/max=1 
 
gen GATEn10a = new_concrete 
recode GATEn10a 1/max=1 
 
gen GATEn11a = new_speech_poor 
recode GATEn11a 1/max=1 
 
gen GATEn12a = new_mute 
recode GATEn12a 1/max=1 
 
alpha GATEn9a GATEn1a2a GATEn4a5a GATEn3a GATEn6a GATEn8a GATEn11a GATEn12a 





gen GATE10point = (GATEntotc)*10 
 
*Recodings - generating numeric variables* 
 
gen Sex = sex 
replace Sex = "0" if sex=="Female" 
replace Sex = "1" if sex=="Male" 
replace Sex = "9" if sex=="Not Known" 
replace Sex = "9" if sex=="Not Specified" 
destring Sex, replace 
recode Sex 9=. 
 
gen Marit = marital_status_id 
replace Marit = "1" if marital_status_id=="Cohabiting" 
replace Marit = "2" if marital_status_id=="Divorced" 
replace Marit = "3" if marital_status_id=="Divorced/Civil Partnership 
Dissolved" 
replace Marit = "4" if marital_status_id=="Married" 
replace Marit = "5" if marital_status_id=="Married/Civil Partner" 
replace Marit = "6" if marital_status_id=="Not Disclosed" 
replace Marit = "7" if marital_status_id=="Not Known" 
replace Marit = "8" if marital_status_id=="Separated" 
replace Marit = "9" if marital_status_id=="Single" 
replace Marit = "10" if marital_status_id=="Widowed" 
replace Marit = "11" if marital_status_id=="Widowed/Surviving Civil 
Partner" 
destring Marit, replace 
 
gen Employ = employment 
replace Employ = "1" if employment=="Employed" 
replace Employ = "2" if employment=="NULL" 
replace Employ = "3" if employment=="Not applicable" 
replace Employ = "4" if employment=="Not disclosed" 
replace Employ = "5" if employment=="Not known" 
replace Employ = "6" if employment=="Other employment status such as in 
education or training" 
replace Employ = "7" if employment=="Retired" 
replace Employ = "8" if employment=="Unemployed" 
replace Employ = "9" if employment=="xNx" 
replace Employ = "10" if employment=="Long-term sick or disabled" 
replace Employ = "11" if employment=="Students that are not actively 
seeking work" 
replace Employ = "12" if employment=="Unpaid voluntary work and not 
actively seeking work" 
destring Employ, replace 
 
gen dep = depression 




replace dep = "1" if depression=="Yes" 
destring dep, replace 
 
*Recodings - creating grouped variables* 
 
gen agegp=age 
recode agegp min/15=. 16/19=1 20/29=2 30/39=3 40/49=4 50/59=5 60/69=6 
70/max=7 
*i.e. number equals decade, below 16 dropped 
 
gen agegp2=age 
recode agegp2 min/15=. 16/39=0 40/max=1 
*i.e. number equals decade, below 16 dropped 
 
gen Sex3 = sex 
replace Sex3 = "0" if sex=="Female" 
replace Sex3 = "1" if sex=="Male" 
replace Sex3 = "2" if sex=="Not Known" 
replace Sex3 = "2" if sex=="Not Specified" 
destring Sex3, replace 
*0 Female 
*1 Male 
*2 Not recorded 
 
gen Marit3 = Marit 





gen Marit4 = Marit 






gen Marit5 = Marit 





*5 Not recorded 
 
gen Employ4 = Employ 






*2 In education 
*3 Retired 
 
gen Employ5 = Employ 
recode Employ5 1=1 2=4 3=4 4=4 5=4 6=2 7=3 8=0 9=4 10=0 11=2 12=0 
*0 Unemployed 
*1 Employed 
*2 In education 
*3 Retired 




gen Honos_psychosis = hallucinations_score_id 
replace Honos_psychosis = "9" if hallucinations_score_id=="NULL" 
replace Honos_psychosis = "9" if hallucinations_score_id=="Missing" 
destring Honos_psychosis, replace 
recode Honos_psychosis 9=. 
recode Honos_psychosis 1=0 2/4=1 
 
gen Honos_psychosis3 = Honos_psychosis 
recode Honos_psychosis3 0=0 1=1 .=2 
*0 No 
*1 Yes 
*2 Not recorded 
 
gen Honos_dep = depressed_mood_score_id 
replace Honos_dep = "9" if depressed_mood_score_id=="NULL" 
replace Honos_dep = "9" if depressed_mood_score_id=="Missing" 
destring Honos_dep, replace 
recode Honos_dep 9=. 
recode Honos_dep 1=0 2/4=1 
 
gen Honos_dep3 = Honos_dep 
recode Honos_dep3 0=0 1=1 .=2 
*0 No 
*1 Yes 
*2 Not recorded 
 
gen Honos_soc = relationship_problems_score_id 
replace Honos_soc = "9" if relationship_problems_score_id=="NULL" 
replace Honos_soc = "9" if relationship_problems_score_id=="Missing" 
destring Honos_soc, replace 
recode Honos_soc 9=. 
recode Honos_soc 1=0 2/4=1 
 
gen Honos_soc3 = Honos_soc 






*2 Not recorded 
 
gen Honos_adl = daily_living_problems_score_id 
replace Honos_adl = "9" if daily_living_problems_score_id=="NULL" 
replace Honos_adl = "9" if daily_living_problems_score_id=="Missing" 
destring Honos_adl, replace 
recode Honos_adl 9=. 
recode Honos_adl 1=0 2/4=1 
 
gen Honos_adl3 = Honos_adl 
recode Honos_adl3 0=0 1=1 .=2 
*0 No 
*1 Yes 
*2 Not recorded 
 
gen dep_any = dep + Honos_dep 
recode dep_any 2=1 
 
gen dep_any3 = dep_any 
recode dep_any3 0=0 1=1 .=2 
*0 No 
*1 Yes 
*2 Not recorded 
 
*Negative symptom definition* 
 
gen GATE10point2plus=GATE10point 
recode GATE10point2plus 1=0 2/max=1 
 
*Inclusion criteria for main analyses* 
 
gen xx=1 


























*Table 1 - negative symptoms prevalences*  
 
tab GATEn1a2a if xx==1 
tab GATEn3a if xx==1 
tab GATEn4a5a if xx==1 
tab GATEn6a if xx==1 
tab GATEn7a if xx==1 
tab GATEn8a if xx==1 
tab GATEn9a if xx==1 
tab GATEn10a if xx==1 
tab GATEn11a if xx==1 
tab GATEn12a if xx==1 
tab GATE10point if xx==1 
 
*Table 2 - 10 point including missing* 
 
tab agegp GATE10point2plus if xx==1, row 
tab Sex3 GATE10point2plus if xx==1, row 
tab Marit5 GATE10point2plus if xx==1, row 
tab Employ5 GATE10point2plus if xx==1, row 




tab Honos_soc3 GATE10point2plus if xx==1, row 
tab Honos_psychosis3 GATE10point2plus if xx==1, row 
tab dep_any3 GATE10point2plus if xx==1, row 
 
logistic GATE10point2plus ib2.agegp if xx==1 
logistic GATE10point2plus ib1.Sex3 if xx==1 
logistic GATE10point2plus ib3.Marit5 if xx==1 
logistic GATE10point2plus i.Employ5 if xx==1 
logistic GATE10point2plus i.Honos_adl3 if xx==1 
logistic GATE10point2plus i.Honos_soc3 if xx==1 
logistic GATE10point2plus i.Honos_psychosis3 if xx==1 
logistic GATE10point2plus i.dep_any3 if xx==1 
 
*Table 2 - 10 point multivariable binary logistic regression including 
missing* 
*N.B. Sex variable not including missing as only 2 cases* 
 
logistic GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
i.Honos_adl3 i.Honos_soc3 i.Honos_psychosis3 i.dep_any3 if xx==1 
 
*Table 3 - adjusted inpatient admission regression including missing* 
*N.B. Sex variable not including missing as only 2 cases* 
logistic ip2011any GATE10point2plus if xx==1 
logistic ip2011any GATE10point2plus ib2.agegp ib1.Sex if xx==1 
logistic ip2011any GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
if xx==1 
logistic ip2011any GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
 
logistic ip2011any GATE10point if xx==1 
logistic ip2011any GATE10point ib2.agegp ib1.Sex if xx==1 
logistic ip2011any GATE10point ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 if 
xx==1 
logistic ip2011any GATE10point ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
 
*eTable 1 - 10 point ordinal logistic regression including missing* 
*N.B. Sex variable not including missing as only 2 cases* 
ologit GATE10point ib2.agegp if xx==1, or 
ologit GATE10point ib1.Sex if xx==1, or 
ologit GATE10point ib3.Marit5 if xx==1, or 
ologit GATE10point i.Employ5 if xx==1, or 
ologit GATE10point i.Honos_adl if xx==1, or 
ologit GATE10point i.Honos_soc if xx==1, or 
ologit GATE10point i.Honos_psychosis if xx==1, or 
ologit GATE10point i.dep_any3 if xx==1, or 
 





*N.B. Sex variable not including missing as only 2 cases* 
ologit GATE10point ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 i.Honos_adl 
i.Honos_soc i.Honos_psychosis i.dep_any3 if xx==1, or 
 
*eTable 2 - 10 point with missing data dropped* 
 
tab agegp GATE10point2plus if xx==1, row 
tab Sex GATE10point2plus if xx==1, row 
tab Marit4 GATE10point2plus if xx==1, row 
tab Employ4 GATE10point2plus if xx==1, row 
tab Honos_adl GATE10point2plus if xx==1, row 
tab Honos_soc GATE10point2plus if xx==1, row 
tab Honos_psychosis GATE10point2plus if xx==1, row 
tab dep_any GATE10point2plus if xx==1, row 
 
logistic GATE10point2plus ib2.agegp if xx==1 
logistic GATE10point2plus ib1.Sex if xx==1 
logistic GATE10point2plus ib3.Marit4 if xx==1 
logistic GATE10point2plus i.Employ4 if xx==1 
logistic GATE10point2plus i.Honos_adl if xx==1 
logistic GATE10point2plus i.Honos_soc if xx==1 
logistic GATE10point2plus i.Honos_psychosis if xx==1 
logistic GATE10point2plus i.dep_any if xx==1 
 
*eTable 2 - 10 point multivariable binary logistic regression with missing 
data dropped* 
logistic GATE10point2plus ib2.agegp ib1.Sex ib3.Marit4 i.Employ4 
i.Honos_adl i.Honos_soc i.Honos_psychosis i.dep_any if xx==1 
 
*eTable 3 - 10 point inpatient admission during 2011 descriptive 
statistics* 
tab GATE10point ip2011any if xx==1, row 
 
*eTable 6 - Age interaction analysis including missing* 
*N.B. Sex variable not including missing as only 2 cases* 
logistic ip2011any GATE10point2plus if xx==1&age<=39 
logistic ip2011any GATE10point2plus if xx==1&age>=40 
logistic ip2011any GATE10point2plus GATE10point2plus#agegp2 if xx==1 
 
logistic ip2011any GATE10point2plus ib2.agegp ib1.Sex if xx==1&age<=39 
logistic ip2011any GATE10point2plus ib2.agegp ib1.Sex if xx==1&age>=40 
logistic ip2011any GATE10point2plus ib2.agegp GATE10point2plus#agegp2 
ib1.Sex if xx==1 
 
logistic ip2011any GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
if xx==1&age<=39 





logistic ip2011any GATE10point2plus ib2.agegp GATE10point2plus#agegp2 
ib1.Sex ib3.Marit5 i.Employ5 if xx==1 
 
logistic ip2011any GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1&age<=39 
logistic ip2011any GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1&age>=40 
logistic ip2011any GATE10point2plus ib2.agegp GATE10point2plus#agegp2 












**** Analyses **** 
 
*Table 3 - adjusted readmission regression including missing* 
*N.B. Sex variable not including missing as only 2 cases* 
logistic Readm GATE10point2plus if xx==1 
logistic Readm GATE10point2plus ib2.agegp ib1.Sex if xx==1 
logistic Readm GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 if 
xx==1 
logistic Readm GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
 
logistic Readm GATE10point if xx==1 
logistic Readm GATE10point ib2.agegp ib1.Sex if xx==1 
logistic Readm GATE10point ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 if xx==1 
logistic Readm GATE10point ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 





*Table 4 - unadjusted readmission regression including missing* 
logistic Readm GATEn1a2a if xx==1 
logistic Readm GATEn3a if xx==1 
logistic Readm GATEn4a5a if xx==1 
logistic Readm GATEn6a if xx==1 
logistic Readm GATEn7a if xx==1 
logistic Readm GATEn8a if xx==1 
logistic Readm GATEn9a if xx==1 
logistic Readm GATEn10a if xx==1 
logistic Readm GATEn11a if xx==1 
logistic Readm GATEn12a if xx==1 
 
*Table 4 - adjusted readmission regression including missing* 
*N.B. Sex variable not including missing as only 2 cases* 
logistic Readm GATEn1a2a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
logistic Readm GATEn3a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
logistic Readm GATEn4a5a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
logistic Readm GATEn6a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
logistic Readm GATEn7a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
logistic Readm GATEn8a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
logistic Readm GATEn9a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
logistic Readm GATEn10a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
logistic Readm GATEn11a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
logistic Readm GATEn12a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
 
*eTable 4 - 10 point readmission descriptive statistics* 
tab GATE10point Readm if xx==1, row 
 
*eTable 6 - Age interaction analysis including missing* 
*N.B. Sex variable not including missing as only 2 cases* 
logistic Readm GATE10point2plus if xx==1&age<=39 
logistic Readm GATE10point2plus if xx==1&age>=40 
logistic Readm GATE10point2plus GATE10point2plus#agegp2 if xx==1 
 
logistic Readm GATE10point2plus ib2.agegp ib1.Sex if xx==1&age<=39 
logistic Readm GATE10point2plus ib2.agegp ib1.Sex if xx==1&age>=40 






logistic Readm GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 if 
xx==1&age<=39 
logistic Readm GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 if 
xx==1&age>=40 
logistic Readm GATE10point2plus ib2.agegp GATE10point2plus#agegp2 ib1.Sex 
ib3.Marit5 i.Employ5 if xx==1 
 
logistic Readm GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1&age<=39 
logistic Readm GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1&age>=40 
logistic Readm GATE10point2plus ib2.agegp GATE10point2plus#agegp2 ib1.Sex 







*Table 3 - adjusted length of stay regression including missing* 
*N.B. Sex variable not including missing as only 2 cases* 
regress lengthofstay GATE10point2plus if xx==1 
regress lengthofstay GATE10point2plus ib2.agegp ib1.Sex if xx==1 
regress lengthofstay GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 
i.Employ5 if xx==1 
regress lengthofstay GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 
i.Employ5 Honos_psychosis3 dep_any3 if xx==1 
 
regress lengthofstay GATE10point if xx==1 
regress lengthofstay GATE10point ib2.agegp ib1.Sex if xx==1 
regress lengthofstay GATE10point ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 if 
xx==1 
regress lengthofstay GATE10point ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
 
*Table 4 - unadjusted length of stay regression including missing* 
regress lengthofstay GATEn1a2a if xx==1 
regress lengthofstay GATEn3a if xx==1 
regress lengthofstay GATEn4a5a if xx==1 




regress lengthofstay GATEn7a if xx==1 
regress lengthofstay GATEn8a if xx==1 
regress lengthofstay GATEn9a if xx==1 
regress lengthofstay GATEn10a if xx==1 
regress lengthofstay GATEn11a if xx==1 
regress lengthofstay GATEn12a if xx==1 
 
*Table 4 - adjusted length of stay regression including missing* 
*N.B. Sex variable not including missing as only 2 cases* 
regress lengthofstay GATEn1a2a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
regress lengthofstay GATEn3a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
regress lengthofstay GATEn4a5a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
regress lengthofstay GATEn6a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
regress lengthofstay GATEn7a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
regress lengthofstay GATEn8a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
regress lengthofstay GATEn9a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
regress lengthofstay GATEn10a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
regress lengthofstay GATEn11a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
regress lengthofstay GATEn12a ib2.agegp ib1.Sex ib3.Marit5 i.Employ5 
Honos_psychosis3 dep_any3 if xx==1 
 
*eTable 5 - 10 point length of stay descriptive statistics* 
sort GATE10pointmax6 
by GATE10pointmax6: summ lengthofstay, detail 
 
*eTable 6 - Age interaction analysis including missing* 
*N.B. Sex variable not including missing as only 2 cases* 
regress lengthofstay GATE10point2plus if xx==1&age<=39 
regress lengthofstay GATE10point2plus if xx==1&age>=40 
regress lengthofstay GATE10point2plus GATE10point2plus#agegp2 if xx==1 
 
regress lengthofstay GATE10point2plus ib2.agegp ib1.Sex if xx==1&age<=39 
regress lengthofstay GATE10point2plus ib2.agegp ib1.Sex if xx==1&age>=40 
regress lengthofstay GATE10point2plus ib2.agegp GATE10point2plus#agegp2 
ib1.Sex if xx==1 
 
regress lengthofstay GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 
i.Employ5 if xx==1&age<=39 
regress lengthofstay GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 




regress lengthofstay GATE10point2plus ib2.agegp GATE10point2plus#agegp2 
ib1.Sex ib3.Marit5 i.Employ5 if xx==1 
 
regress lengthofstay GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 
i.Employ5 Honos_psychosis3 dep_any3 if xx==1&age<=39 
regress lengthofstay GATE10point2plus ib2.agegp ib1.Sex ib3.Marit5 
i.Employ5 Honos_psychosis3 dep_any3 if xx==1&age>=40 
regress lengthofstay GATE10point2plus ib2.agegp GATE10point2plus#agegp2 
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Abstract 
Observational research using data from electronic health records (EHR) is a rapidly growing area, which promises 
both increased sample size and data richness - therefore unprecedented study power. However, in many medical 
domains, large amounts of potentially valuable data are contained within the free text clinical narrative. Manually 
reviewing free text to obtain desired information is an inefficient use of researcher time and skill. Previous work has 
demonstrated the feasibility of applying Natural Language Processing (NLP) to extract information. However, in 
real world research environments, the demand for NLP skills outweighs supply, creating a bottleneck in the 
secondary exploitation of the EHR. To address this, we present TextHunter, a tool for the creation of training data, 
construction of concept extraction machine learning models and their application to documents. Using confidence 
thresholds to ensure high precision (>90%), we achieved recall measurements as high as 99% in real world use 
cases. 
Introduction 
The increasing use of electronic health records (EHR) provides potentially transformative opportunities for clinical 
research in the breadth and depth of data contained within them. However, unstructured clinical notes are often the 
most valuable source of phenotypic/contextual information because of limitations in the scope and acceptability of 
structured fields. In response to this challenge, Natural Language Processing (NLP) has been employed to extract 
appropriate assertions in a structured format amenable to the needs of researchers1. While significant success has 
been achieved in many areas, the demand for ever more variables to be extracted from the clinical narrative is 
currently bottlenecked by the limited supply of technical skills2. For example, rule based approaches to novel 
problems are often effective, but require a certain degree of technical knowledge and experience, which can be too 
time-consuming and thus expensive to produce in high volume. Proposed solutions include ontological or dictionary 
mapping techniques, which are appropriate where there are well-constructed resources; however, the standards 
imposed by these may not be easy to adapt to real world clinical sub-languages3, or where there is controversy about 
the appropriate use of clinical language4. Machine Learning (ML) approaches are an increasingly popular means of 
circumventing rule based systems, but require even more technical expertise and are limited by the availability and 
ease of creating appropriate training data5,6. Finally, although progress has been made in the development of publicly 
available corpora for evaluating different clinical NLP methodologies7, these offer no guarantee that the 
performance obtained by models trained on such data will provide a generalizable solution (for example, for work 
on EHRs in different medical domains, dialects, languages, or work cultures)8. 
These issues form barriers to progress for groups who have access to unstructured clinical data, but do not have 
sufficient technical capabilities to trial the wealth of information extraction techniques on offer. In recent years this 
has prompted the development of tools such as Arc9 to democratize access to generic information extraction 
capabilities. However, there are currently no free tools available that offer a full end-to-end solution for concept 
level extraction, including the principle tasks of: 
1) Extracting instances of concepts from a database or large collection of documents 
2) Creating sufficient training data specific to a concept to enable a machine learning approach 
3) The configuration and testing of an  (ML) algorithm for the given concept  
4) The application of the model to the entire document set of interest, and the subsequent export of results into 
a familiar format 
  
In order to make concept extraction technologies accessible to groups without informatics support, we have 
developed the TextHunter tool to address these tasks. 
Methods 
Data: The South London and Maudsley mental health case register 
The South London and Maudsley NHS Trust (SLAM) is the largest mental health organization in Europe, and is a 
virtual monopoly provider of mental health services to 1.2 million individuals within its geographical catchment 
area (Lambeth, Southwark, Lewisham and Croydon boroughs in South London). In 2007-08, funding from the 
British National Institute for Health Research supported the development of the Clinical Record Interactive Search 
(CRIS) database. CRIS operates as a pseudonymized version of SLAM’s EHR system, accessible for researchers via 
its distinctive, patient-led information governance model10. CRIS houses more than 230,000 de-identified patient 
records, which in turn represent over 20 million free text documents. The CRIS system continues to grow at a rate of 
approximately 170,000 free text documents per month. Clinical information documented in unstructured text is of 
particular value in mental health research where there is an increasing emphasis on using dimensional symptom 
scales to define mental illness rather than discrete diagnostic categories11–14. While CRIS also has large amounts of 
data contained within structured fields, the development of TextHunter was precipitated by the needs of many 
disparate groups of researchers who require access to the wealth of additional information contained within the 
clinical narrative. 
TextHunter System Description 
TextHunter is a program that guides a user through all of the required processes to create and apply a concept 
extraction model for a selection of documents from start to finish. It performs six important tasks, the end result of 
which delivers a structured representation of a concept. Its intended use case is typically phenotype cohort 
identification, although it can be employed for more generic purposes. The program is built from open source 
libraries, and uses the GATE library as its core NLP engine15. The ML element uses the Support Vector Machine 
(SVM) based ‘Batch Learning’ plugin supplied with GATE16. In consideration of the rigorous information 
governance requirements of clinical data, TextHunter is designed to operate as a standalone ‘offline’ program on 
desktop hardware, although its multithreaded design enables its deployment on more powerful workstations/virtual 
machines to handle larger datasets. It is capable of connecting to commercial database environments such Microsoft 
SQL Server to process massive datasets, but for succinctness, only its standalone operation mode is described here. 
The underlying principle of TextHunter is ‘Find, Annotate, Build, Apply’ - respectively addressing the four key 
problems described above. The integration of these concepts into a single system creates the possibility of providing 
lay users with access to more advanced ML techniques, such as active learning. Each phase of the TextHunter 
pipeline is described below: 
1. Search Phase 
This phase addresses task 1). The first stage of the TextHunter pipeline requires a user to define a list of keywords, 
regular expressions and/or phrases to describe their concept of interest. The user then directs the program to a 
directory holding the text files of interest. Upon executing the ‘search’ phase, each document is scanned for 
mentions of the user’s expressions. When a mention is identified, a short section of text consisting of multiple 
sentences, including the sentence where the concept mention was found, and up to two sentences either side of the 
sentence of interest is extracted. This is stored in an embedded file based database, along with a copy of the 
underlying document. Deconstructing documents in this way facilitates the downstream management of text 
instances for annotation and classification. 
2. Annotation Phase 
This phase addresses task 2). The user is directed to TextHunter’s annotation interface, which has been specifically 
designed for the rapid annotation of concept instances. We define an instance as a group of one to five sentences 
centered on a concept keyword, and its classification as defined below: 
i) Positive – the example is a relevant hit and is an appropriate positive example of the user’s concept 
  
ii) Negative - the example is a relevant hit and is an appropriate negated example of the user’s concept 
iii) Unknown - the example is a relevant hit but the user is unable to ascertain the correct classification, or the 
example is irrelevant 
In this phase, the user is required to produce a ‘test’ corpus for model validation (typically of 100-300 instances), 
which are randomly selected from all instances in the document set. This is followed by the production of a ‘seed’ 
corpus to be used in training models. This also numbers about 100-300 instances, but is enriched by ensuring no 
identical instances are present. In real world clinical datasets, the required semantic context that enables the 
classification of a concept instance may cross sentence boundaries. To ensure appropriate features are available for 
training, the user can specify the required ‘context’ (up to two sentences before and two sentences after) needed to 
make the classification, centered on the sentence containing the concept keyword. These boundaries are arbitrarily 
chosen by the GATE sentence splitter module, although we expect that only in very rare cases will more than five 
sentences be required to express medical concepts as they are normally found in EHRs. 
3. Feature selection/Model Building Phase 
This phase addresses task 3). Here, TextHunter builds and evaluates a range of models against the task, using 
different features and SVM parameters each time. The default feature vector used by TextHunter is a classic bag of 
words using part-of-speech tags and token stems from the user specified context around a concept. When applying a 
model to unseen data, TextHunter creates feature vectors from up to six different combinations of sentences around 
the sentence containing the concept term. The classification resulting from the feature vector producing the highest 
overall confidence is chosen as the result. In addition, TextHunter has a modular design that allows developments 
from the clinical NLP community to be integrated into its core pipeline via GATE creole plugins. Currently, 
TextHunter takes features of the GATE implementation of the ConText algorithm17, which uses hand crafted rules to 
determine whether a concept is negated, temporally irrelevant or refers to a subject other than the patient. Stop word 
removal is also explored during feature selection. 
Cross validation of the training data is used to mitigate the dangers of overfitting the model to a small amount of 
data. The model producing the best F1 score is taken forward for testing against the human labeled ‘test’ corpus, 
which is never used in model training. A range of easy to interpret output files are produced, containing estimates of 
‘real world’ performance the user might expect. 
4. Application Phase 
 
This phase addresses task 4). This phase allows the user to apply the best performing model to all instances of text in 
their dataset, as captured in the search phase. As with the model building phase, combinations of sentences are tested 
around the concept. The classification that results from the combination with the highest confidence is chosen as the 
final result. Once this stage is complete, the user may export the output into several formats. 
 
5. Active Learning Phase (optional) 
Conceptually, active learning is an iterative process whereby an ML algorithm selects instances that it has difficulty 
classifying and presents them to a human annotator for labeling. These are then fed back into the model, with the 
intention that the new model arising will be better at classifying similar, difficult examples. TextHunter supports a 
‘simple margin’ inspired method of active learning18. A seed model is constructed from randomly selected instances 
of text, as described above. This model is then applied to a large sample of the entire population of relevant text 
instances. For each classification the model makes, it also assigns a level of certainty, between -1 and +1. 
Theoretically, highly positive scores are representative of easy to classify ‘positive’ instances, whereas highly 
negative scores are representative of easy to classify ‘negative’ or ‘unknown’ instances. Instances with a certainty 
score close to 0 are thus ‘difficult’, and presented to the user for labeling in order to retrain the classifier. 
Use cases 
To evaluate the performance of TextHunter, we defined three real world use cases of concept extraction. Examples 
of search expressions and typical instances for each use case are detailed in Table 1: 
  
Case Study 1: Cannabis Smoking 
Cannabis use has been indicated as a potentially aggravating factor in patients suffering from mental illness19. 
Through the vast amount of electronic documentation generated in the course of patient care, we attempted to 
identify a patient’s cannabis smoking status based upon reports by mental health professionals. The CRIS database 
contains intra-profession clinical correspondence style documents and clinical notes resulting from patient contact. 
Each type of document may contain references to cannabis usage by the patient. In this study, our objective was to 
use TextHunter to build a classifier to identify current or historical cannabis usage. We conducted a review of the 
most common nouns and slang terms used to describe cannabis in SLAM, to produce a list of expressions which 
formed the basis for finding instances to classify. A psychiatrist then produced multiple sets of annotations using the 
standard TextHunter procedure, making use of the active learning functionality. Although it was not possible to 
double annotate the training data, we adopted a restrictive manual coding strategy in order to allow as little 
subjectivity as possible (for example, by classifying mentions pertaining to future events, or 
tangential/circumstantial references into our predefined ‘unknown’ class). 
Case Study 2: Psychosis Symptomatology 
Patients suffering from psychosis can exhibit a wide range of symptoms, which in turn inform the nature of their 
treatment plan. Common tools to quantify symptomatology in psychosis include such instruments as the Positive 
and Negative Symptom Scale and the Clinical Assessment Interview for Negative Symptoms12,13. These depend on 
an assessment of the patient’s presentation in regard to a wide range of possible symptoms. Our previous work to 
capture some of these from clinical notes with ML approaches has been described20,21. In this case study, we used 
TextHunter to capture two additional symptoms: delusional symptoms and evidence of hallucinations, using the 
standard TextHunter workflow. The annotated data for ‘delusions’ were generated by a clinical informatician, with a 
random sample checked for accuracy and consistency by a psychiatrist. In the case of ‘hallucinations’, all 
annotations were generated by a public health physician. In both cases, the restrictive coding strategy as described 
above was employed. 





for search phase 
Fictitious examples of instances (Parentheses indicates typical 






ZZZZZ told me that he continues to smoke cannabis only no other 
illicit drugs. (positive) 






She is continuing to experience hallucinations and is becoming 
increasingly distressed by these. (positive) 
Staff observed him to rambling and delusional, repeating himself and 






Case Study 3: Ethnicity 
Ethnicity is a key variable in many epidemiological and clinical studies. Although ethnicity can theoretically be 
captured via the structured elements in SLAM’s EHR system, in reality, it is often not recorded in the course of 
routine clinical practice. However, as with many other variables, ethnicity is often referenced in clinical free text. 
The purpose of this case study was therefore to classify instances of text describing a patient’s ethnicity, into one of 
17 ethnic groups. A range of terms was selected in association with each ethnic group, and a ‘positive’ classification 
was made if the context for the term was suggestive of the patient belonging to that group. A single researcher 
produced the annotated dataset for training/testing, using a similarly restrictive coding strategy. 
In each case study, a sample of the evaluation instances were double annotated by an individual in a related 
profession to generate inter-annotator agreement statistics. 
Results 
In all case studies, we used 10 fold cross validation for the model building phase, which took approximately one 
hour on a desktop computer with a Core 2 Duo E7500  processor. 
In the cannabis smoking study, we used 13 terms to capture cannabis mentions. The CRIS database yielded 663,979 
mentions of cannabis. For the psychosis symptomatology study, the search phase found 603,818 mentions of 
delusions, and 703,996 mentions of hallucinations. Each symptom was represented by a single term in the search 
phase. Finally, there were 3,444,435 mentions of concepts potentially related to ethnicity, resulting from 277 terms 
commonly used to define our 17 ethnic identities. 
Traditionally, the performances of information extraction algorithms in NLP are described in terms of precision, 
recall and the F1 statistic. However, the high level of noise commonly associated with EHR based observational 
research necessitates the capture of high quality data in order to generate clearly defined cohorts. This data quality 
requirement restricts the use of automated concept extraction techniques to those that can be shown to have a high 
true positive rate, relative to the inherent predictive value of a mention of a concept. For example, a mention of a 
cannabis synonym will refer to a patient’s current or past use 70% of the time, whereas a mention of a term denoting 
ethnicity will refer to a patient’s actual ethnicity only 20% of the time (Table 1). A further consideration of the real 
world viability of a given model is the longitudinal nature of the electronic health record. A patient may have 
numerous contacts with a health service over a number of years, creating multiple instances of time independent 
concepts. For example, a patient may have multiple references to their cannabis consumption habits, especially if it 
is identified as a factor in their illness. Similarly, a patient’s ethnicity may be described in service referral letters 
generated during the course of their care. Only one positive instance needs to be captured precisely for a high quality 
output to be achieved. However, spurious data points are more problematic. Given these factors, it is more practical 
to develop information extraction tools that favor precision over recall in most use cases. For this reason, in Table 2 
we describe the recall statistic at two arbitrarily defined levels of precision (90% and 95%), which are identified by 
filtering the classified instances in the test set via the classification confidence threshold. We present Receiver-
Operator Characteristic (ROC) plots for each case study in Figure 1. For brevity, we only report the highest F1 
achieved without any confidence filtering (note, this is not necessarily the same model that achieves the highest 
recall at the 90%/95% precision threshold). 
The best performance was seen in the hallucinations case study, with over 97 % recall obtained at the 95% precision 
threshold. The worst performance was observed in the ethnicity study, where recall reached only 9% at 90% 
precision, and declined with further training. 
Different problems required different features in order to obtain the best overall result. In Table 3, we present the 
types of features that were found to be most useful in each case study.  
The rate of training data production varied moderately between the studies, the slowest recorded at approximately 
100 instances labeled per hour, and the fastest at roughly 230 instances per hour. Since different individuals 
annotated each study, further comparisons were not possible. Anecdotal reports from the annotators suggested that 
the process of annotating instances selected via active learning was slower than the randomly selected instances in 
the seed set. 
  
Table 2: Performance statistics for TextHunter ‘positive’ instances (‘unknown’ and ‘negative’ instances are grouped 
together). 
1
Observed Agreement and Cohen’s Kappa. 2Baseline precision assumes presence of keyword is a 
‘positive’ instance (by definition, recall is 100%), and provides a measure of how predictive a mention is of a 
concept without any processing applied. P
 
= precision, R = recall, F1 = harmonic mean of precision and recall. 
3
Parentheses indicate count of training instances in the model building phase (subsequent active learning iterations 
increase the number of training instances available). 
4
Recall measured at precision levels of 90% and 95%, attained 
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P = 82% 
R = 75% 
F1 = 0.78 
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N/A ~3 hours 
(396) (805) 
 














128 No No 0.6 polynomial 
Delusions 136 No No 0.6 polynomial 
Hallucinations 88 Yes No 0.5 polynomial 
Ethnicity 24 Yes Yes 0.7 polynomial 
 
Discussion: 
In our analysis, we used TextHunter to extract a diverse set of concepts that are typically in demand in clinical 
research environments. We arbitrarily set two desired precision standards, and adopted strategies to try to maximize 
the recall given this requirement. Three of the four test cases reached over 70% recall at the lower precision cut-off 
of 90%. We do not attempt to tackle the question of what constitutes acceptable performance for research 
applications here. Nevertheless, we have confidence that the range of case studies investigated here establishes a 
  
proof of concept in enabling end users to create and deliver information extraction solutions independently of 
significant NLP expertise. 
 
Figure 1: Receiver Operator Characteristic for TextHunter models on ‘test’ data, generated with SVM confidence 
thresholds. 
Given our limited range of test cases, the SVM parameters and additional features used varied greatly, even between 
the two conceptually similar problems explored in psychosis symptomatology. This substantiates our approach of 
testing a range of models to find the best solution for a given problem. However, a predominant factor in the 
algorithms’ ability to reach higher levels of recall is the predictive value that a simple mention of a concept produces 
(i.e. how likely a human annotator is to label a randomly selected mention of a concept as ‘positive’). For instance, 
the ROC curve produced for the ethnicity study compares favorably with that of the cannabis study, and we 
achieved a substantial performance benefit over the baseline precision for our list of ethnicity terms.  However, 
because of our self-imposed requirement of a minimum 90% precision, the recall for ethnicity falls very quickly as 
this threshold is approached. Intuitively, in high noise datasets where ‘positive’ mentions of a concept are rarer, the 
concept extraction problem is significantly more challenging. In addition, the low predictive value of ethnicity terms 
means the ‘positive’ class will be less represented than the ‘negative’ or ‘unknown’ classes in the model. Currently, 
TextHunter makes no adjustment for unbalanced classes, and future work could investigate mitigation strategies for 
this, such as using uneven margins 22. It should also be noted that we were required to use many more terms to 
capture mentions of ethnicity, which may be indicative of the inherent difficulty of defining concepts that are largely 
social constructs. 
In the case of the cannabis study, we were able to improve the model substantially by providing additional training 
data through active learning. We did not try to quantify the added benefit of adopting an active learning 
 
  
methodology over randomly selecting new instances. However, others have previously demonstrated that active 
learning can accelerate the development of machine learning models in clinical NLP18,23,24. Active learning did not 
produce an additional benefit in the hallucinations case study, although the model resulting from the seed data had 
already produced a very high F1 statistic. Here, our application of confidence filters was not required, as the 
performance of the model generated from the seed annotations surpassed our precision requirement of 95%. In the 
case of ethnicity, adopting an active learning approach noticeably depreciated the quality of the model. To 
investigate, we conducted a subjective review of the instances that active learning retrieved. This revealed that many 
were incoherent strings of text, seemingly resulting from jumbled emails, faxes and other malformed documents. 
Since these were not representative of natural language, their inclusion in training the model possibly introduced 
more noise than benefit. Previous reports have highlighted the difficulties of applying general NLP tools on clinical 
text8,25, and we suspect that this scenario is not uncommon in real world EHR systems. One possible mitigation 
strategy would be to employ document classification methods to filter out malformed documents and/or a more 
sophisticated active learning methodology, such that new training data are more representative of the instances of 
interest. Nevertheless, an SVM approach as implemented in TextHunter appears to be valid for simple concepts that 
tend be succinctly expressed - for example, if it can be defined with a relatively short list of keywords, is not over-
complicated by frequent ungrammatical usage (such as in lists or questionnaire text) and has a baseline precision of 
at least 60%. 
It was not practical to double annotate our training data fully, so we are only able to provide inter-annotator 
agreement (IAA) statistics for a subset of the total test set in each case study. Despite our limited set, our data 
suggest relatively high levels of agreement, highlighting a high degree of objectivity in the expression of concepts in 
clinical text. However, clinical constructs in mental illness are often subtle. Initial reports from annotators in each 
case study suggested that the annotation process itself influenced their own views on the interpretation of notes 
created by others. Specifically, the exposure to a wide range of writing styles from other clinicians may introduce 
unforeseeable subjectivity into the annotation process. Regardless, methods that place subject matter experts (rather 
than NLP specialists) in the role of defining a concept are likely to be less subjective, as any subjectivity introduced 
by the annotation process will likely be compounded by attempting to convey the subtleties to a non-expert third 
party. Any clinical subjectivity may then be mitigated by a process of iterative discussion and re-annotation to 
produce well defined annotation guidelines. A potentially useful future development of TextHunter may be to 
incorporate a model of clinical data, such as the Clinical Element Model
26
. This would encourage the re-use of 
standard definitions of concepts, thus promoting greater interoperability with NLP tools. 
A notable shortcoming of the TextHunter methodology was the ethnicity case study, which had the highest Kappa 
statistic but the lowest F1 score from the seed data. This highlights the divide between human and machine 
interpretation, and the need for more complex reasoning systems to resolve more difficult problems. 
Conclusion 
The requirement to develop this software was driven by an imbalance between the demand for concept extraction 
and the supply of skilled individuals capable of delivering solutions to the needs of researchers. We have shown that 
it is feasible to package an appropriate suite of tools into a simple interface, and that this enables researchers to 
produce concept extraction models without input from NLP specialists. TextHunter uses a flexible SVM based 
algorithm as a generic, user friendly information extraction capability. We have validated the methodology with a 
variety of typical problems, and produced high precision and relatively high recall models. Although it is not 
suitable for all tasks, we argue that the ‘solve small problems quickly’ approach to information extraction is 
appropriate for many types of variable likely to be of interest to researchers, and offers the attractive advantage of 
rapidly generating models that have been trained on data sourced from the intended target. Finally, the simple 
annotation interface enables a rapid annotation process, with labeled data stored in a standard, reusable format. The 
pipeline style operation of GATE and the open source licence of TextHunter should encourage the future 
development of additional features to improve performance and expedite its use on more complex NLP problems. 
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7. Conclusions 
7.1 Summary of key findings 
Three studies were performed using data obtained from the SLaM BRC Case Register in order to 
investigate clinical outcomes in psychotic disorders relating to high risk clinical services (chapter 3), 
cannabis use (chapter 4) and negative symptoms (chapter 5). 
Chapter 3 demonstrates that presentation with FEP to a high risk service is associated with better 
clinical outcomes (as indexed by reduced number of inpatient days, reduced frequency of hospital 
admission and reduced likelihood of compulsory admission) when compared to other clinical 
services. Around one third of patients presenting to a high risk service are found to already be 
experiencing their first episode of psychosis.[6,122] Prior to this study, little was known about the 
future clinical outcomes of this group. The findings in chapter 3 suggest that high risk services may 
not only support people who are vulnerable to psychosis, but may also play an important role in 
improving outcomes in people who have already developed a psychotic disorder. 
The findings in chapter 4 suggest that a history of cannabis use is associated with a greater 
frequency of psychiatric hospital admissions, increased likelihood of compulsory hospital admissions 
and greater number of inpatient days in the five years following presentation to an early 
intervention service with FEP. Furthermore, these associations were partly mediated by an increase 
in the number of unique antipsychotics prescribed. Previous studies suggest that cannabis is 
associated with an increased risk of developing a psychotic disorder.[50,51] However, prior to this 
study, little was known about the association of cannabis with clinical outcomes in people with an 
established psychotic disorder. The findings in chapter 4 suggest that cannabis use is associated with 
worse clinical outcomes in people with FEP which are partly mediated through a failure of 
antipsychotic treatment. 
Chapter 5 demonstrates that negative symptoms are frequently present in people with 
schizophrenia and that they are associated with increased likelihood of hospital admission, 
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readmission and number of inpatient days. Previous studies investigating negative symptoms in 
psychosis have involved relatively small research samples using detailed clinical questionnaires 
which may not be practical to apply in the clinical setting.[123] The findings from chapter 5, which 
are based on a large sample of patients receiving mental healthcare in a real‐world setting, indicate 
an important role of negative symptoms in predicting poor clinical outcomes. 
7.2 Strengths and limitations 
The studies reported in this thesis were based on largescale analysis of clinical data from EHRs. A key 
strength of this approach is the availability of large volumes of data, thereby increasing statistical 
power to address research questions which would have otherwise been unfeasible to investigate in 
observational or interventional studies involving direct patient recruitment.[65,66] For example, it 
would not be feasible to perform a prospective interventional study to investigate the effect of a 
high risk service on clinical outcomes in people with FEP. The large sample size available in an 
electronic case register derived from EHRs is coupled with the availability of rich clinical data 
including free text documents from clinical assessments and correspondence. These documents 
contain detailed clinical information including the nature of presenting symptoms which would not 
normally be available in an electronic case register derived from administrative healthcare data. In 
chapters 4 and 5, the combination of NLP techniques with large volumes of EHR data permitted 
analysis of data on cannabis use and negative symptoms from large numbers of patients which 
would otherwise have been difficult to obtain by face‐to‐face clinical interview or by manually 
reading clinical documents. 
Another strength of EHR data is that they represent naturalistic data collected in the course of 
providing standard clinical care to patients within a mental healthcare service. This means that the 
findings drawn from these data are generalizable to the population that normally receives 
healthcare from mental health services. This is in contrast to data obtained from direct recruitment 
to observational and interventional studies, when strict inclusion criteria and specialised clinical 
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assessment and intervention can result in findings which are not representative of standard clinical 
practice.[124] A further benefit of EHR data is that they are less prone to observation bias than data 
from a study involving direct recruitment.[125] At the time when they were documenting clinical 
data in EHRs, clinicians were agnostic to the possibility that their data may later be used for research 
purposes. In particular, in the study reported in chapter 5, clinicians were not specifically seeking to 
elicit the presence or absence of negative symptoms. This may have resulted in a reduced 
prevalence of negative symptoms in the SLaM BRC Case Register data compared to previous studies 
involving specialised research instruments specifically designed to obtain data on negative 
symptoms. However, the benefit of analysing EHR data to investigate negative symptoms is that 
clinicians were unbiased with respect to the future use of their records for this purpose and so their 
assessments in EHRs may be more representative of the prevalence of negative symptoms elicited in 
standard clinical practice. 
The primary limitation in drawing conclusions from the EHR data is that they are observational, and 
so any association of a predictor with subsequent clinical outcomes does not necessarily 
demonstrate an aetiological association. Another difficulty is that by virtue of being naturalistic, 
clinical data were not comprehensively collected for all the patients included in the studies. This 
resulted in some missing covariate data. Sensitivity analyses including missing data as a separate 
category in multivariable regression analyses did not result in meaningful changes to the findings. 
However, there were other variables which were not possible to analyse in detail due to a lack of 
consistent clinical documentation. These included details on medication dose, duration, 
concordance, side effects and reason for discontinuation (if applicable) which would have helped to 
better explain the finding that cannabis is associated with an increase in the number of unique 
antipsychotics prescribed to people with FEP (chapter 4). A furether limitation is lack of 
documentation on change in nature and degree of symptomatology over time which limited the 
analysis of negative symptoms in schizophrenia (chapter 5) to the presence and absence of negative 
symptoms without examining degree or severity of symptoms. 
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Related to this issue, by virtue of the fact that clinical data are only documented in EHRs when 
patients receive care from clinical services. This means that on the balance of probability, NLP 
techniques are likely to obtain more data from patients who have a greater degree and frequency of 
contact with mental health service. It is possible that the absence of documentation on a patient 
could have been biased by the fact that they were well, and so did not require mental healthcare 
services. Conversely, the absence of documentation could reflect disengagement from mental health 
services by people who are unwell or experiencing a relapse of psychotic symptoms. Therefore, NLP 
techniques may have underestimated the presence of cannabis use (chapter 4) or negative 
symptoms (chapter 5) in patients who had less contact with mental health services by virtue of 
having been thought to be well enough not to require these services or to be unwell because of 
disengagement from mental health services. 
A further limitation in EHR data is the degree to which constructs documented in clinical records 
represent the clinical presentation to which they refer within individual patients and the degree to 
which they are comparable between different patients. It is not possible to know whether different 
clinicians (with different levels of expertise and experience) who assessed the same patients would 
have reported the same findings. Nonetheless, it is likely that if a feature of a patient’s history or 
mental state is particularly relevant to their clinical presentation (e.g. if it influences subsequent 
treatment decisions and management), it is likely to have been documented in the course of their 
clinical care. Likewise, patients are often observed and assessed by a range of different mental 
healthcare professionals including doctors, nurses, psychologists and other allied healthcare 
professionals. This would increase the likelihood that relevant presenting features are documented 
at some point in a patient’s EHR. 
7.3 Application of CRIS and NLP methods in other healthcare centres 
The widespread use of EHR systems in mental healthcare services raises the possibility of applying 
the data extraction methods described in this thesis in other healthcare centres. Following the 
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implementation of CRIS in SLaM, a collaboration has developed to implement the CRIS software in 
five providers of mental healthcare in Southeast England: SLaM, Camden and Islington, West London 
Mental Health, Cambridgeshire and Peterborough and Oxford Health NHS Trusts.[126] This 
collaboration demonstrates the potential for the integration of a data extraction and assembly 
framework based on Microsoft SQL Server (i.e. the CRIS tool) to be implemented in different 
healthcare settings using different EHR systems. 
However, the generalisability of CRIS to other EHR systems depends on the data structure and 
framework used to store clinical data. While the composition of structured text fields may vary 
between different EHR systems, those storing core clinical data such as age, gender, ethnicity and 
other sociodemographic data are likely to be present among all systems. Beyond structured fields, 
free text clinical data from assessments and correspondence stored in unstructured fields are also 
likely to be present as free text records are the most widely used to store clinical data.[98] It is likely 
that the NLP approaches employed in this thesis could be applied to free text clinical records from 
other healthcare centres. However, the extent to which NLP algorithms derived in one centre could 
be directly translated to another EHR system remains uncertain. 
It is possible that local variations in the documentation of clinical information may affect the ability 
of NLP software derived in one healthcare centre to accurately identify data in another centre, even 
if it is written in the same human language. This may be due to local variations in vocabulary used by 
clinicians to describe clinical phenotypes, differences in spelling and grammar or variation in the 
vocabulary used by patients to describe their clinical presentation.[127] However, within the UK, 
these differences are unlikely to be large. 
One method of overcoming this limitation may be to derive NLP algorithms which are unique to 
individual healthcare providers. The same key words used to derive the NLP algorithms to identify 
cannabis use and negative symptoms in this thesis could be used to generate a reference and 
training dataset using free text clinical data from an EHR system in another healthcare centre. This 
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training data could then be used to generate an NLP algorithm which is specific to the EHR system in 
which it is to be applied. Further work is needed to evaluate the potential for this approach or 
whether NLP algorithms derived in EHR system could be directly applied in another. 
7.4 Future research 
The studies reported in this thesis demonstrate the potential for EHR data (supplemented by NLP) to 
contribute to mental health research. In these studies, prospectively recorded clinical data were 
analysed in retrospect to examine the impact of high risk clinical services, cannabis and negative 
symptoms on clinical outcomes. The findings from these studies prompt further research with two 
aims: firstly, to address the limitations described in section 6.2 in order to improve the method and 
secondly, to consider how the methods developed as a consequence of this work could be used for 
secondary purposes. 
The extent to which data obtained from EHRs using NLP represent an accurate portrayal of the 
clinical presentation of an individual patient (i.e. construct validity) remains unclear. In order to 
address this limitation, future studies may benefit from combining data obtained using NLP with 
data obtained using structured diagnostic interviews which have already been validated in several 
research samples.[43,128] For example, one could compare the results of an NLP assessment of 
negative symptoms in EHRs with data obtained from the direct evaluation of negative symptoms in 
the same patient sample, using psychopathological rating scales. Similarly, clinical outcomes in FEP 
patients who had initially presented to different types of service could be assessed through follow‐
up interviews and compared with the outcomes derived from the application of CRIS to the samples’ 
EHRs. 
A further consideration is the heterogeneity between volume and quality of clinical documentation 
in different patients, which introduces heterogeneity into the data that NLP methods are used to 
examine. Clinical entries can be made by clinicians from a variety of different health professions (e.g. 
doctors, nurses, occupational therapists, psychologists), and a variety of different people within each 
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profession. Most of the information recorded is in unstructured clinical documents, and the 
frequency of entries, and the volume of information is uncontrolled. In the studies reported in this 
thesis, and in the literature more generally, no attempt has been made to standardise the analyses 
to take this variability into account. One approach to address this issue would be to investigate 
methods of standardising EHR data prior to the application of NLP analyses. This could include 
adjusting for total volume of clinical documentation per patient, or the development of additional 
NLP applications to automatically identify particular types of clinical document (such as discharge 
summaries and outpatient clinical letters) that are likely to yield the most relevant and high‐quality 
data. This approach may help to improve the precision of NLP data extraction. An alternative 
approach may be to develop methods to improve standardisation of data entry by means of 
structured text fields. The use of NLP on clinical assessment data recorded in unstructured free text 
could be used as a screening tool to highlight clinical features which are relevant to a patient’s 
clinical presentation and prompt clinicians to complete a structured assessment tool. For example, 
NLP applications to ascertain negative symptoms (described in chapter 5) could be applied in 
realtime to an individual patient’s clinical record and prompt clinicians to consider completing a 
standardised assessment tool such as the Brief Negative Symptoms Scale (BNSS)[43] or the Scale for 
the Assessment of Negative Symptoms (SANS).[44] This would allow for NLP applications to support 
more focussed clinical assessments which are tailored towards a patient’s individual clinical 
presentation. 
In addition to epidemiological research using historical EHR data, the data extraction methods 
developed in this thesis have the potential to be applied to live EHR data for the purposes of 
supporting clinical decision‐making. Even at the individual patient level, the volume of clinical 
documentation for a patient with a long history of contact with mental health services (possibly 
several hundreds of pages in length) can make it unfeasible for clinicians to review the entire 
unstructured free text record prior to assessing or reviewing a patient. NLP offers the opportunity to 
automatically extract clinically useful information which could be fed back to clinicians to help 
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support clinical assessment and treatment planning in real‐time. In order to facilitate this, future 
research would need to focus on developing additional NLP applications to extract the presence of 
other symptoms relevant to patients with psychotic disorders (e.g. positive, affective and cognitive 
symptoms) as well as better delineating the evolution of clinical parameters identified using NLP 
(e.g. cannabis use or negative symptoms) over time. 
A further potential is for automated data extraction tools to support automated clinical prediction 
tools. One of the challenges faced by clinicians in treating individuals with psychotic disorders is that 
it is currently not possible to predict prognosis or response to treatment. Between 20‐40% of people 
who develop a psychotic disorder are admitted to hospital in the first year following presentation to 
mental health services with a mean duration of admission of 2 months.[129] However, at present, it 
is not possible to predict how long an individual patient is likely to spend in hospital. Similarly, about 
a third of patients with psychosis do not respond well to conventional antipsychotic medication. 
Again, this is not predictable on the basis of their presenting clinical features, and can only be 
determined through a lengthy processing of trial and error, with the evaluation of a series of 
different medications over several weeks. Future studies could explore the possibility of using 
structured and unstructured EHR data to develop tools to predict the likely duration of hospital 
admission or the response to treatment. Such an approach may allow patients and their carers to 
better plan their recovery and future as well as reducing anxiety surrounding the uncertainty of their 
illness and may facilitate clinical decision making. The identification of patients who are unlikely to 
respond to conventional treatment would allow them to be offered alternative treatments (such as 
clozapine) at a much earlier stage. There are inherent challenges to this approach related to whether 
clinical prediction tools derived from one sample could be generalised to another sample either in 
the same healthcare provider or in another provider. Previous studies attempting to apply machine 
learning techniques to neuroimaging data for the purposes of individual clinical prediction have 
highlighted limitations in the ability of such tools to make predictions outside of the research sample 
from which they were derived.[117] However, it is thought that by combining multimodal data (e.g. 
7. Conclusions 
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genetics, neuroimaging, serum biomarkers), it may be possible to overcome this limitation. A 
number of ongoing studies including EU‐GEI,[130] OPTIMISE,[131] PSYSCAN[132] and STRATA[133] 
are investigating the possibility of combining multimodal data to make predictions on risk of 
developing psychosis and likelihood of response to antipsychotic treatment. 
7.5 Summary 
The application of data extraction methods (including NLP) to obtain EHR data provides an 
opportunity to conduct clinical research in samples of patients that are much larger than can be 
directly recruited to conventional research projects. Using these methods, I have demonstrated that 
people with FEP who present to high risk services have better clinical outcomes than those who 
present to other services, that people with FEP who use cannabis have worse clinical outcomes than 
those who do not, and that negative symptoms in people with schizophrenia are common and are 
associated with particularly poor outcomes. The methods developed in these studies have the 
potential to instruct automated clinical prediction to support clinical decision making at an individual 
patient level. 
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